WO2023239629A1 - Compounds and pharmaceutical compositions that degrade cdk2 - Google Patents
Compounds and pharmaceutical compositions that degrade cdk2 Download PDFInfo
- Publication number
- WO2023239629A1 WO2023239629A1 PCT/US2023/024397 US2023024397W WO2023239629A1 WO 2023239629 A1 WO2023239629 A1 WO 2023239629A1 US 2023024397 W US2023024397 W US 2023024397W WO 2023239629 A1 WO2023239629 A1 WO 2023239629A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ring
- compound
- pharmaceutically acceptable
- tautomer
- stereoisomer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 350
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 38
- 101150073031 cdk2 gene Proteins 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 153
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 163
- 229910052739 hydrogen Inorganic materials 0.000 claims description 160
- 239000001257 hydrogen Substances 0.000 claims description 160
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 142
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 131
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 129
- -1 cyano, hydroxy Chemical group 0.000 claims description 121
- 239000000203 mixture Substances 0.000 claims description 112
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 107
- 125000003118 aryl group Chemical group 0.000 claims description 102
- 125000000217 alkyl group Chemical group 0.000 claims description 101
- 229910052757 nitrogen Inorganic materials 0.000 claims description 101
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 claims description 90
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims description 90
- 125000005843 halogen group Chemical group 0.000 claims description 90
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 89
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 87
- 201000010099 disease Diseases 0.000 claims description 85
- 125000005842 heteroatom Chemical group 0.000 claims description 82
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 80
- 208000035475 disorder Diseases 0.000 claims description 78
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 72
- 229910052760 oxygen Inorganic materials 0.000 claims description 69
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 63
- 125000001072 heteroaryl group Chemical group 0.000 claims description 60
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 57
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- 125000004432 carbon atom Chemical group C* 0.000 claims description 55
- 229910052717 sulfur Inorganic materials 0.000 claims description 53
- 125000002947 alkylene group Chemical group 0.000 claims description 44
- 201000011510 cancer Diseases 0.000 claims description 43
- 239000007787 solid Substances 0.000 claims description 36
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 33
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 33
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 31
- 229910052805 deuterium Inorganic materials 0.000 claims description 31
- 229910052721 tungsten Inorganic materials 0.000 claims description 29
- 230000001419 dependent effect Effects 0.000 claims description 28
- 102100037854 G1/S-specific cyclin-E2 Human genes 0.000 claims description 27
- 101000738575 Homo sapiens G1/S-specific cyclin-E2 Proteins 0.000 claims description 27
- 125000001153 fluoro group Chemical group F* 0.000 claims description 27
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 26
- 230000001404 mediated effect Effects 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 21
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 16
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 16
- 206010040070 Septic Shock Diseases 0.000 claims description 15
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 15
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 15
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 15
- 201000002510 thyroid cancer Diseases 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 206010009944 Colon cancer Diseases 0.000 claims description 13
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 11
- 208000002193 Pain Diseases 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 11
- 230000002018 overexpression Effects 0.000 claims description 11
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 11
- 206010005003 Bladder cancer Diseases 0.000 claims description 10
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 10
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 10
- 102000016736 Cyclin Human genes 0.000 claims description 10
- 108050006400 Cyclin Proteins 0.000 claims description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
- 206010040047 Sepsis Diseases 0.000 claims description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 10
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 10
- 201000010881 cervical cancer Diseases 0.000 claims description 10
- 206010017758 gastric cancer Diseases 0.000 claims description 10
- 208000005017 glioblastoma Diseases 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 208000037803 restenosis Diseases 0.000 claims description 10
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 10
- 201000011549 stomach cancer Diseases 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- CNMOHEDUVVUVPP-UHFFFAOYSA-N piperidine-2,3-dione Chemical group O=C1CCCNC1=O CNMOHEDUVVUVPP-UHFFFAOYSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 206010028289 Muscle atrophy Diseases 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 230000001537 neural effect Effects 0.000 claims description 6
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 5
- 206010000599 Acromegaly Diseases 0.000 claims description 5
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 5
- 208000030090 Acute Disease Diseases 0.000 claims description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010061424 Anal cancer Diseases 0.000 claims description 5
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 5
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 5
- 206010006811 Bursitis Diseases 0.000 claims description 5
- 206010006895 Cachexia Diseases 0.000 claims description 5
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 5
- 206010063094 Cerebral malaria Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 208000000094 Chronic Pain Diseases 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 241000701022 Cytomegalovirus Species 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 206010014824 Endotoxic shock Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 5
- 208000001640 Fibromyalgia Diseases 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 5
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 206010018338 Glioma Diseases 0.000 claims description 5
- 201000005569 Gout Diseases 0.000 claims description 5
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 5
- 208000009889 Herpes Simplex Diseases 0.000 claims description 5
- 208000007514 Herpes zoster Diseases 0.000 claims description 5
- 208000017604 Hodgkin disease Diseases 0.000 claims description 5
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 5
- 241000701806 Human papillomavirus Species 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 5
- 208000004554 Leishmaniasis Diseases 0.000 claims description 5
- 206010024229 Leprosy Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000016604 Lyme disease Diseases 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 5
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010033963 Parathyroid tumour Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 5
- 206010034299 Penile cancer Diseases 0.000 claims description 5
- 206010035664 Pneumonia Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 5
- 208000033464 Reiter syndrome Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 5
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 5
- 201000010001 Silicosis Diseases 0.000 claims description 5
- 208000000491 Tendinopathy Diseases 0.000 claims description 5
- 206010043255 Tendonitis Diseases 0.000 claims description 5
- 208000004760 Tenosynovitis Diseases 0.000 claims description 5
- 208000007536 Thrombosis Diseases 0.000 claims description 5
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 5
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 5
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 208000005298 acute pain Diseases 0.000 claims description 5
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 5
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 5
- 201000010105 allergic rhinitis Diseases 0.000 claims description 5
- 201000011165 anus cancer Diseases 0.000 claims description 5
- 230000002917 arthritic effect Effects 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 201000001531 bladder carcinoma Diseases 0.000 claims description 5
- 208000019664 bone resorption disease Diseases 0.000 claims description 5
- 201000008275 breast carcinoma Diseases 0.000 claims description 5
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 208000020832 chronic kidney disease Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 5
- 230000000593 degrading effect Effects 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 230000004761 fibrosis Effects 0.000 claims description 5
- 208000024908 graft versus host disease Diseases 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 230000002163 immunogen Effects 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
- 208000037906 ischaemic injury Diseases 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 206010024627 liposarcoma Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 206010025135 lupus erythematosus Diseases 0.000 claims description 5
- 230000001589 lymphoproliferative effect Effects 0.000 claims description 5
- 201000004792 malaria Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 5
- 201000006958 oropharynx cancer Diseases 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 208000002865 osteopetrosis Diseases 0.000 claims description 5
- 201000008968 osteosarcoma Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 210000003899 penis Anatomy 0.000 claims description 5
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims description 5
- 208000002574 reactive arthritis Diseases 0.000 claims description 5
- 206010038038 rectal cancer Diseases 0.000 claims description 5
- 201000001275 rectum cancer Diseases 0.000 claims description 5
- 201000006402 rhabdoid cancer Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 230000036303 septic shock Effects 0.000 claims description 5
- 201000003708 skin melanoma Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 206010042863 synovial sarcoma Diseases 0.000 claims description 5
- 201000004595 synovitis Diseases 0.000 claims description 5
- 201000004415 tendinitis Diseases 0.000 claims description 5
- 210000001685 thyroid gland Anatomy 0.000 claims description 5
- 201000006134 tongue cancer Diseases 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 208000017997 tumor of parathyroid gland Diseases 0.000 claims description 5
- 241000712461 unidentified influenza virus Species 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 5
- 206010046885 vaginal cancer Diseases 0.000 claims description 5
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 238000011374 additional therapy Methods 0.000 claims description 4
- 230000002411 adverse Effects 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 206010020843 Hyperthermia Diseases 0.000 claims description 3
- 231100000632 Spindle poison Toxicity 0.000 claims description 3
- 230000002152 alkylating effect Effects 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000000340 anti-metabolite Effects 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 229940100197 antimetabolite Drugs 0.000 claims description 3
- 239000002256 antimetabolite Substances 0.000 claims description 3
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims description 3
- 230000008512 biological response Effects 0.000 claims description 3
- 238000000315 cryotherapy Methods 0.000 claims description 3
- 238000009261 endocrine therapy Methods 0.000 claims description 3
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 230000036031 hyperthermia Effects 0.000 claims description 3
- 238000009217 hyperthermia therapy Methods 0.000 claims description 3
- 229910001410 inorganic ion Inorganic materials 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- 239000000649 purine antagonist Substances 0.000 claims description 3
- 239000003790 pyrimidine antagonist Substances 0.000 claims description 3
- 150000002431 hydrogen Chemical group 0.000 claims 27
- 108091007914 CDKs Proteins 0.000 abstract description 13
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract description 11
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract description 11
- 230000034512 ubiquitination Effects 0.000 abstract description 7
- 238000010798 ubiquitination Methods 0.000 abstract description 7
- 238000006243 chemical reaction Methods 0.000 description 84
- 235000002639 sodium chloride Nutrition 0.000 description 70
- 239000000243 solution Substances 0.000 description 62
- 210000004027 cell Anatomy 0.000 description 58
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 56
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 50
- 125000000623 heterocyclic group Chemical group 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 28
- 238000005481 NMR spectroscopy Methods 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 238000004128 high performance liquid chromatography Methods 0.000 description 27
- 238000000746 purification Methods 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 125000003342 alkenyl group Chemical group 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- 125000000304 alkynyl group Chemical group 0.000 description 23
- 239000012453 solvate Substances 0.000 description 23
- 230000015556 catabolic process Effects 0.000 description 22
- 238000006731 degradation reaction Methods 0.000 description 22
- 125000004404 heteroalkyl group Chemical group 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 21
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 20
- 238000004587 chromatography analysis Methods 0.000 description 20
- 235000019439 ethyl acetate Nutrition 0.000 description 20
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 238000002955 isolation Methods 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 18
- 238000002425 crystallisation Methods 0.000 description 18
- 230000008025 crystallization Effects 0.000 description 18
- 125000004043 oxo group Chemical group O=* 0.000 description 18
- 238000010626 work up procedure Methods 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 150000001412 amines Chemical class 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 230000002062 proliferating effect Effects 0.000 description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 15
- 150000001721 carbon Chemical group 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 14
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 13
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 229940002612 prodrug Drugs 0.000 description 12
- 239000000651 prodrug Substances 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 11
- 125000006239 protecting group Chemical group 0.000 description 11
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 239000012124 Opti-MEM Substances 0.000 description 10
- 102000044159 Ubiquitin Human genes 0.000 description 10
- 108090000848 Ubiquitin Proteins 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 235000019253 formic acid Nutrition 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000012442 inert solvent Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 8
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 125000001188 haloalkyl group Chemical group 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 125000003107 substituted aryl group Chemical group 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 6
- 102100032783 Protein cereblon Human genes 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 235000011054 acetic acid Nutrition 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 239000001301 oxygen Chemical group 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 5
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 125000003636 chemical group Chemical group 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000011888 foil Substances 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 210000005096 hematological system Anatomy 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000013456 study Methods 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 239000011593 sulfur Chemical group 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 208000006994 Precancerous Conditions Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical group CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000006574 non-aromatic ring group Chemical group 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 239000000700 radioactive tracer Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-Tetramethylpiperidine Substances CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 3
- ITIMXDXLMZTDMV-UHFFFAOYSA-N 3-(3,3-dimethoxycyclopentyl)-3-oxopropanenitrile Chemical compound COC1(CC(CC1)C(CC#N)=O)OC ITIMXDXLMZTDMV-UHFFFAOYSA-N 0.000 description 3
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- TXNLQUKVUJITMX-UHFFFAOYSA-N 4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine Chemical compound CC(C)(C)C1=CC=NC(C=2N=CC=C(C=2)C(C)(C)C)=C1 TXNLQUKVUJITMX-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 108091092878 Microsatellite Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003426 co-catalyst Substances 0.000 description 3
- 238000006880 cross-coupling reaction Methods 0.000 description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 108700043045 nanoluc Proteins 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 102000027450 oncoproteins Human genes 0.000 description 3
- 108091008819 oncoproteins Proteins 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000005017 substituted alkenyl group Chemical group 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
- 238000004808 supercritical fluid chromatography Methods 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- PCBLUDLZHRFKSP-QFBILLFUSA-N (4-nitrophenyl) [(1R,3S)-3-[3-(phenylmethoxycarbonylamino)-1H-pyrazol-5-yl]cyclopentyl] carbonate Chemical compound C(O[C@H]1C[C@H](CC1)C1=NNC(=C1)NC(=O)OCC1=CC=CC=C1)(OC1=CC=C(C=C1)[N+](=O)[O-])=O PCBLUDLZHRFKSP-QFBILLFUSA-N 0.000 description 2
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101000908058 Homo sapiens Dihydrolipoyl dehydrogenase, mitochondrial Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 101710132695 Ubiquitin-conjugating enzyme E2 Proteins 0.000 description 2
- KWSFQMNIURLZBH-SIKLNZKXSA-N [(1R,3S)-3-[1-tert-butyl-5-(phenylmethoxycarbonylamino)pyrazol-3-yl]cyclopentyl] (4-nitrophenyl) carbonate Chemical compound C(O[C@H]1C[C@H](CC1)C1=NN(C(=C1)NC(=O)OCC1=CC=CC=C1)C(C)(C)C)(OC1=CC=C(C=C1)[N+](=O)[O-])=O KWSFQMNIURLZBH-SIKLNZKXSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- GEWUGXSJBKRVCE-UHFFFAOYSA-N benzyl N-[2-tert-butyl-5-(3,3-dimethoxycyclopentyl)pyrazol-3-yl]carbamate Chemical compound C(C)(C)(C)N1N=C(C=C1NC(OCC1=CC=CC=C1)=O)C1CC(CC1)(OC)OC GEWUGXSJBKRVCE-UHFFFAOYSA-N 0.000 description 2
- PCMHACWNZMLJQH-UHFFFAOYSA-N benzyl N-[2-tert-butyl-5-(3-oxocyclopentyl)pyrazol-3-yl]carbamate Chemical compound C(C)(C)(C)N1N=C(C=C1NC(OCC1=CC=CC=C1)=O)C1CC(CC1)=O PCMHACWNZMLJQH-UHFFFAOYSA-N 0.000 description 2
- XAKMHSGRYJJSDE-JKSUJKDBSA-N benzyl N-[2-tert-butyl-5-[(1S,3R)-3-hydroxycyclopentyl]pyrazol-3-yl]carbamate Chemical compound C(C)(C)(C)N1N=C(C=C1NC(OCC1=CC=CC=C1)=O)[C@@H]1C[C@@H](CC1)O XAKMHSGRYJJSDE-JKSUJKDBSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 239000012973 diazabicyclooctane Substances 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 2
- 230000036267 drug metabolism Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 235000019000 fluorine Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- CBVJMGDRQPEDJV-UHFFFAOYSA-N methyl 3,3-dimethoxycyclopentane-1-carboxylate Chemical compound COC(=O)C1CCC(OC)(OC)C1 CBVJMGDRQPEDJV-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- HIAIZEPNWNXJBP-UHFFFAOYSA-N tert-butyl 2-piperidin-4-ylacetate Chemical compound CC(C)(C)OC(=O)CC1CCNCC1 HIAIZEPNWNXJBP-UHFFFAOYSA-N 0.000 description 2
- KLVOTIIVGDSRRO-UHFFFAOYSA-N tert-butyl 4-bromo-3-fluorobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(Br)C(F)=C1 KLVOTIIVGDSRRO-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000004001 thioalkyl group Chemical group 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- WYQBCZUEZOFZFT-WCCKRBBISA-N (2s)-2-methylazetidine;hydrochloride Chemical compound Cl.C[C@H]1CCN1 WYQBCZUEZOFZFT-WCCKRBBISA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000006653 (C1-C20) heteroaryl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- 125000006654 (C3-C12) heteroaryl group Chemical group 0.000 description 1
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000006655 (C3-C8) heteroaryl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000005926 1,2-dimethylbutyloxy group Chemical group 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- TXZFWPHJZKOMQY-UHFFFAOYSA-N 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperidine-4-carbaldehyde Chemical compound O=CC1CCN(CC1)C1=CC=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=C1 TXZFWPHJZKOMQY-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- AGPZPJHWVWZCMG-UHFFFAOYSA-N 2-(4-formylphenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(C=O)C=C1 AGPZPJHWVWZCMG-UHFFFAOYSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- MTAODLNXWYIKSO-UHFFFAOYSA-N 2-fluoropyridine Chemical compound FC1=CC=CC=N1 MTAODLNXWYIKSO-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- YTKVMOBHMCOGHZ-UHFFFAOYSA-N 3-(3-oxo-6-piperazin-1-yl-1H-isoindol-2-yl)piperidine-2,6-dione Chemical compound O=C1N(CC2=C1C=CC(=C2)N1CCNCC1)C1CCC(=O)NC1=O YTKVMOBHMCOGHZ-UHFFFAOYSA-N 0.000 description 1
- CMRQAKJTXKOGSF-UHFFFAOYSA-N 3-(6-bromo-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1C2=CC(Br)=CC=C2C(=O)N1C1CCC(=O)NC1=O CMRQAKJTXKOGSF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- BSGZHYIRZWPADY-UHFFFAOYSA-N 4-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]benzoic acid Chemical compound CC(C)(C)OC(=O)CC1=CC=C(C(O)=O)C=C1 BSGZHYIRZWPADY-UHFFFAOYSA-N 0.000 description 1
- RMYOGXPGIDWJLU-UHFFFAOYSA-N 4-bromo-3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C(F)=C1 RMYOGXPGIDWJLU-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- 230000035495 ADMET Effects 0.000 description 1
- 238000002878 ADMET assay Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 102000012698 DDB1 Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100170004 Dictyostelium discoideum repE gene Proteins 0.000 description 1
- 101100170005 Drosophila melanogaster pic gene Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 102000018700 F-Box Proteins Human genes 0.000 description 1
- 108010066805 F-Box Proteins Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001030591 Homo sapiens Mitochondrial ubiquitin ligase activator of NFKB 1 Proteins 0.000 description 1
- 101000835998 Homo sapiens SRA stem-loop-interacting RNA-binding protein, mitochondrial Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 208000026709 Liddle syndrome Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 102100038531 Mitochondrial ubiquitin ligase activator of NFKB 1 Human genes 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- 229910021585 Nickel(II) bromide Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229910021120 PdC12 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 108010068086 Polyubiquitin Proteins 0.000 description 1
- 102100037935 Polyubiquitin-C Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102000034442 RING-type E3 ubiquitin transferases Human genes 0.000 description 1
- 108030001238 RING-type E3 ubiquitin transferases Proteins 0.000 description 1
- 102100025491 SRA stem-loop-interacting RNA-binding protein, mitochondrial Human genes 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108010005705 Ubiquitinated Proteins Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- BOGSOFADOWIECK-UHFFFAOYSA-N [N].C=1C=NNC=1 Chemical compound [N].C=1C=NNC=1 BOGSOFADOWIECK-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000010535 acyclic diene metathesis reaction Methods 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- XAKMHSGRYJJSDE-CVEARBPZSA-N benzyl N-[2-tert-butyl-5-[(1R,3S)-3-hydroxycyclopentyl]pyrazol-3-yl]carbamate Chemical compound C(C)(C)(C)N1N=C(C=C1NC(OCC1=CC=CC=C1)=O)[C@H]1C[C@H](CC1)O XAKMHSGRYJJSDE-CVEARBPZSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007960 cellular response to stress Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000007819 coupling partner Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 101150077768 ddb1 gene Proteins 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N deuterated methanol Substances [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- OCMNCWNTDDVHFK-UHFFFAOYSA-L dichloronickel;1,2-dimethoxyethane Chemical compound Cl[Ni]Cl.COCCOC OCMNCWNTDDVHFK-UHFFFAOYSA-L 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000005469 ethylenyl group Chemical group 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000716 hydrazinylidene group Chemical group [*]=NN([H])[H] 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- MILUBEOXRNEUHS-UHFFFAOYSA-N iridium(3+) Chemical compound [Ir+3] MILUBEOXRNEUHS-UHFFFAOYSA-N 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000005445 isotope effect Effects 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
- 208000007282 lymphomatoid papulosis Diseases 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- KTGCFXSELRVRFH-UHFFFAOYSA-N methyl 3-oxocyclopentane-1-carboxylate Chemical compound COC(=O)C1CCC(=O)C1 KTGCFXSELRVRFH-UHFFFAOYSA-N 0.000 description 1
- 125000004492 methyl ester group Chemical group 0.000 description 1
- 150000004702 methyl esters Chemical group 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- IPLJNQFXJUCRNH-UHFFFAOYSA-L nickel(2+);dibromide Chemical compound [Ni+2].[Br-].[Br-] IPLJNQFXJUCRNH-UHFFFAOYSA-L 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- HRVXPXCISZSDCC-UHFFFAOYSA-N piperidine-4-carbaldehyde Chemical compound O=CC1CCNCC1 HRVXPXCISZSDCC-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000005470 propylenyl group Chemical group 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- KDOLGICVVPEEHO-UHFFFAOYSA-N pyrrolidine-3-carbaldehyde Chemical compound O=CC1CCNC1 KDOLGICVVPEEHO-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- DLQYXUGCCKQSRJ-UHFFFAOYSA-N tris(furan-2-yl)phosphane Chemical compound C1=COC(P(C=2OC=CC=2)C=2OC=CC=2)=C1 DLQYXUGCCKQSRJ-UHFFFAOYSA-N 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009447 viral pathogenesis Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Definitions
- This disclosure provides compounds and pharmaceutically acceptable salts thereof that are useful as modulators of targeted ubiquitination.
- the compounds disclosed herein bind to and/or degrade one or more cyclin dependent kinases (CDKs) and, accordingly, are useful in treating abnormal cell growth such as cancer.
- CDKs cyclin dependent kinases
- pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts thereof, and methods of using such compounds and their salts in the treatment of various CDK-mediated diseases or disorders.
- Cyclin-Dependent Kinases and related serine/threonine protein kinases are important cellular enzymes that perform essential features in regulating cell division and proliferation.
- CDKs 1-4, 6, 10, and 11 have been reported to play a direct role in cell cycle progression whereas CDKs 3,5, and 7-9 may play an indirect role (e.g., through activation of other CDKs, regulation of transcription or neuronal functions).
- CDK2 Overexpression of CDK2 is associated with abnormal regulation of the cell -cycle. Cyclin E, the regulatory cyclin for CDK2, is frequently overexpressed in cancer. Such overexpression has been associated with poor outcomes in breast cancer including triple negative breast cancer.
- Ubiquitin-Proteasome Pathway is a critical pathway that regulates key regulator proteins and degrades misfolded or abnormal proteins. UPP is central to multiple cellular processes, and if defective or imbalanced, it leads to pathogenesis of a variety of diseases. The covalent attachment of ubiquitin to specific protein substrates is achieved through the action of E3 ubiquitin ligases.
- E3 ubiquitin ligases which facilitate the ubiquitination of different proteins in vivo, which can be divided into four families: HECT-domain E3s, U-box E3s, monomeric RING E3s and multi-subunit E3s. See e.g., Li et al. “Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle’s dynamics and signaling.” PLOS One 2008, (3) 1487; Bemdsen et al. “New insights into ubiquitin E3 ligase mechanism” Nat. Struct. Mol. Biol. 2014, 21:301; Deshaies et al.
- UPP plays a key role in the degradation of short-lived and regulatory proteins important in a variety of basic cellular processes, including regulation of the cell cycle, modulation of cell surface receptors and ion channels, and antigen presentation.
- the pathway has been implicated in several forms of malignancy, in the pathogenesis of several genetic diseases (including cystic fibrosis, Angelman’s syndrome, and Liddle syndrome), in immune surveillance/viral pathogenesis, and in the pathology of muscle wasting. Many diseases are associated with an abnormal UPP and negatively affect cell cycle and division, the cellular response to stress and to extracellular modulators, morphogenesis of neuronal networks, modulation of cell surface receptors, ion channels, the secretory pathway, DNA repair, and biogenesis of organelles.
- cystic fibrosis including cystic fibrosis, Angelman’s syndrome, and Liddle syndrome
- Many diseases are associated with an abnormal UPP and negatively affect cell cycle and division, the cellular response to stress and to extracellular modulators, morphogenesis of neuronal networks, modulation of cell surface receptors, ion channels, the secretory pathway, DNA repair, and biogenesis of organelles.
- the UPP is used to induce selective protein degradation, including use of fusion proteins to artificially ubiquitinate target proteins and synthetic small-molecule probes to induce proteasome- dependent degradation.
- Compounds that act as molecular glues can induce or stabilize protein-protein interactions between a target protein and an E3 ubiquitin ligase ligand, leading to protein ubiquitination and subsequent proteasome-mediated degradation via the recruitment to E3 ubiquitin ligase and subsequent ubiquitination.
- These drug-like molecules offer the possibility of temporal control over protein expression.
- Such compounds are capable of inducing the inactivation of a protein of interest upon addition to cells or administration to an animal or human, and could be useful as biochemical reagents and lead to a new paradigm for the treatment of diseases by removing pathogenic or oncogenic proteins. See e.g., Crews, Chem. & Biol. 2010, 17 (6): 551; Schneekloth and Crews, Chem Bio Chem., 2005, 6 (1): 40.
- CDKs cyclin dependent kinases
- An advantage of the compounds provided herein is that a broad range of pharmacological activities are possible, consistent with the degradation/inhibition of CDKs and modulation of targeted ubiquitination.
- the disclosure provides methods of using the compounds described herein for the treatment or amelioration of a disease condition, such as cancer, e.g., breast cancer, in a subject in need thereof.
- the disclosed compounds are represented by formula I’: r or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein
- Y is N or C-V
- Ring C is wherein the solid bond 1 attaches Ring C to Y and the solid bond 2 attaches Ring C to L;
- V is selected from hydrogen, deuterium, and fluoro
- X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy;
- R 12 and R 12 are independently selected from hydrogen, deuterium, and fluoro; or R 12 and R 12 together are oxo; n is 0 or 1; p is 0 or 1;
- R 3 and R 4 are independently hydrogen or CH3; or R 3 and R 4 together with the carbon atom to which they are attached form a C3-C6 cycloalkyl;
- R 13 is hydrogen or -CH 2 -OR 14 ;
- R 14 is -C(O)-R 15 or -P(O)(OR 16 ) 2 ;
- R 15 is C1-C4 alkyl or C1-C4 alkoxy; each R 16 is independently hydrogen or C1-C4 alkyl;
- Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4- to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
- Y 1 is -O- or -CH2-
- Z is -O- or -CH2-
- R 1 and R 2 are independently selected from hydrogen, Ci-Cg alkyl, I -(C3-Cg cycloalkyl), and L 1 -(4- to 7-membered heterocycloalkyl), wherein said Ci-Cg alkyl, G-Cg cycloalkyl and 4- to 7- membered heterocycloalkyl is optionally substituted by one to four R 8 ;
- R 1 and R 2 taken together with the nitrogen atom to which they are attached form a 3- to 11- membered ring optionally containing an additional heteroatom or heteroatom group selected from O, N, N(R 17 ), and S(O) m as a ring member, wherein said 3- to 11-membered ring is optionally substituted by one to four R 8 ;
- R 17 is hydrogen, C1-C4 alkyl, or C(O)-(Ci-C4 alkyl);
- R 18 is hydrogen, C1-C4 alkyl, C1-C4 fluoroalkyl, or C(O)-(Ci-C4 alkyl); m is 0, 1 or 2;
- L 1 is a bond or a C1-C2 alkylene optionally substituted with one to four R 9 ;
- Ring A is selected from Cg-Cio aryl ring; C4-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein Ring A is substituted with from 0 to 3 R 7 moieties, and each R 7 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n ;
- R 10 and R 11 are each independently H or C1-C4 alkyl
- Ring B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein Ring B is substituted with from 0 to 3 R 8 moieties, wherein each R 8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n , or Ring B is absent; a, b, and c are independently 0 or
- R 9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy.
- Ring C is wherein the solid bond 1 attaches Ring C to the piperidinedione ring and the solid bond 2 attaches Ring C to L;
- V is selected from hydrogen, deuterium, and fluoro
- X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy;
- R 12 and R 12 are independently selected from hydrogen, deuterium, and fluoro; or R 12 and R 12 together are oxo; n is 0 or 1; p is 0 or 1;
- R 13 is hydrogen or -CH2-OR 14 ;
- R 14 is C(O)-R 15 or -P(O)(OR 16 ) 2 ;
- R 15 is C1-C4 alkyl or C1-C4 alkoxy; each R 16 is independently hydrogen or C1-C4 alkyl;
- Ring D is selected from G-Go aryl ring, C5-G cycloalkyl ring, 4- to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
- R 1 and R 2 are independently selected from hydrogen, Ci-Cg alkyl, L’-G-G, cycloalkyl, and L 1 -4-7 membered heterocycloalkyl, wherein said Ci-Cg alkyl, -G, cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by one to four R 8 ;
- R 1 and R 2 taken together with the nitrogen atom to which they are attached form a 4- to 6- membered ring optionally containing an additional heteroatom selected from O, N, N(R 17 ), and S(O) m as a ring member, wherein said 4- to 6-membered ring is optionally substituted by one to four R 8 ;
- R 17 is hydrogen, Ci-G alkyl, or C(O)-Ci-C4 alkyl
- R 18 is hydrogen, Ci-G alkyl, C1-4 fluoroalkyl, or C(O)-Ci-C4 alkyl; m is 0, 1 or 2;
- L 1 is a bond or a G-G alkylene optionally substituted with one to four R 9 ;
- Ring A is selected from Cg-Go aryl ring; G-G cycloalkyl ring; G-G cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R 7 moieties, and each R 7 is independently selected from halo, hydroxy, cyano, G-G alkyl, G-G fluoroalkyl, G-G alkoxy, G-G fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n ;
- R 10 and R 11 are each independently H or G-G alkyl
- Ring B is selected from G-Go aryl; G-G cycloalkyl ring; G-G cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R 8 moieties, wherein each R 8 is independently selected from halo, hydroxy, cyano, G-G alkyl, G-G fluoroalkyl, G-G alkoxy, G-G fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n , or B is absent; a, b, and c are independently 0 or 1 ; each of W and W 2 , if present, is independently
- the disclosed compounds are represented by formula IA: or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein
- V is hydrogen
- X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy;
- R 12 and R 12 are hydrogen, or R 12 and R 12 together are oxo; n is 0 or 1; p is 0 or 1;
- R 13 is hydrogen
- Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4 to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6 to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 5-10 membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
- Z is -O- or -CH2-
- R 1 and R 2 are independently selected from hydrogen, Ci-Cg alkyl, L 1 -(C3-Cg cycloalkyl), and L 1 -(4- to 7-membered heterocycloalkyl), wherein said Ci-Cg alkyl, C’s-Cg cycloalkyl and 4- to 7- membered heterocycloalkyl is optionally substituted by one to four R 8 ;
- R 1 and R 2 taken together with the nitrogen atom to which they are attached form a 3- to 11- membered ring optionally containing an additional heteroatom or heteroatom group selected from O, N(R 17 ), and S(O) m as a ring member, wherein said 3- to 6-membered ring is optionally substituted by one to four R 8 ;
- R 17 is hydrogen, C1-C4 alkyl, or C(O)-Ci-C4 alkyl;
- R 18 is hydrogen, C1-C4 alkyl, C1-4 fluoroalkyl, or C(O)-Ci-C4 alkyl; m is 0, 1 or 2;
- L 1 is a bond or a C1-C2 alkylene optionally substituted with one to four R 9 ;
- Ring A is selected from Cg-Cio aryl ring; C4-C6 cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to
- R 10 and R 11 are each independently H or C1-C4 alkyl
- B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to
- W 2 if present, is Ci-Cg alkylene optionally substituted with 1 to 3 R 9 and W 1 , if present, is -C(O)-, O, S, NR 18 or Ci-Cg alkylene optionally substituted with 1 to 3 R 9 provided that the aggregate sum of carbon atoms in W 1 and W 2 is no more than 4; and
- R 9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy; or when W is absent then W 1 is C4-C8 heteroalkylene containing 1 to 3 oxygen atoms.
- the disclosed compounds are represented by formula IB:
- V is hydrogen
- X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy;
- R 12 and R 12 are hydrogen, or R 12 and R 12 together are oxo; n is 0 or 1; p is 0 or 1;
- R 13 is hydrogen
- Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4- to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 5-10 membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
- Z is -O- or -CH2-
- R 1 and R 2 are independently selected from hydrogen, Ci-Cg alkyl, L'-G-Cg cycloalkyl, and L 1 -4-7 membered heterocycloalkyl, wherein said Ci-Cg alkyl, C -Cg cycloalkyl and 4- to 7-membered heterocycloalkyl is optionally substituted by one to four R 8 ;
- R 1 and R 2 taken together with the nitrogen atom to which they are attached form a 3- to 11- membered ring optionally containing an additional heteroatom or heteroatom group selected from O, N(R 17 ), and S(O) m as a ring member, wherein said 3- to 6-membered ring is optionally substituted by one to four R 8 ;
- R 17 is hydrogen, C1-C4 alkyl, or C(O)-Ci-C4 alkyl
- R 18 is hydrogen, C1-C4 alkyl, C1-C4 fluoroalkyl, or C(O)-Ci-C4 alkyl; m is 0, 1 or 2;
- L 1 is a bond or a C1-C2 alkylene optionally substituted with one to four R 9 ;
- L is represented by the formula: wherein:
- Ring A is selected from Cg-Cio aryl ring; C4-C6 cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to
- R 10 and R 11 are each independently H or C1-C4 alkyl
- B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to
- W 2 if present, is Ci-Cg alkylene optionally substituted with 1 to 3 R 9 and W 1 , if present, is -C(O)-, O, S, NR 18 or Ci-Cg alkylene optionally substituted with 1 to 3 R 9 provided that the aggregate sum of carbon atoms in W 1 and W 2 is no more than 4;
- R 9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy; and when W 2 is absent then W 1 further comprises C4-C8 heteroalkylene containing 1 to 3 oxygen atoms.
- the disclosed compounds are represented by formula III: or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein
- Y is N or C-V
- Ring C is wherein the solid bond 1 attaches Ring C to Y and the solid bond 2 attaches Ring C to L;
- V is selected from hydrogen, deuterium, and fluoro
- X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and Cwfluoroalkyloxy;
- R 12 and R 12 are independently selected from hydrogen, deuterium, and fluoro; or R 12 and R 12 together are oxo; n is 0 or 1; p is 0 or 1;
- R 3 and R 4 are independently hydrogen, halo, or CH3; or R 3 and R 4 together with the carbon atom to which they are attached form a C3-C6 cycloalkyl;
- Y 1 is -O- or -CH2-
- Z 1 is -O-, and R 5 is selected from Cg-Cio aryl; 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms; C3-C6 cycloalkyl ring; and C1-C3 alkyl optionally substituted with C1-C3 alkoxy or phenyl; wherein the Cg-Cio aryl and the 6-membered heteroaryl ring are substituted with 0 to 2 R 6 , and each R 6 is independently selected from halo, cyano, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyl; or -Z’-IV is hydrogen;
- R 13 is hydrogen or -CH2-OR 14 ;
- R 14 is C(O)-R 15 or -P(O)(OR 16 ) 2 ;
- R 15 is C1-C4 alkyl or C1-C4 alkoxy; each R 16 is independently hydrogen or C1-C4 alkyl;
- Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4- to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
- R 18 is hydrogen, C1-C4 alkyl, C1-C4 fluoroalkyl, or C(O)-Ci-C4 alkyl;
- L is represented by the formula: wherein: Ring A is selected from Cg-Cio aryl ring; C4-C6 cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R 7 moieties, and each R 7 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n ;
- R 10 and R 11 are each independently H or C1-C4 alkyl
- Ring B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R 8 moieties, wherein each R 8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n , or B is absent; a, b, and c are independently 0 or 1
- R 9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy.
- X is hydrogen or halo. In some embodiments, X is fluoro.
- Ring D is a Cg-Cio aryl ring. In some embodiments, Ring D is a Cs-Cg cycloalkyl ring. In some embodiments, Ring D is a 6 to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms. In some embodiments, Ring D is a 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms. In some embodiments, Ring D is absent. In some embodiments, Ring D is absent,
- Ring A is a 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring
- a is zero in L, and the compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is represented by formula Ila:
- a and c are zero in L, and the compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is represented by formula lib:
- B is a 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and B is substituted with from 0 to 3 R 8 moieties, wherein each R 8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, -NR 10 R n , and -C(O)NR 10 R n [0026]
- L is
- a and c are zero and B is absent in L, and the compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is represented by formula lie:
- b is 1 and W 1 is O or CH2.
- L is
- b is 0. In some embodiments, L is
- b is 1 and W 1 is -CH2-.
- L is
- b is 0. In some embodiments, L is .
- n is 0. In some embodiments, n is 1. In some embodiments, p is 1.
- R 1 and R 2 are independently selected from hydrogen and Ci-Cg alkyl.
- R 1 and R 2 taken together with the nitrogen atom to which they are attached form a 3 - to 11 -membered ring optionally containing an additional heteroatom or heteroatom group selected from O, N, N(R 17 ), and S(O) m as a ring member, wherein said 4- to 6-membered ring is optionally
- Z is -O-. In some embodiments, Z is -CH2-. In some embodiments, Y is C-V. In some embodiments, V is hydrogen. In some embodiments, Y is N. In some embodiments, Y 1 is -CH2-.
- R 5 is Cg-Cw aryl substituted with 0 to 2 R 6 . In some embodiments, R 5 is
- R 5 is .
- -Z’-R 2 is hydrogen.
- the compound is selected from Table 1 or Table 2, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
- the compounds as described herein modulate CDK2. In some embodiments, the compounds as described herein bind to CDK2. In some embodiments, the compounds as described herein degrade CDK2. [0038] In some embodiments, this disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof. In some embodiments, the pharmaceutical composition comprises an effective amount of the compound, such as an amount effective for modulating or degrading CDK2.
- this disclosure provides a method for modulating or degrading CDK2, which method comprises contacting CDK2 with a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, under conditions wherein CDK2 is bound to said compound and modulated or degraded.
- a compound as described herein e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, under conditions wherein CDK2 is bound to said compound and modulated or degraded.
- this disclosure provides a method for modulating or degrading CDK2 in a subject, which method comprises administering to said subject a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient, under conditions wherein said CDK2 is bound to said compound and modulated or degraded.
- a compound as described herein e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient, under conditions wherein said CDK2 is bound to said compound and modulated or degraded.
- this disclosure provides a method for treating a CDK2 dependent disease or disorder, or a disease or disorder that is mediated, at least in part by, CDK2, or a disease characterized by amplification or overexpression of cyclin El (CCNE1) or cyclin E2 (CCNE2) or both CCNE1 and CCNE2, in a subject in need thereof, which method comprises administering to said subject an effective amount of a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient.
- a compound as described herein e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound
- this disclosure provides a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, for use in treating a CDK2 dependent disease or disorder, or a disease or disorder that is mediated, at least in part by, CDK2, or is a disease characterized by amplification or overexpression of cyclin El (CCNE1) or cyclin E2 (CCNE2) or both CCNE1 and CCNE2.
- CCNE1 cyclin El
- CCNE2 cyclin E2
- this disclosure provides a use of a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, in the preparation of a medicament for treating a CDK2 dependent disease or disorder, or a disease or disorder that is mediated, at least in part by, CDK2, or is a disease characterized by amplification or overexpression of cyclin El (CCNE1) or cyclin E2 (CCNE2) or both CCNE1 and CCNE2.
- CCNE1 cyclin El
- CCNE2 cyclin E2
- the CDK2 dependent disease or disorder or the disease or disorder that is mediated, at least in part by, CDK2 is one or more selected from liposarcoma, glioblastoma, bladder cancer, adrenocortical cancer, multiple myeloma, colorectal cancer, non-small cell lung cancer, Human Papilloma Virus-associated cervical, oropharyngeal, penis, anal, thyroid, or vaginal cancer or Epstein- Barr Virus-associated nasopharyngeal carcinoma, gastric cancer, rectal cancer, thyroid cancer, Hodgkin lymphoma, and diffuse large B-cell lymphoma.
- the CDK2 dependent disease or disorder or the disease or disorder that is mediated, at least in part by, CDK2 is selected from prostate cancer, breast carcinoma, lymphomas, leukemia, myeloma, bladder carcinoma, colon cancer, cutaneous melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, renal cancer, glioblastoma multiform, glioma, thyroid cancer, parathyroid tumor, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, cholangiocarcinoma, gastric cancer, soft tissue sarcomas, rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid cancers, cancer for which the immune response is deficient, an immunogenic cancer, and Ewing’s sarcoma.
- the CDK2 dependent disease or disorder or the disease or disorder that is mediated, at least in part by, CDK2 is selected from rheumatoid arthritis; inflammation; autoimmune disease; lymphoproliferative conditions; acromegaly; rheumatoid spondylitis; osteoarthritis; gout, other arthritic conditions; sepsis; septic shock; endotoxic shock; gram-negative sepsis; toxic shock syndrome; asthma; adult respiratory distress syndrome; chronic obstructive pulmonary disease; chronic pulmonary inflammation; inflammatory bowel disease; Crohn's disease; psoriasis; eczema; ulcerative colitis; pancreatic fibrosis; hepatic fibrosis; acute and chronic renal disease; irritable bowel syndrome; pyresis; restenosis; cerebral malaria; stroke and ischemic injury; neural trauma; Alzheimer's disease; Huntington's disease; Parkinson's disease; acute and chronic pain; allergic r
- this disclosure provides a method for treating hyperplasias in a subject in need thereof which method comprises administering to said subject an effective amount of a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient.
- a compound as described herein e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient.
- this disclosure provides a method for treating cancer in a subject in need thereof which method comprises administering to said subject an effective amount of a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient.
- a compound as described herein e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient.
- the cancer treated in the methods described herein is breast cancer, such as triple negative breast cancer.
- the methods disclosed herein further comprise administering to the subject one or more additional therapies or therapeutic agents.
- the one or more additional therapies or therapeutic agents are one or more selected from surgery, radiotherapy, endocrine therapy, biologic response modifiers, hyperthermia and cryotherapy, agents to attenuate any adverse effects, alkylating drugs, antimetabolites, purine antagonists and pyrimidine antagonists, spindle poisons, podophyllotoxins, antibiotics, nitrosoureas, inorganic ions, enzymes, and hormones.
- This disclosure provides compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds and compositions to treat diseases, disorders, or conditions mediated, at least in part, by CDK2.
- CDK2 diseases, disorders, or conditions mediated, at least in part, by CDK2.
- a dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent.
- -C(O)NH2 is attached through the carbon atom.
- a dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning.
- a wavy line or a dashed line drawn through a line in a structure indicates a specified point of attachment of a group. Unless chemically or structurally required, no directionality or stereochemistry is indicated or implied by the order in which a chemical group is written or named.
- C u-V indicates that the following group has from u to v carbon atoms.
- Ci-6 alkyl indicates that the alkyl group has from 1 to 6 carbon atoms.
- compositions and methods when used to define compositions and methods means that the compositions and methods so modified include at least the recited elements and do not include other materials or steps that would materially affect the basic and novel characteristic(s) of the claimed disclosure.
- a composition or method “consisting essentially of’ recited elements could include other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed disclosure.
- compositions and methods when used to define compositions and methods means that the compositions and methods so modified include the recited elements and do not include more than trace amounts of other ingredients or do not include other substantial method steps. Embodiments defined by each of these transition terms are within the scope of this disclosure.
- alkyl refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., C1-20 alkyl), 1 to 12 carbon atoms (i.e., C1-12 alkyl), 1 to 8 carbon atoms (i.e., C1-8 alkyl), 1 to 6 carbon atoms (i.e., C1-6 alkyl), or 1 to 4 carbon atoms (i.e., C1-4 alkyl).
- alkyl groups include, e.g., methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3 -hexyl, and 3 -methylpentyl.
- butyl includes n-butyl (i.e., -(CFE CFfi), sec-butyl (i.e., -CH(CH3)CH2CH3), isobutyl (i.e., - CH 2 CH(CH 3 )2), and tert-butyl (i.e., -C(CH3)3); and “propyl” includes n-propyl (i.e., -(CFE CFfi) and isopropyl (i.e., -CH( CThfi).
- a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, a divalent heteroaryl group, etc.
- a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, a divalent heteroaryl group, etc.
- an “alkylene” group or an “alkylenyl” group for example, methylenyl, ethylenyl, and propylenyl
- an “arylene” group or an “arylenyl” group for example, phenylenyl or napthylenyl, or quinolinyl for heteroarylene
- Alkenyl refers to an alkyl group containing at least one (e.g., 1-3, or 1) carbon-carbon double bond and having from 2 to 20 carbon atoms (i.e., C2-20 alkenyl), 2 to 12 carbon atoms (i.e., C2-12 alkenyl), 2 to 8 carbon atoms (i.e., C2-8 alkenyl), 2 to 6 carbon atoms (i.e., C2-6 alkenyl), or 2 to 4 carbon atoms (i.e., C2-4 alkenyl).
- alkenyl groups include, e.g., ethenyl, propenyl, butadienyl (including 1,2-butadienyl and 1,3 -butadienyl).
- Alkynyl refers to an alkyl group containing at least one (e.g., 1-3, or 1) carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e., C2-20 alkynyl), 2 to 12 carbon atoms (i.e., C2-12 alkynyl), 2 to 8 carbon atoms (i.e., C2-8 alkynyl), 2 to 6 carbon atoms (i.e., C2-6 alkynyl), or 2 to 4 carbon atoms (i.e., C2-4 alkynyl).
- alkynyl also includes those groups having one triple bond and one double bond.
- Alkoxy refers to the group “alkyl-O-”. Examples of alkoxy groups include, e.g., methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1 ,2-dimethylbutoxy .
- Alkylthio refers to the group “alkyl-S-”.
- Alkylsulfmyl refers to the group “alkyl-S(O)-”.
- Alkylsulfonyl refers to the group “alkyl-S(O)2-”.
- Alkylsulfonylalkyl refers to -alkyl-S(O)2-alkyl.
- acyl refers to a group -C(O)R y , wherein R y is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
- R y is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
- acyl include, e.g., formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, and benzoyl.
- “Amido” refers to both a “C-amido” group which refers to the group -C(0)NR y R z and an “N- amido” group which refers to the group -NR y C(0)R z , wherein R y and R z are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein, or R y and R z are taken together to form a cycloalkyl or heterocyclyl; each of which may be unsubstituted or substituted, as defined herein.
- Amino refers to the group -NR y R z wherein R y and R z are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
- “Amidino” refers to -C(NR y )(NR z 2), wherein R y and R z are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
- Aryl refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic) including fused systems.
- aryl has 6 to 20 ring carbon atoms (i.e., Cg-20 aryl), 6 to 12 carbon ring atoms (i.e., Cg-i2 aryl), or 6 to 10 carbon ring atoms (i.e., Cg-io aryl).
- Examples of aryl groups include, e.g., phenyl, naphthyl, fluorenyl, and anthryl.
- Aryl does not encompass or overlap in any way with heteroaryl defined below.
- the resulting ring system is heteroaryl regardless of point of attachment. If one or more aryl groups are fused with a heterocyclyl, the resulting ring system is heterocyclyl regardless of point of attachment. If one or more aryl groups are fused with a cycloalkyl, the resulting ring system is cycloalkyl regardless of point of attachment.
- Carbamoyl refers to both an “0-carbamoyl” group which refers to the group -0-C(0)NR y R z and an “N-carbamoyl” group which refers to the group -NR y C(0)0R z , wherein R y and R z are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
- Carboxyl ester or “ester” refer to both -0C(0)R x and -C(0)0R x , wherein R x is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
- Cycloalkyl refers to a saturated or partially unsaturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems.
- the term “cycloalkyl” includes cycloalkenyl groups (i.e., the cyclic group having at least one double bond) and carbocyclic fused ring systems having at least one sp 3 carbon atom (i.e., at least one non-aromatic ring).
- cycloalkyl has from 3 to 20 ring carbon atoms (i.e., C3-20 cycloalkyl), 3 to 14 ring carbon atoms (i.e., C3-14 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C3-12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C3-8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C3-6 cycloalkyl).
- Monocyclic groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- Polycyclic groups include, for example, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, adamantyl, norbomyl, decalinyl, 7,7-dimethyl-bicyclo[2.2. l]heptanyl, and the like.
- cycloalkyl is intended to encompass any non-aromatic ring which may be fused to an aryl ring, regardless of the attachment to the remainder of the molecule.
- cycloalkyl also includes “spirocycloalkyl” when there are two positions for substitution on the same carbon atom, for example spiro[2.5]octanyl, spiro[4.5]decanyl, or spiro [5.5 ]undecanyl .
- Imino refers to a group -C(NR y )R z , wherein R y and R z are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
- “Imido” refers to a group -C(O)NR y C(O)R z , wherein R y and R z are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
- Halogen refers to atoms occupying group VIIA of the periodic table, such as fluoro, chloro, bromo, or iodo.
- Haloalkyl refers to an unbranched or branched alkyl group as defined above, wherein one or more (e.g., 1 to 6 or 1 to 3) hydrogen atoms are replaced by a halogen.
- a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached.
- Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be, but are not necessarily, the same halogen.
- haloalkyl examples include, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3 -bromo-2 -fluoropropyl, 1,2-dibromoethyl, and the like.
- Haloalkoxy refers to an alkoxy group as defined above, wherein one or more (e.g., 1 to 6 or 1 to 3) hydrogen atoms are replaced by a halogen.
- Hydroxyalkyl refers to an alkyl group as defined above, wherein one or more (e.g., 1 to 6 or 1 to 3) hydrogen atoms are replaced by a hydroxy group.
- “Heteroalkyl” refers to an alkyl group in which one or more of the carbon atoms (and any associated hydrogen atoms), excluding any terminal carbon atom(s), are each independently replaced with the same or different heteroatomic group, provided the point of attachment to the remainder of the molecule is through a carbon atom.
- the term “heteroalkyl” includes unbranched or branched saturated chain having carbon and heteroatoms.
- 1, 2 or 3 carbon atoms may be independently replaced with the same or different heteroatomic group.
- Heteroatomic groups include, but are not limited to, -NR y -, -O-, -S-, -S(O)-, -S(O)2-, and the like, wherein R y is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
- heteroalkyl groups include, e.g., ethers (e.g., -CH2OCH3, - CH(CH 3 )OCH 3 , -CH2CH 2 OCH 3 , -CH2CH2OCH2CH 2 OCH 3 , etc ), thioethers (e.g., -CH 2 SCH 3 , - CH(CH 3 )SCH 3 , -CH2CH2SCH 3 ,-CH2CH2SCH2CH 2 SCH 3 , etc ), sulfones (e.g, -CH 2 S(O) 2 CH 3 , - CH(CH 3 )S(O) 2 CH 3 , -CH2CH 2 S(O)2CH 3 , -CH2CH2S(O)2CH2CH 2 OCH 3 , etc ), and amines (e.g., - CH 2 NR y CH 3 , -CH(CH 3 )NR y CH 3 , -CH2CH 2CH
- Heteroaryl refers to an aromatic group having a single ring, multiple rings or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- heteroaryl includes 1 to 20 ring carbon atoms (i.e., C1-20 heteroaryl), 3 to 12 ring carbon atoms (i.e., C3-12 heteroaryl), or 3 to 8 carbon ring atoms (i.e., C 3 -8 heteroaryl), and 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur.
- heteroaryl includes 5-10 membered ring systems, 5-7 membered ring systems, or 5-6 membered ring systems, each independently having 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur.
- heteroaryl groups include, e.g., acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzofuranyl, benzothiazolyl, benzothiadiazolyl, benzonaphthofuranyl, benzoxazolyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, isoquinolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxid
- fused- heteroaryl rings examples include, but are not limited to, benzo [d]thiazolyl, quinolinyl, isoquinolinyl, benzo [b]thiophenyl, indazolyl, benzo [d] imidazolyl, pyrazolo[l,5-a]pyridinyl, and imidazo[l,5- a]pyridinyl, where the heteroaryl can be bound via either ring of the fused system. Any aromatic ring, having a single or multiple fused rings, containing at least one heteroatom, is considered a heteroaryl regardless of the attachment to the remainder of the molecule (i.e., through any one of the fused rings). Heteroaryl does not encompass or overlap with aryl as defined above.
- Heterocyclyl used interchangeably with “heterocycloalkyl”- refers to a saturated or partially unsaturated cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- heterocyclyl includes heterocycloalkenyl groups (i.e., the heterocyclyl group having at least one double bond), bridged-heterocyclyl groups, fused-heterocyclyl groups, and spiro-heterocyclyl groups.
- Any non-aromatic ring containing at least one heteroatom is considered a heterocyclyl, regardless of the attachment (i.e., can be bound through a carbon atom or a heteroatom).
- the term heterocyclyl is intended to encompass any non-aromatic ring containing at least one heteroatom, which ring may be fused to a cycloalkyl, an aryl, or heteroaryl ring, regardless of the attachment to the remainder of the molecule.
- heterocyclyl has 2 to 20 ring carbon atoms (i.e., C2-20 heterocyclyl), 2 to 12 ring carbon atoms (i.e., C2-12 heterocyclyl), 2 to 10 ring carbon atoms (i.e., C2-10 heterocyclyl), 2 to 8 ring carbon atoms (i.e., C2-8 heterocyclyl), 3 to 12 ring carbon atoms (i.e., C3-12 heterocyclyl), 3 to 8 ring carbon atoms (i.e., C3-8 heterocyclyl), or 3 to 6 ring carbon atoms (i.e., C3-6 heterocyclyl); having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur, or oxygen.
- ring carbon atoms i.e., C2-20 heterocyclyl
- 2 to 12 ring carbon atoms i.
- heterocyclyl groups include, e.g., azetidinyl, azepinyl, benzodioxolyl, benzo[b][l,4]dioxepinyl, 1,4-benzodioxanyl, benzopyranyl, benzodioxinyl, benzopyranonyl, benzofuranonyl, dioxolanyl, dihydropyranyl, hydropyranyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, furanonyl, imidazolinyl, imidazolidinyl, indolinyl, indolizinyl, isoindolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-
- heterocyclyl also includes “spiroheterocyclyl” when there are two positions for substitution on the same carbon atom.
- spiro-heterocyclyl rings include, e.g., bicyclic and tricyclic ring systems, such as oxabicyclo[2.2.2]octanyl, 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6- azaspiro[3.4]octanyl, and 6-oxa-l-azaspiro[3.3]heptanyl.
- fused-heterocyclyl rings include, but are not limited to, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrothieno[2,3- c]pyridinyl, indolinyl, and isoindolinyl, where the heterocyclyl can be bound via either ring of the fused system.
- “Sulfonyl” refers to the group -S(O)2R y , where R y is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
- Examples of sulfonyl are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.
- “Sulfinyl” refers to the group -S(O)R y , where R y is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
- R y is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
- Examples of sulfinyl are methylsulfinyl, ethylsulfinyl, phenylsulfinyl, and toluenesulfinyl.
- “Sulfonamide” refers to the groups -SC>2NR y R z and -NR y SC>2R z , where R y and R z are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
- substituted means any of the above groups (i.e., alkyl, alkenyl, alkynyl, alkylene, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl, and/or heteroalkyl) wherein at least one (e.g., 1 to 5 or 1 to 3) hydrogen atom is replaced by a bond to a non-hydrogen atom such as, but not limited to alkyl, alkenyl, alkynyl, alkoxy, alkylthio, acyl, amido, amino, amidino, aryl, aralkyl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, cycloalkyl, cycloalkylalkyl, guanadino, halo, haloalkyl, haloalkoxy, hydroxyalkyl
- substituted includes any of the above alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl groups in which one or more (e.g., 1 to 5 or 1 to 3) hydrogen atoms are independently replaced with deuterium, halo, cyano, nitro, azido, oxo, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR g R h , -NR g C(0)R h , “substituted” also means any of the above groups in which one or more (e.g., 1 to 5 or 1 to 3) hydrogen atoms are replaced with -C(O)R g , -C(O)OR g , -C(O)NR g R h , -CH 2 SO 2 R
- substituted also means any of the above groups in which one or more (e.g., 1 to 5 or 1 to 3) hydrogen atoms are replaced by a bond to an amino, cyano, hydroxy, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, and/or heteroarylalkyl, or two of R g and R h are taken together with the atoms to which they are attached to form a heterocyclyl ring unsubstituted or substituted with oxo, halo, or alkyl unsubstituted or substituted with oxo, halo, amino, hydroxy, or alk
- impermissible substitution patterns e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms. Such impermissible substitution patterns are well known to the skilled artisan.
- substituted may describe other chemical groups defined herein.
- any compound or structure given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds (i.e., the amount of labeled forms is above the natural abundance for that form). These forms of compounds may also be referred to as “isotopically enriched analogs.” Isotopically labeled compounds have structures depicted herein, except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
- isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, n C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 36 C1, 123 I, and 125 I, respectively.
- isotopically labeled compounds of the present disclosure for example those into which radioactive isotopes such as 3 H and 14 C are incorporated.
- Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.
- PET positron emission tomography
- SPECT single-photon emission computed tomography
- isotopically enriched analogs includes “deuterated analogs” of compounds described herein in which one or more hydrogens is/are replaced by deuterium, such as a hydrogen on a carbon atom. Such compounds exhibit increased resistance to metabolism and are thus useful for increasing the half-life of any compound when administered to a mammal, particularly a human. See, for example, Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci. 5(12): 524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.
- Deuterium labelled or substituted therapeutic compounds of the disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to absorption, distribution, metabolism, and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements, and/or an improvement in therapeutic index.
- An 18 F, 3 H, or n C labeled compound may be useful for PET or SPECT or other imaging studies.
- Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. It is understood that deuterium in this context is regarded as a substituent in a compound described herein.
- the concentration of such a heavier isotope, specifically deuterium may be defined by an isotopic enrichment factor.
- any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom.
- a position is designated specifically as “H” or “hydrogen,” the position is understood to have hydrogen at its natural abundance isotopic composition.
- any atom specifically designated as a deuterium (D) is meant to represent deuterium.
- the compounds of this disclosure are capable of forming acid and/or base salts by virtue of the presence of amino, and/or carboxyl groups, or groups similar thereto.
- “Pharmaceutically acceptable” or “physiologically acceptable” refer to compounds, salts, compositions, dosage forms, and other materials which are useful in preparing or suitable for use in a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.
- pharmaceutically acceptable salt of a given compound refers to salts that exhibit the intended efficacy of the reference compound and which are not biologically or otherwise undesirable, e.g., due to toxicity or other properties.
- “Pharmaceutically acceptable salts” or “physiologically acceptable salts” include, for example, salts with inorganic acids, and salts with an organic acid.
- the free base can be obtained by basifying a solution of the acid salt.
- an addition salt particularly a pharmaceutically acceptable addition salt
- a suitable organic solvent may be used to prepare nontoxic pharmaceutically acceptable addition salts.
- Pharmaceutically acceptable acid addition salts may be prepared from inorganic or organic acids. Salts derived from inorganic acids include, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- Salts derived from organic acids include, e.g., acetic acid, propionic acid, gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methane sulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.
- pharmaceutically acceptable base addition salts can be prepared from inorganic or organic bases.
- Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, aluminum, ammonium, calcium, and magnesium salts.
- Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, such as alkyl amines (i.e., NfLfalkyl)).
- dialkyl amines i.e., HN(alkyl)2), trialkyl amines (i.e., N(alkyl)3), substituted alkyl amines (i.e., NfLfsubstitiitcd alkyl)), di(substituted alkyl) amines (i.e., HN(substituted alkyl)2), tri(substituted alkyl) amines (i.e., N(substituted alkylfi).
- alkenyl amines i.e., NH2(alkenyl)
- dialkenyl amines i.e., HN(alkenyl)2)
- trialkenyl amines i.e., N(alkenyl)3
- substituted alkenyl amines i.e., NH2(substituted alkenyl)
- di(substituted alkenyl) amines i.e., HN(substituted alkenyl ⁇
- Suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
- Tautomers are in equilibrium with one another.
- amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, the amide containing compounds are understood to include their imidic acid tautomers. Likewise, the imidic acid containing compounds are understood to include their amide tautomers.
- the compounds described herein, or their pharmaceutically acceptable salts may include an asymmetric center and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S')- or, as (D)- or (L)- for amino acids.
- the present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms, and various combinations thereof.
- (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and/or fractional crystallization.
- Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC).
- HPLC high pressure liquid chromatography
- a “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable .
- the present disclosure contemplates various stereoisomers, or mixtures thereof, and includes “enantiomers,” which refers to two stereoisomers whose molecules are non-superimposeable mirror images of one another.
- ‘Diastereomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
- Prodrug means any compound which releases an active parent drug according to a structure described herein in vivo when such prodrug is administered to a mammalian subject.
- Prodrugs of a compound described herein are prepared by modifying functional groups present in the compound described herein in such a way that the modifications may be cleaved in vivo to release the parent compound.
- Prodrugs may be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds.
- Prodrugs include compounds described herein wherein a hydroxy, amino, carboxyl, or sulfhydryl group in a compound described herein is bonded to any group that may be cleaved in vivo to regenerate the free hydroxy, amino, or sulfhydryl group, respectively.
- Examples of prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), amides, guanidines, carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional groups in compounds described herein, and the like. Preparation, selection, and use of prodrugs is discussed in T. Higuchi and V.
- Subject refers to a mammal.
- the mammal can be a human or non-human mammalian organism.
- a “patient” refers to a human subject.
- Treating” or “treatment” of a disease or disorder in a subject refers to inhibiting the disease or disorder or arresting its development or ameliorating or causing regression of the disease or disorder.
- “effective amount” refers to an amount of a compound described herein that is sufficient to achieve the intended effect, such as modulating CDK2 or treating a disease or disorder afflicting a subject.
- administering refers to any art recognized form of administration to a subject including injection (e.g., intravenous, subcutaneous, intramuscular), oral (including oral gavage), pulmonary, transdermal, sublingual, transmucosal (e.g., vaginal, nasal, etc.), and the like.
- injection e.g., intravenous, subcutaneous, intramuscular
- oral including oral gavage
- pulmonary e.g., transdermal, sublingual
- transmucosal e.g., vaginal, nasal, etc.
- ubiquitin ligase refers to a family of proteins that facilitate the transfer of ubiquitin to a specific substrate protein, targeting the substrate protein for degradation.
- an E3 ubiquitin ligase protein that alone or in combination with an E2 ubiquitin-conjugating enzyme causes the attachment of ubiquitin to a lysine on a target protein, and subsequently targets the specific protein substrates for degradation by the proteasome.
- E3 ubiquitin ligase alone or in complex with an E2 ubiquitin conjugating enzyme is responsible for the transfer of ubiquitin to targeted proteins.
- the ubiquitin ligase is involved in polyubiquitination such that a second ubiquitin is attached to the first; a third is attached to the second, and so forth.
- Polyubiquitination marks proteins for degradation by the proteasome.
- Mono- ubiquitinated proteins are not targeted to the proteasome for degradation, but may instead be altered in their cellular location or function, for example, via binding other proteins that have domains capable of binding ubiquitin.
- different lysines on ubiquitin can be targeted by an E3 to make chains. The most common lysine is Lys48 on the ubiquitin chain. This is the lysine used to make polyubiquitin, which is recognized by the proteasome.
- this disclosure provides a compound of formula F: r or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein
- Y is N or C-V
- Ring C is wherein the solid bond 1 attaches Ring C to Y and the solid bond 2 attaches Ring C to L;
- V is selected from hydrogen, deuterium, and fluoro
- X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy;
- R 12 and R 12 are independently selected from hydrogen, deuterium and fluoro; or R 12 and R 12 together are oxo; n is 0 or 1; p is 0 or 1;
- R 3 and R 4 are independently hydrogen or CH3; or R 3 and R 4 together with the carbon atom to which they are attached form a C3-C6 cycloalkyl;
- R 13 is hydrogen or -CH 2 -OR 14 ;
- R 14 is -C(O)-R 15 or -P(O)(OR 16 ) 2 ;
- R 15 is C1-C4 alkyl or C1-C4 alkoxy; each R 16 is independently hydrogen or C1-C4 alkyl;
- Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4- to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
- Y 1 is -O- or -CH 2 -;
- Z is -O- or -CH 2 -;
- R 1 and R 2 are independently selected from hydrogen, Ci-Cg alkyl, L 1 -(G-Cg cycloalkyl), and L 1 -(4- to 7-membered heterocycloalkyl), wherein said Ci-Cg alkyl, G-Cg cycloalkyl and 4- to 7- membered heterocycloalkyl is optionally substituted by one to four R 8 ;
- R 1 and R 2 taken together with the nitrogen atom to which they are attached form a 3- to 11- membered ring optionally containing an additional heteroatom or heteroatom group selected from O, N, N(R 17 ), and S(O) m as a ring member, wherein said 3- to 6-membered ring is optionally substituted by one to four R 8 ;
- R 17 is hydrogen, C1-C4 alkyl, or C(0)-(G-C4 alkyl);
- R 18 is hydrogen, C1-C4 alkyl, C1-4 fluoroalkyl, or C(O)-Ci-C4 alkyl; m is 0, 1 or 2;
- L 1 is a bond or a G-C 2 alkylene optionally substituted with one to four R 9 ;
- Ring A is selected from Cg-Cio aryl ring; C4-C6 cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R 7 moieties, and each R 7 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n ;
- R 10 and R 11 are each independently H or C1-C4 alkyl
- Ring B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R 8 moieties, wherein each R 8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n , or B is absent; a, b, and c are independently 0 or 1
- R 9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy.
- this disclosure provides a compound of formula I:
- Ring C is wherein the solid bond 1 attaches Ring C to the piperidinedione ring and the solid bond 2 attaches Ring C to L;
- V is selected from hydrogen, deuterium, and fluoro
- X is selected from hydrogen, halo, hydroxy, cyano, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 alkoxy, and C1-4 fluoroalkyloxy;
- R 12 and R 12 are independently selected from hydrogen, deuterium and fluoro or R 12 and R 12 together are oxo; n is 0 or 1; p is 0 or 1;
- R 13 is hydrogen or -CH2-OR 14 ;
- R 14 is -C(O)-R 15 or -P(O)(OR 16 ) 2 ;
- each R 16 is independently hydrogen or C1-C4 alkyl
- Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4 to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6 to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
- R 1 and R 2 are independently selected from hydrogen, Ci-Cg alkyl, L'-C’s-Cg cycloalkyl, and I -4-7 membered heterocycloalkyl, wherein said Ci-Cg alkyl, C -Cg cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by one to four R 8 ;
- R 1 and R 2 taken together with the nitrogen atom to which they are attached form a 4- to 6-membered ring optionally containing an additional heteroatom selected from O, N, N(R 17 ), and S(O) m as a ring member, wherein said 4- to 6-membered ring is optionally substituted by one to four R 8 ;
- R 17 is hydrogen, C1-C4 alkyl, or C(O)-Ci-C4 alkyl
- R 18 is hydrogen, C1-C4 alkyl, C1-4 fluoroalkyl, or C(O)-Ci-C4 alkyl; m is 0, 1 or 2;
- L 1 is a bond or a C1-C2 alkylene optionally substituted with one to four R 9 ;
- Ring A is selected from Cg-Cio aryl ring; C4-C6 cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R 7 moieties, and each R 7 is independently selected from halo, hydroxy, cyano, C1-4 alkyl, Ci-4fluoroalkyl, C1-4 alkoxy, C1-4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n ;
- R 10 and R 11 are each independently H or C1-C4 alkyl
- Ring B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R 8 moieties, wherein each R 8 is independently selected from halo, hydroxy, cyano, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 alkoxy, C 1-4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n , or B is absent; a, b, and c are independently 0 or 1 ; each of W and W 2 , if
- R 9 is independently selected from halo, cyano, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 alkoxy, and C1-4 fluoroalkyloxy.
- this disclosure provides a compound of formula IA:
- Ring C is wherein the solid bond 1 attaches Ring C to the piperidinedione ring and the solid bond 2 attaches Ring C to L;
- V is hydrogen
- X is selected from hydrogen, halo, hydroxy, cyano, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 alkoxy, and C Mfluoroalkyloxy ;
- R 12 and R 12 are hydrogen or R 12 and R 12 together are oxo; n is 0 or 1; p is 0 or 1;
- R 13 is hydrogen
- Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4 to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6 to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 5-10 membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
- R 1 and R 2 are independently selected from hydrogen, Ci-Cg alkyl, L'-C’s-Cg cycloalkyl, and I -4-7 membered heterocycloalkyl, wherein said Ci-Cg alkyl, C -Cg cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by one to four R 8 ;
- R 1 and R 2 taken together with the nitrogen atom to which they are attached form a 3 - to 6-membered ring optionally containing an additional heteroatom selected from O, N(R 17 ), and S(O) m as a ring member, wherein said 3- to 6-membered ring is optionally substituted by one to four R 8 ;
- R 17 is hydrogen, C1-C4 alkyl, or C(O)-Ci-C4 alkyl
- R 18 is hydrogen, C1-C4 alkyl, C1-4 fluoroalkyl, or C(O)-Ci-C4 alkyl; m is 0, 1 or 2;
- L 1 is a bond or a C1-C2 alkylene optionally substituted with one to four R 9 ;
- Ring A is selected from Cg-Cio aryl ring; C4-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 10- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R 7 moieties, and each R 7 is independently selected from halo, hydroxy, cyano, CM alkyl, Ci-4fluoroalkyl, C alkoxy, CM fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n ;
- R 10 and R 11 are each independently H or C1-C4 alkyl
- B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11- membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4 to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R 8 moieties, wherein each R 8 is independently selected from halo, hydroxy, cyano, CM alkyl, CM fluoroalkyl, CM alkoxy, C 1-4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n , or B is absent; b and c are independently 0 or 1 ;
- W 2 if present, is Ci-Cg alkylene optionally substituted with 1 to 3 R 9 and W 1 , if present, is -C(O)-, O, S, NR 18 or Ci-Cg alkylene optionally substituted with 1 to 3 R 9 provided that the aggregate sum of carbon atoms in W 1 and W 2 is no more than 4; and
- R 9 is independently selected from halo, cyano, CM alkyl, CM fluoroalkyl, CM alkoxy, and CM fluoroalkyloxy or when W is absent then W 1 is C4-C8 heteroalkylene containing 1 to 3 oxygen atoms.
- Ring C is wherein the solid bond 1 attaches Ring C to the piperidinedione ring and the solid bond 2 attaches Ring C to L;
- V is hydrogen;
- X is selected from hydrogen, halo, hydroxy, cyano, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 alkoxy, and C wfluoroalkyloxy ;
- R 12 and R 12 are hydrogen or R 12 and R 12 together are oxo; n is 0 or 1; p is 0 or 1;
- R 13 is hydrogen
- Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4 to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6 to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 5-10 membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
- R 1 and R 2 are independently selected from hydrogen, Ci-Cg alkyl, L'-C’s-Cg cycloalkyl, and I -4-7 membered heterocycloalkyl, wherein said Ci-Cg alkyl, C -Cg cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by one to four R 8 ;
- R 1 and R 2 taken together with the nitrogen atom to which they are attached form a 3 - to 6-membered ring optionally containing an additional heteroatom selected from O, N(R 17 ), and S(O) m as a ring member, wherein said 3- to 6-membered ring is optionally substituted by one to four R 8 ;
- R 17 is hydrogen, C1-C4 alkyl, or C(O)-Ci-C4 alkyl
- R 18 is hydrogen, C1-C4 alkyl, C1-4 fluoroalkyl, or C(O)-Ci-C4 alkyl; m is 0, 1 or 2;
- L 1 is a bond or a C1-C2 alkylene optionally substituted with one to four R 9 ;
- Ring A is selected from Cg-Cio aryl ring; C4-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 10- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R 7 moieties, and each R 7 is independently selected from halo, hydroxy, cyano, C1-4 alkyl, Ci-4fluoroalkyl, C1-4 alkoxy, C1-4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n ;
- R 10 and R 11 are each independently H or C1-C4 alkyl
- B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11- membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4 to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R 8 moieties, wherein each R 8 is independently selected from halo, hydroxy, cyano, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 alkoxy, Ci-4fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n , or B is absent; b and c are independently 0 or 1 ;
- W 2 if present, is Ci-Cg alkylene optionally substituted with 1 to 3 R 9 and W 1 , if present, is -C(O)-, O, S, NR 18 or Ci-Cg alkylene optionally substituted with 1 to 3 R 9 provided that the aggregate sum of carbon atoms in W 1 and W 2 is no more than 4;
- R 9 is independently selected from halo, cyano, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 alkoxy, and C1-4 fluoroalkyloxy; and when W 2 is absent then W 1 further comprises C4-C8 heteroalkylene containing 1 to 3 oxygen atoms.
- Y is N or C-V
- Ring C is wherein the solid bond 1 attaches Ring C to Y and the solid bond 2 attaches Ring C to L;
- V is selected from hydrogen, deuterium, and fluoro
- X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and Ci-4fluoroalkyloxy;
- R 12 and R 12 are independently selected from hydrogen, deuterium, and fluoro; or R 12 and R 12 together are oxo; n is 0 or 1; p is 0 or 1;
- R 3 and R 4 are independently hydrogen, halo, or CH3; or R 3 and R 4 together with the carbon atom to which they are attached form a C3-C6 cycloalkyl; Y 1 is -O- or -CH 2 -;
- Z 1 is -O-, and R 5 is selected from Cg-Cw aryl; 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms; C3-C6 cycloalkyl ring; and C1-C3 alkyl optionally substituted with C1-C3 alkoxy or phenyl; wherein the Cg-Cw aryl and the 6-membered heteroaryl ring are substituted with 0 to 2 R 6 , and each R 6 is independently selected from halo, cyano, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyl; or -Z ⁇ R 5 is hydrogen;
- R 13 is hydrogen or -CH 2 -OR 14 ;
- R 14 is C(O)-R 15 or -P(O)(OR 16 ) 2 ;
- R 15 is C1-C4 alkyl or C1-C4 alkoxy; each R 16 is independently hydrogen or C1-C4 alkyl;
- R 18 is hydrogen, C1-C4 alkyl, C1-4 fluoroalkyl, or C(O)-Ci-C4 alkyl;
- Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4- to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
- Ring A is selected from Cg-Cio aryl ring; C4-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R 7 moieties, and each R 7 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n ;
- R 10 and R 11 are each independently H or C1-C4 alkyl
- Ring B is selected from Cg-Cw aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R 8 moieties, wherein each R 8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n , or B is absent; a, b, and c are independently 0 or 1 ;
- R 9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy.
- R 12 and R 12 are independently selected from hydrogen, deuterium, and fluoro. In some embodiments, R 12 and R 12 are hydrogen. In some embodiments, R 12 and R 12 are fluoro. In some embodiments, R 12 and R 12 are deuterium. In some embodiments, R 12 and R 12 together are oxo.
- Ring C is In some embodimetns, Ring C is
- X is hydrogen or halo. In some embodiments, X is hydrogen. In some embodiments, X is halo. In some embodiments, X is fluoro or chloro. In some embodiments, X is hydrogen, fluoro, or chloro.
- X is hydroxy. In some embodiments, X is cyano. In some embodiments, X is C1-C4 alkyl. In some embodiments, X is C1-C4 fluoroalkyl. In some embodiments, X is C1-C4 alkoxy. In some embodiments, X is C1-C4 fluoroalkyloxy.
- Y is C-V. In some embodiments, Y is N.
- V is hydrogen. In some embodiments, V is deuterium. In some embodiments, V is fluoro.
- R 13 is hydrogen. In some embodiments, R 13 is -CH2-OR 14 . [0121] In some embodiments, R 14 is -C(O)-R 15 . In some embodiments, R 14 is -P(O)(OR 16 )2.
- R 15 is C1-C4 alkyl. In some embodiments, R 15 is C1-C4 alkoxy.
- n is 0. In some embodiments, n is 1.
- R 3 and R 4 are independently hydrogen or CH3. In some embodiments, R 3 and R 4 are hydrogen. In some embodiments, R 3 is hydrogen and R 4 is CH3. In some embodiments, R 3 and R 4 are CH3. In some embodiments, R 3 and R 4 together with the carbon atom to which they are attached form a C3-C6 cycloalkyl. In some embodiments, R 3 and R 4 together with the carbon atom to which they are attached form cyclopropyl.
- p is 1. In some embodiments, p is 0.
- Y 1 is -O-. In some embodiments, Y 1 is -CH2-.
- Z is -O-. In some embodiments, Z is -CH2-.
- Z 1 is -O-
- R 5 is selected from Cg-Cio aryl; 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms; C3-C6 cycloalkyl ring; and C1-C3 alkyl optionally substituted with C1-C3 alkoxy or phenyl; wherein the Cg-Cio aryl and the 6-membered heteroaryl ring are substituted with 0 to 2 R 6 , and each R 6 is independently selected from halo, cyano, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyl.
- R 5 is Cg-Cio aryl, wherein the Cg-Cio aryl is substituted with 0 to 2 R 6 , and each R 6 is independently selected from halo, cyano, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4
- R 5 is 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, wherein the 6-membered heteroaryl ring is substituted with 0 to 2 R 6 , and each R 6 is independently selected from halo, cyano, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyl.
- R 5 is C3-Cg cycloalkyl ring. In some embodiments, R 5 is [0132] In some embodiments, R 5 is C1-C3 alkyl optionally substituted with C1-C3 alkoxy or phenyl. In some embodiments,
- -Z’-I is hydrogen
- Ring D is a Cg-Cio aryl ring. In some embodiments, Ring D is a Cs-Cg cycloalkyl ring. In some embodiments, Ring D is a 4- to 5 -membered heterocycloalkyl ring with 1 ring nitrogen atom. In some embodiments, Ring D is a 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms. In some embodiments, Ring D is a 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms. In some embodiments, Ring D is absent.
- Ring A is Cg-Cio aryl ring substituted with from 0 to 3 R 7 moieties. In some embodiments, Ring A is C4-Cg cycloalkyl ring substituted with from 0 to 3 R 7 moieties. In some embodiments, Ring A is Cs-Cg cycloalkenyl ring substituted with from 0 to 3 R 7 moieties. In some embodiments, Ring A is 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O, wherein Ring A is substituted with from 0 to 3 R 7 moieties.
- Ring A is 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, wherein Ring A is substituted with from 0 to 3 R 7 moieties.
- Ring A is 4- to 11- membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein Ring A is substituted with from 0 to 3 R 7 moieties.
- Ring A is a 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring
- Ring B is Cg-Cio aryl, wherein Ring B is substituted with from 0 to 3 R 8 moieties, wherein each R 8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n .
- Ring B is Cs-Cg cycloalkyl ring, wherein Ring B is substituted with from 0 to 3 R 8 moieties, wherein each R 8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n .
- Ring B is Cs-Cg cycloalkenyl ring, wherein Ring B is substituted with from 0 to 3 R 8 moieties, wherein each R 8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n .
- Ring B is 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; wherein Ring B is substituted with from 0 to 3 R 8 moieties, wherein each R 8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR 10 R n , and - C(O)NR 10 R n .
- Ring B is 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; wherein Ring B is substituted with from 0 to 3 R 8 moieties, wherein each R 8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n .
- Ring B is 4- to 11-membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein Ring B is substituted with from 0 to 3 R 8 moieties, wherein each R 8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR 10 R n , and -C(O)NR 10 R n .
- Ring B is absent.
- a is zero in L which is then represented by formula Ila:
- a and c are zero in L which is then represented by formula lib: lib where each of b, Ring A, B, and W 1 is as defined herein.
- a and c are zero and B is absent in L which is then represented by formula lie: where each of b, Ring A, W 1 is as defined herein.
- b is 1 and W 1 is O or CH2. In some embodiments, L is
- B is missing, c is zero and W 1 is CH2.
- b is 0.
- L is ,
- R 1 and R 2 are independently selected from hydrogen, Ci-Cg alkyl, L 1 - (C3-C6 cycloalkyl), and L 1 -(4- to 7-membered heterocycloalkyl), wherein said Ci-Cg alkyl, Cs-Cg cycloalkyl and 4- to 7-membered heterocycloalkyl is optionally substituted by one to four R 8 .
- R 1 and R 2 are independently selected from hydrogen and Ci-Cg alkyl.
- R 1 and R 2 taken together with the nitrogen atom to which they are attached form a 3- to 11 -membered ring optionally containing an additional heteroatom or heteroatom group selected from O, N, N(R 17 ), and S(O) m as a ring member, wherein said 3- to 11-membered ring is optionally substituted by one to four R 8 .
- this disclosure provides for a method for modulating or degrading CDK2, which method comprises contacting CDK2 with a compound of formula I’, I, IA, IB, or III, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, under conditions wherein CDK2 is modulated or degraded.
- a method to modulate or degrade CDK2 in a subject comprises administering to said subject an effective amount of a compound of formula I’, I, IA, IB, or III, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient.
- a method for treating cancer in a subject in need thereof comprises selecting a subject whose cancer is mediated at least in part by CDK2 and administering to said subject an effective amount of a compound of formula I’, I, IA, IB, or III, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient.
- protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions.
- Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and P. G. M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley, New York, 1999, and references cited therein.
- the starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof.
- many of the starting materials are available from commercial suppliers such as Sigma Aldrich (St. Louis, Missouri, USA), Bachem (Torrance, California, USA), Emka-Chemce (St. Louis, Missouri, USA).
- the synthetic realization and optimization of the bifunctional molecules as described herein may be approached in a step-wise or modular fashion.
- identification of compounds that bind to the target molecules can involve high or medium throughput screening campaigns if no suitable ligands are immediately available. It is not unusual for initial ligands to require iterative design and optimization cycles to improve suboptimal aspects as identified by data from suitable in vitro and pharmacological and/or ADMET assays. Part of the optimization/SAR campaign would be to probe positions of the ligand that are tolerant of substitution and that might be suitable places on which to attach the linker chemistry previously referred to herein. Where crystallographic or NMR structural data are available, these can be used to focus such a synthetic effort.
- the tert-butyl ester (t-Bu) protecting group is removed under conventional conditions.
- the t-Bu group is illustrative only and other conventional carboxylic acid blocking groups such as benzyl, methyl, ethyl and the like could be used.
- a stoichiometric amount of a suitably substituted amine compound, compound 5A in a diluent such as tetrahydrofuran, dioxane, DMF and the like typically in the presence of a suitable base such as diisopropylethylamine, pyridine, triethylamine and the like.
- a suitable base such as diisopropylethylamine, pyridine, triethylamine and the like.
- the reaction is typically maintained at from about 20 °C to about 60 °C until it is substantially complete.
- Conventional workup of the reaction solution can be followed by isolation/purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 6A.
- the pyrazole nitrogen of compound 6A is protected with ethyl formate group.
- At least a stoichiometric amount of ethyl carbonochloridate, 7A is combined with compound 6A in an inert diluent such as dichloromethane, dichloroethane, THF, and the like.
- the reaction is typically maintained at from about 20 °C to about 50 °C until it is substantially complete.
- Conventional workup of the reaction solution can be followed by isolation/purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 8 A.
- the ethyl formate group is illustrative only and other conventional amino blocking groups such as benzyl, t-butoxycarbonyl (Boc), 9-fluorenylmethoxycarbonyl (Fmoc), benzyloxycarbonyl (Cbz) and the like could be used.
- the benzyloxycarbonyl (Cbz) protecting group is removed by conventional conditions to provide for compound 9A.
- the Cbz group is illustrative only and other conventional amino blocking groups such as benzyl, 9-fluorenylmethoxycarbonyl (Fmoc), benzyloxycarbonyl (Cbz), p-nitrobenzyloxy carbonyl and the like.
- conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 9A.
- a conventional Buchwald-Hartwig amination reaction wherein at least a stoichiometric equivalent of a mono-protected diamine, compound 11A, is combined with compound 10A, in an inert diluent such as DMF, dioxane, toluene, and the like, typically in the presence of a palladium catalyst (e.g, Pd(dba)2, Pd2(dba)3, PdC12[P(o-tolyl)3]2) and a suitable base such as sodium tert-butoxide, LiHMDS, cesium carbonate, and the like.
- a palladium catalyst e.g, Pd(dba)2, Pd2(dba)3, PdC12[P(o-tolyl)3]2
- a suitable base such as sodium tert-butoxide, LiHMDS, cesium carbonate, and the like.
- the reaction is typically maintained at from 80° to 120°C for a period of time sufficient for substantial completion of the reaction as evidenced by e.g., thin layer chromatography.
- Conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 12A.
- the methyl ester protecting group is removed under conventional basic hydrolytic conditions to provide for compound 13 A.
- the methyl ester group is illustrative only and other conventional carboxylic acid protecting groups such as benzyl, ethyl, tert-butyl and the like can be used.
- conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 13 A.
- the t-butoxycarbonyl (t-BOC) protecting group is removed by conventional conditions.
- the t-BOC group is illustrative only and other conventional amino blocking groups such as benzyl, 9-fluorenylmethoxycarbonyl (Fmoc), benzyloxycarbonyl (Cbz), p-nitrobenzyloxycarbonyl and the like.
- conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 17A.
- the reaction is typically conducted in an inert solvent such as DME, THF, DMF, and the like under a blue LED.
- the reaction is typically maintained at from 20°C to 60°C until it is substantially complete.
- Conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography, and the like to provide for compound 20A.
- the trimethylsilylethoxymethy (SEM) and t-butoxycarbonyl (t-BOC) protecting group are removed by conventional conditions.
- SEM and t-BOC group are illustrative only and other conventional amino blocking groups such as benzyl, 9-fluorenyhnethoxycarbonyl (Fmoc), benzyloxycarbonyl (Cbz), p-nitrobenzyloxycarbonyl and the like could be used.
- conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 21 A.
- the reaction is typically conducted in an inert solvent such as DME, THF, DMF, and the like under a blue LED.
- the reaction is typically maintained at from 20°C to 60°C until it is substantially complete.
- Conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography, and the like to provide for compound 23A.
- the trimethylsilylethoxymethy (SEM) protecting group is removed by conventional conditions.
- SEM group are illustrative only and other conventional amino blocking groups such as benzyl, 9-fluorenylmethoxycarbonyl (Fmoc), benzyloxycarbonyl (Cbz), p- nitrobenzyloxycarbonyl and the like could be used.
- conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 24 A.
- the reaction is typically conducted at from about 0° to about 30° C for a period of time sufficient for substantial completion of the reaction as evidenced by e.g., thin layer chromatography.
- conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 25A.
- the ethyl formate and N- protecting groups are removed by conventional conditions, such as basic hydrolytic or acidic conditions to provide for compound 26A.
- the ethyl formate group is illustrative only and other conventional N-pyrazole protecting groups such as benzyl, tert-butyl and the like can be used.
- conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPEC), and the like to provide for compound 26A.
- the reaction is typically conducted at from about 0° to about 30° C for a period of time sufficient for substantial completion of the reaction as evidenced by e.g., thin layer chromatography.
- conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 28 A.
- protecting group strategies and/or functional group interconversions may be required to facilitate the preparation of the desired materials.
- Such chemical processes are well known to the synthetic organic chemist and many of these may be found in texts such as "Greene's Protective Groups in Organic Synthesis” Peter G. M. Wuts and Theodora W. Greene (Wiley), and “Organic Synthesis: The Disconnection Approach” Stuart Warren and Paul Wyatt (Wiley).
- reaction in Scheme 8 at least a stoichiometric amount of a suitable amine, compound 26A is combined with compound 24A under conventional reductive amination reaction conditions well known in the art including the use of NaCNBtU. NaBH(OAc)3, NaBH 4 and the like.
- the reaction is typically conducted in an inert solvent such as MeCN, MeOH, THF, and the like.
- the reaction is typically conducted at from about 0 °C to about 30 °C for a period of time sufficient for substantial completion of the reaction as evidenced by e.g., thin layer chromatography.
- conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like are optionally used to provide a compound of formula I.
- reaction in Scheme 9 at least a stoichiometric amount of a suitable amine, compound 28A is combined with compound 21A under conventional reductive amination reaction conditions well known in the art including the use of NaCNBHs. NaBH(OAc)3, NaBPh and the like.
- the reaction is typically conducted in an inert solvent such as MeCN, MeOH, THF, and the like.
- the reaction is typically conducted at from about 0 °C to about 30 °C for a period of time sufficient for substantial completion of the reaction as evidenced by e.g., thin layer chromatography.
- conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like are optionally used to provide a compound of formula I.
- reaction in Scheme 10 at least a stoichiometric amount of a suitable amine, compound 28A is combined with compound 17A under conventional reductive amination reaction conditions well known in the art including the use of NaCNBHs. NaBH(OAc)3, NaBtE and the like.
- the reaction is typically conducted in an inert solvent such as MeCN, MeOH, THF, and the like.
- the reaction is typically conducted at from about 0 °C to about 30 °C for a period of time sufficient for substantial completion of the reaction as evidenced by e.g., thin layer chromatography.
- conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like are optionally used to provide a compound of formula I.
- the compounds and compositions described herein are useful in methods for treating a CDK2 dependent disease or disorder or a disease or disorder that is mediated, at least in part, by CDK2.
- the CDK2 dependent disease or disorder is a disease characterized by amplification or overexpression of cyclin El (CCNE1) or cyclin E2 (CCNE2) or both CCNE1 and CCNE2.
- the methods comprise administering to a subject suffering from a CDK2 dependent disease or disorder an effective amount of a compound as described herein, e.g., a compound of formula F, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient.
- a compound as described herein e.g., a compound of formula F, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient.
- a compound as described herein e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient, for use in treating a CDK2 dependent disease or disorder or a disease or disorder that is mediated, at least in part, by CDK2, or is a disease characterized by amplification or overexpression of cyclin El (CCNE1) or cyclin E2 (CCNE2) or both CCNE1 and CCNE2.
- CCNE1 cyclin El
- CCNE2 cyclin E2
- a compound as described herein e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient for use in treating an CDK2 dependent disease or disorder.
- a compound as described herein e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, in the preparation of a medicament for treating a CDK2 dependent disease or disorder or a disease or disorder that is mediated, at least in part, by CDK2, or is a disease characterized by amplification or overexpression of cyclin El (CCNE1) or cyclin E2 (CCNE2) or both CCNE1 and CCNE2.
- CCNE1 cyclin El
- CCNE2 cyclin E2
- the method relates to a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient, for use in manufacture of a medicament for reducing CDK2 protein levels where reduction of such protein levels treats or ameliorates the disease or disorder.
- a compound as described herein e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient, for use in manufacture of a medicament for reducing CDK2 protein levels where reduction of such protein levels treats or ameliorates the disease or disorder.
- the methods described herein comprise use of a prodrug of a compound as described herein.
- the method relates a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient wherein the CDK2 degradation at 1 pM concentration of the compound as described herein is in the range of about 25%-99%.
- the CDK2 degradation is measured by the assay described in the biological example. In some embodiments, the CDK2 degradation is from about 25% to about 50%, from about 45% to about 70%, from about 65% to about 90% or from about 75% to about 99%.
- the CDK2 degradation is from about 25% to about 35%, from about 35% to about 45%, from about 45% to about 55%, from about 55% to about 65%, from about 65% to about 75%, from about 75% to about 85%, from about 85% to about 99%. In some embodiments, the CDK2 degradation is more than 60%. In some embodiments, the CDK2 degradation is more than 70%. In some embodiments, the CDK2 degradation is more than 80%. In some embodiments, the CDK2 degradation is more than 90%.
- CDK2 dependent diseases or disorders such as cancers including, but not limited to, liposarcoma, glioblastoma, bladder cancer, adrenocortical cancer, multiple myeloma, colorectal cancer, non-small cell lung cancer, Human Papilloma Virus-associated cervical, oropharyngeal, penis, anal, thyroid, or vaginal cancer or Epstein- Barr Virus-associated nasopharyngeal carcinoma, gastric cancer, rectal cancer, thyroid cancer, Hodgkin’s lymphoma, or non-Hodgkin’s lymphoma (e.g., diffuse large B-cell lymphoma).
- cancers including, but not limited to, liposarcoma, glioblastoma, bladder cancer, adrenocortical cancer, multiple myeloma, colorectal cancer, non-small cell lung cancer, Human Papilloma Virus-associated cervical, oropharyngeal, penis,
- the cancer may be selected from prostate cancer, breast carcinoma, lymphomas, leukemia, myeloma, bladder carcinoma, colon cancer, cutaneous melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, renal cancer, glioblastoma multiform, glioma, thyroid cancer, parathyroid tumor, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, cholangiocarcinoma, gastric cancer, soft tissue sarcomas, rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid cancers, cancer for which the immune response is deficient, an immunogenic cancer, and Ewing’s sarcoma.
- the CDK2 -dependent disease or disorder is a disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triplenegative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, and gastrointestinal stromal tumor (GIST).
- NSCLC non-small cell lung cancer
- TNBC triplenegative breast cancer
- NPC nasopharyngeal cancer
- mssCRC microsatellite stable colorectal cancer
- thymoma thymoma
- carcinoid gastrointestinal stromal tumor
- the cancer is selected from non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myelogenous leukemia, and gastrointestinal stromal tumor (GIST).
- the CDK2 -dependent disease or disorder is a disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple- negative breast cancer (TNBC), nasopharyngeal cancer (NPC), and microsatellite stable colorectal cancer (mssCRC).
- compounds or compositions described herein are active against solid tumors.
- the compounds of the disclosure can be administered in effective amounts to treat or prevent or reduce the risks of developing a disease or disorder as discussed herein and/or to prevent or reduce the rate of the development or progression thereof in a subject.
- methods of using the compounds of the present application comprise administering to a subject in need thereof a therapeutically effective amount of a compound as described herein.
- compounds as described herein are useful in the treatment of proliferative disorders (e.g., cancer, benign neoplasms, inflammatory disease, and autoimmune diseases).
- proliferative disorders e.g., cancer, benign neoplasms, inflammatory disease, and autoimmune diseases.
- levels of cell proteins of interest e.g., pathogenic and oncogenic proteins are modulated, or their growth is inhibited or the proteins are degraded by contacting said cells with an compound or composition, as described herein.
- the compounds are useful in treating cancer.
- methods for the treatment of cancer comprising administering a therapeutically effective amount of a compound or composition, as described herein, to a subject in need thereof.
- a method for the treatment of cancer comprising administering a therapeutically effective amount of a compound, or a pharmaceutical composition comprising a compound as described herein to a subject in need thereof, in such amounts and for such time as is necessary to achieve the desired result.
- the compounds of present application are administered orally or intravenously.
- a “therapeutically effective amount” of the compound or pharmaceutical composition is that amount effective for killing or inhibiting the growth of tumor cells.
- the compounds and compositions, according to the method of the present application may be administered using any amount and any route of administration effective for killing or inhibiting the growth of tumor cells.
- the expression “amount effective to kill or inhibit the growth of tumor cells,” as used herein, refers to a sufficient amount of agent to kill or inhibit the growth of tumor cells.
- the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease, the particular anticancer agent, its mode of administration, and the like.
- Another aspect of the application relates to a method of treating or lessening the severity of a disease or condition associated with a proliferation disorder in a patient, said method comprising a step of administering to said patient, a compound described herein (e.g., compound of formula I’, formula I, or formula III) or a composition comprising said compound.
- a compound described herein e.g., compound of formula I’, formula I, or formula III
- a composition comprising said compound.
- the compounds and compositions, according to the method of the present application may be administered using any amount and any route of administration effective for the treatment of cancer and/or disorders associated with cell hyperproliferation.
- the expression “effective amount” as used herein refers to a sufficient amount of agent to inhibit proliferation, or refers to a sufficient amount to reduce the effects of cancer.
- the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the diseases, the particular anticancer agent, its mode of administration, and the like.
- the present application also provides methods of protecting against a proliferative disorder in a subject in need thereof or the treatment of a proliferative disorder in a subject in need thereof by administering a therapeutically effective amount of compound or composition as described herein to a subject in need of such treatment.
- the proliferative disorder can be cancer or a precancerous condition.
- the present application also provides the use of compound as described herein for the preparation of a medicament useful for the prevention of a proliferative disorder.
- proliferative disorder refers to conditions in which unregulated or abnormal growth, or both, of cells can lead to the development of an unwanted condition or disease, which may or may not be cancerous.
- exemplary proliferative disorders of the application encompass a variety of conditions wherein cell division is deregulated.
- Exemplary proliferative disorder include, but are not limited to, neoplasms, benign tumors, malignant tumors, pre-cancerous conditions, in situ tumors, encapsulated tumors, metastatic tumors, liquid tumors, solid tumors, immunological tumors, hematological tumors, cancers, carcinomas, leukemias, lymphomas, sarcomas, and rapidly dividing cells.
- a proliferative disorder includes a precancer or a precancerous condition.
- a proliferative disorder includes cancer.
- the methods provided herein are used to treat or alleviate a symptom of cancer.
- cancer includes solid tumors, as well as, hematologic tumors and/or malignancies.
- precancer cell or “precancerous cell” is a cell manifesting a proliferative disorder that is a precancer or a precancerous condition.
- cancer cell or “cancerous cell” is a cell manifesting a proliferative disorder that is a cancer. Any reproducible means of measurement may be used to identify cancer cells or precancerous cells. Cancer cells or precancerous cells can be identified by histological typing or grading of a tissue sample (e.g., a biopsy sample). Cancer cells or precancerous cells can be identified through the use of appropriate molecular markers.
- non-cancerous conditions or disorders include, but are not limited to, rheumatoid arthritis; inflammation; autoimmune disease; lymphoproliferative conditions; acromegaly; rheumatoid spondylitis; osteoarthritis; gout, other arthritic conditions; sepsis; septic shock; endotoxic shock; gramnegative sepsis; toxic shock syndrome; asthma; adult respiratory distress syndrome; chronic obstructive pulmonary disease; chronic pulmonary inflammation; inflammatory bowel disease; Crohn's disease; psoriasis; eczema; ulcerative colitis; pancreatic fibrosis; hepatic fibrosis; acute and chronic renal disease; irritable bowel syndrome; pyresis; restenosis; cerebral malaria; stroke and ischemic injury; neural trauma; Alzheimer's disease; Huntington's disease; Parkinson's disease; acute and chronic pain; allergic rhinitis; allergic conjunctivitis; chronic heart
- a “proliferative disorder of the hematologic system” is a proliferative disorder involving cells of the hematologic system.
- a proliferative disorder of the hematologic system can include lymphoma, leukemia, myeloid neoplasms, mast cell neoplasms, myelodysplasia, benign monoclonal gammopathy, lymphomatoid granulomatosis, lymphomatoid papulosis, polycythemia vera, chronic myelocytic leukemia, agnogenic myeloid metaplasia, and essential thrombocythemia.
- a proliferative disorder of the hematologic system can include hyperplasia, dysplasia, and metaplasia of cells of the hematologic system.
- One skilled in the art may refer to general reference texts for detailed descriptions of known techniques discussed herein or equivalent techniques. These texts include Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (2005); Sambrook et al., Molecular Cloning, A Laboratory Manual (3rd edition), Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
- levels of cell proteins of interest e.g., pathogenic and oncogenic proteins are modulated, or their growth is inhibited by contacting said cells with an compound or composition, as described herein.
- the compounds are useful in treating cancer.
- the present application provides pharmaceutically acceptable derivatives of the compounds described herein, and methods of treating a subject using such derivative, pharmaceutical compositions thereof, or either of these in combination with one or more additional therapeutic agents.
- Other therapies or anticancer agents that may be used in combination with the compounds and compositions disclosed herein including surgery, radiotherapy, endocrine therapy, biologic response modifiers (interferons, interleukins, and tumor necrosis factor (TNF), to name a few), hyperthermia and cryotherapy, agents to attenuate any adverse effects (e.g., antiemetics), and other approved chemotherapeutic drugs, including, but not limited to, alkylating drugs (mechlorethamine, chlorambucil, Cyclophosphamide, Melphalan, Ifosfamide), antimetabolites (Methotrexate), purine antagonists and pyrimidine antagonists (6-Mercaptopurine, 5-Fluorouracil, Cytarabine, Gemcitabine), spindle poison
- a pharmaceutical composition as described herein, comprising a compound as disclosed herein further comprise one or more additional therapeutically active ingredients (e.g., a chemotherapeutic agent and/or a palliative agent).
- additional therapeutically active ingredients e.g., a chemotherapeutic agent and/or a palliative agent.
- palliative refers to treatment that is focused on the relief of symptoms of a disease and/or side effects of a therapeutic regimen, but is not considered to be curative.
- palliative treatments encompass painkillers, antinausea medications and anti-sickness drugs.
- chemotherapy, radiotherapy and surgery can all be used palliatively (that is, to reduce symptoms without going for cure; e.g., for shrinking tumors and reducing pressure, bleeding, pain and other symptoms of cancer).
- Administration of the disclosed compounds and pharmaceutical compositions can be accomplished via any mode of administration for therapeutic agents. These modes include systemic or local administration such as oral, nasal, parenteral, transdermal, subcutaneous, vaginal, buccal, rectal or topical administration modes.
- compositions comprising a compound of Formula I’, Formula I, or Formula III, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier may further include an excipient, diluent, or surfactant.
- compositions can be in solid, semi-solid or liquid dosage form, such as, for example, injectables, tablets, suppositories, pills, timerelease capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices.
- injectables tablets, suppositories, pills, timerelease capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices.
- they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, and all using forms well known to those skilled in the pharmaceutical arts.
- compositions for oral administration include tablets and gelatin capsules comprising a compound of the disclosure and a pharmaceutically acceptable carrier, such as a) a diluent, e.g., purified water, triglyceride oils, such as hydrogenated or partially hydrogenated vegetable oil, or mixtures thereof, com oil, olive oil, sunflower oil, safflower oil, fish oils, such as EPA or DHA, or their esters or triglycerides or mixtures thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and/or glycine; b) a lubricant, e.g., silica, talcum, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and/or polyethylene glycol, stearic acid,
- Illustrative liquid pharmaceutical compositions such as injectable compositions can, for example, be prepared by dissolution, dispersion, etc.
- a compound as described herein can be dissolved in or mixed with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form an injectable isotonic solution or suspension.
- a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like
- Proteins such as albumin, chylomicron particles, or serum proteins can be used to solubilize the disclosed compounds.
- Parental injectable administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions.
- Injectable s can be prepared in conventional forms, either as liquid solutions or suspensions or solid forms suitable for dissolving in liquid prior to injection.
- the disclosed compounds can be formulated as a suppository that can be prepared from fatty emulsions or suspensions; using polyalkylene glycols such as propylene glycol, as the carrier.
- the disclosed compounds can be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
- Liposomes can be formed from a variety of phospholipids, containing cholesterol, stearylamine or phosphatidylcholines.
- a fdm of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, as described in U.S. Pat. No. 5,262,564, which is hereby incorporated by reference in its entirety.
- Disclosed compounds can be delivered by the use of monoclonal antibodies as individual carriers to which the disclosed compounds are coupled.
- the disclosed compounds can also be coupled with soluble polymers as targetable drug carriers.
- Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspanamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues.
- the disclosed compounds can be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, poly orthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and cross-linked or amphipathic block copolymers of hydrogels.
- a polymer e.g., a poly carboxy lie acid polymer, or a polyacrylate.
- the disclosure provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of the present disclosure.
- the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
- a container, divided bottle, or divided foil packet An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
- the kit of the disclosure may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
- the kit of the disclosure typically comprises directions for administration.
- compositions of this disclosure can include one or more physiologically acceptable inactive ingredients that facilitate processing of active molecules into preparations for pharmaceutical use.
- compositions are comprised of, in general, a compound of this disclosure in combination with at least one pharmaceutically acceptable excipient.
- Acceptable excipients are nontoxic, aid administration, and do not adversely affect the therapeutic benefit of the claimed compounds.
- excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
- Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like.
- Liquid and semi-solid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.
- liquid carriers, particularly for injectable solutions include water, saline, aqueous dextrose, and glycols.
- Compressed gases may be used to disperse a compound of this disclosure in an aerosol form.
- Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.
- Other suitable pharmaceutical excipients and their formulations are described in Remington’s Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990).
- compositions of this disclosure may, if desired, be presented in a pack or dispenser device containing one or more unit dosage forms containing the active ingredient.
- a pack or device may, for example, comprise metal or plastic foil, such as a blister pack, or glass, and rubber stoppers such as in vials.
- the pack or dispenser device may be accompanied by instructions for administration.
- Compositions comprising a compound of this disclosure that can be formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
- the amount of the compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound of this disclosure based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. In one embodiment, the compound is present at a level of about 1-80 wt %. Representative pharmaceutical formulations are described below. Formulation Examples
- Ingredient capsule mg compound of this disclosure 200 lactose, spray-dried 148 magnesium stearate 2
- Ingredient Amount compound of this disclosure 1.0 g fumaric acid 0.5 g sodium chloride 2.0 g methyl paraben 0.15 g propyl paraben 0.05 g granulated sugar 25.0 g sorbitol (70% solution) 13.00 g
- a suppository of total weight 2.5 g is prepared by mixing the compound of this disclosure with Witepsol® H-15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition:
- the dosage regimen utilizing the disclosed compound is selected in accordance with a variety of factors including type, species, age, weight, sex, and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the patient; and the particular disclosed compound employed.
- a physician or veterinarian can determine and prescribe an effective amount of a compound as described herein to treat or prevent the disease or disorder presented.
- Effective dosage amounts of the disclosed compounds when used for the indicated effects, range from about 0.5 mg to about 5000 mg of the disclosed compound as needed to treat the condition.
- Compositions for in vivo or in vitro use can contain about 0.5, 5, 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, or 5000 mg of the disclosed compound, or, in a range of from one amount to another amount in the list of doses.
- the compositions are in the form of a tablet that can be scored.
- the resulting solution was stirred for 12 hours at 50°C.
- the mixture was quenched with water (0.1 mL).
- the mixture was purified by pre-HPLC [Phenomenex Luna Cis 100 mm x 40 mm x 3 pm; 25 to 55% 1% formic acid in water in ACN] and lyophilized to give 2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-l,3- dioxoisoindolin-5-yl)piperazin-l-yl)methyl)phenyl)acetic acid.
- reaction mixture was diluted with H2O (20 mL) and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with brine (3 x 10 mL), dried over Na2SC>4, fdtered and concentrated under reduced pressure to give tert-butyl 2-(4-(4-(2- (2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazine-l-carbonyl)phenyl)acetate which was used in next step directly without purification.
- reaction was purified by prep-HPLC (column: Welch Xtimate Cis 180 mm x 70 mm x 10 pm; mobile phase: [H2O (+0.01%TFA)-ACN]; gradient: 35 %-65% B over 20.0 min) and lyophilized to give 4-( 1 -(2-(2,6-dioxopiperidin-3-yl)- 1 ,3 -dioxoisoindolin-5 -yl)piperidin-4-yl)-3 -fluorobenzoic acid.
- the compounds disclosed herein preferably contain (lR,3S)-cyclopentyl or (lR,3S)-cyclopentyl; such preferred compounds would exclude compounds in Table 1 lacking (1R,3S)- cyclopentyl or (lR,3S)-cyclopentyl.
- HEK-293T cells were harvested ca. 75% confluent with trypsin and plated (500,000 cells/well) in a 6-well tissue culture plate in 2 m of Dulbecco’s Modified Eagle Medium (DMEM) + 10% Fetal Bovine Serum (FBS) and incubated overnight at 37 °C.
- DMEM Modified Eagle Medium
- FBS Fetal Bovine Serum
- the NanoLuc-CRBN fusion vector contains the coding region of human E3 ligase component cereblon (CRBN) fused to the C-terminus of the NanoLuc luciferase coding region.
- CRBN human E3 ligase component cereblon
- a mixture of 10 ng Nluc-CRBN and 990 ng DDB1 Expression Vector was added to 125 pL Opti-Minimum Essential Medium (Opti-MEMTM; Thermo Fisher) along with 2 pL P3000 reagent (Thermo Fisher) in a 1.5 mb epppendorf tube.
- This solution was added to Lipofectamine 3000 transfection reagent (5 pL; Thermo Fisher) in Opti-MEM (125 pL), mixed well, and incubated for 15 minutes at room temperature. The transfection mixture was added dropwise to cells and incubated overnight at 37 °C, 5% CO2. Following transfection, cells were washed once with PBS, and trypsin (250 pL) was added and incubated 30-45 sec to dislodge cells. Complete media (2 mL) was added to resuspend cells to form a single cell suspension.
- Opti-MEM 3 mL; wash step repeated x2). After final resuspension in 5 mL Opti-MEM, cells were counted and resuspended at 200,000 cells/mL in Opti-MEM.
- Cereblon target engagement was monitored by Bioluminescence Resonance Energy Transfer (BRET) in transfected HEK-293T cells using the NanoBRET TE Intracellular E3 Ligase Assay (Promega). Briefly, 384-well plates (white opaque plates, Coming 3574, low binding surface) were seeded with transfected HEK-293T cells (38 pL/well). 2 pL of 10 pM CRBN tracer (diluted 1:5 in Tracer Dilution Buffer) was added to each well. Plates were centrifuged at 320x g for 1 min at room temperature.
- BRET Bioluminescence Resonance Energy Transfer
- Test compounds were added in a 11 -point dilution series (typically 10 pM to 100 pM) using a TECAN D300e Digital Dispenser. Plates were shaken for 2 minutes on a microplate shaker to mix compounds. Plates were centrifuged at 320x g for 1 min at room temperature, and subsequently incubated for 2 hours at 37 °C.
- HiBiT- CDK2 HEK293T cells were harvested ca. 75% confluent with trypsin and plated (500,000 cells/well) in a 6-well tissue culture plate in 2 mL of Dulbecco’s Modified Eagle Medium (DMEM) + 10% Fetal Bovine Serum (FBS) and incubated overnight at 37 °C.
- DMEM Modified Eagle Medium
- FBS Fetal Bovine Serum
- CDK2 degradation assays were carried out by harvesting the HiBiT- CDK2 HEK293T reporter ceil lines and resuspending the cells in media formulated for reduced background fluorescence.
- the respective cell lines were seeded at a density of 4,000 cells/well into 384 well white opaque TC plates (Greiner 781080-20). The cells were incubated overnight to allow for attachment to the assayplate (37°C with humidified air and 5% CO2 for all incubations). Dilutions of the compounds were prepared in dimethyl sulfoxide (DMSO) from 10 mM compound stock solutions in DMSO.
- DMSO dimethyl sulfoxide
- the assayplates were treated with appropriate concentrations of the compounds by dispensing the DMSO dilutions in quadruplicate wells with an upper limit of 0.5% final DMSO. After a 6-hour incubation with the compounds.
- HiBiT lytic buffer, 1: 100 LgBiT and 1:50 HiBiT were added at 30pl/welI, and plates were incubated at room temperature for 2 hours covered with foil. Images were acquired using the ClarioStar plate reader system (cells maintained at 37 °C during imaging). Cell Reporter Xpress software was utilized to segment cells and determine fluorescence intensities, which were used to construct dose-response curves and calculation of degradation DC50S (GraphPad Prism). The percent degradation amounts were calculated visually from the curves generated at a concentration of 1 and 10 micromolar.
- HEK-293T cells were harvested ca. 75% confluent with trypsin and plated (500,000 cells/well) in a 6-well tissue culture plate in 2 mL of Dulbecco’s Modified Eagle Medium (DMEM) + 10% Fetal Bovine Serum (FBS) and incubated overnight at 37 °C.
- DMEM Modified Eagle Medium
- FBS Fetal Bovine Serum
- CDK2 target engagement was monitored by Bioluminescence Resonance Energy Transfer (BRET) in transfected HEK-293T cells using the NanoBRET Assay. Briefly, 384-well plates (white opaque plates, Coming 3574, low binding surface) were seeded with transfected HEK-293T cells (38 pL/well). 2 pL of 10 pM K-10 tracer (diluted 1:5 in Tracer Dilution Buffer) was added to each well. Plates were centrifuged at 320x g for 1 min at room temperature. Test compounds were added in a 10- point dilution series (typically 10 pMto 100 pM) using a TECAN D300e Digital Dispenser. Plates were shaken for 20 secondss on a microplate shaker to mix compounds. Plates were centrifuged at 320x g for 1 min at room temperature, and subsequently incubated for 2 hours at 37 °C.
- BRET Bioluminescence Resonance Energy Transfer
- Table 5 and Table 6 show results from the assays described above.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This disclosure provides compounds and pharmaceutically acceptable salts thereof that are useful as modulators of targeted ubiquitination. The compounds disclosed herein bind to and degrade one or more cyclin dependent kinases 2 (CDK2).
Description
COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE CDK2
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S. Provisional Application 63/349,523, filed June 6, 2022, the contents of which are incorporated by reference herein in their entirety.
FIELD
[0002] This disclosure provides compounds and pharmaceutically acceptable salts thereof that are useful as modulators of targeted ubiquitination. The compounds disclosed herein bind to and/or degrade one or more cyclin dependent kinases (CDKs) and, accordingly, are useful in treating abnormal cell growth such as cancer. Also disclosed are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts thereof, and methods of using such compounds and their salts in the treatment of various CDK-mediated diseases or disorders.
STATE OF THE ART
[0003] Cyclin-Dependent Kinases and related serine/threonine protein kinases are important cellular enzymes that perform essential features in regulating cell division and proliferation. CDKs 1-4, 6, 10, and 11 have been reported to play a direct role in cell cycle progression whereas CDKs 3,5, and 7-9 may play an indirect role (e.g., through activation of other CDKs, regulation of transcription or neuronal functions).
[0004] Overexpression of CDK2 is associated with abnormal regulation of the cell -cycle. Cyclin E, the regulatory cyclin for CDK2, is frequently overexpressed in cancer. Such overexpression has been associated with poor outcomes in breast cancer including triple negative breast cancer.
[0005] Ubiquitin-Proteasome Pathway (UPP) is a critical pathway that regulates key regulator proteins and degrades misfolded or abnormal proteins. UPP is central to multiple cellular processes, and if defective or imbalanced, it leads to pathogenesis of a variety of diseases. The covalent attachment of ubiquitin to specific protein substrates is achieved through the action of E3 ubiquitin ligases.
[0006] There are over 600 E3 ubiquitin ligases which facilitate the ubiquitination of different proteins in vivo, which can be divided into four families: HECT-domain E3s, U-box E3s, monomeric RING E3s and multi-subunit E3s. See e.g., Li et al. “Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle’s dynamics and signaling.” PLOS One 2008, (3) 1487; Bemdsen et al. “New insights into ubiquitin E3 ligase mechanism” Nat. Struct. Mol. Biol. 2014, 21:301; Deshaies et al. “RING domain E3 ubiquitin ligases” Ann. Rev. Biochem. 2009, 78:399; Sprattetal. “RBRE3 ubiquitin ligases: new structures, new insights, new questions” Biochem. 2014, 458:421; and Wang et al., “Roles of F-box proteins in cancer” Nat. Rev. Cancer. 2014, 14:233.
[0007] UPP plays a key role in the degradation of short-lived and regulatory proteins important in a variety of basic cellular processes, including regulation of the cell cycle, modulation of cell surface receptors and ion channels, and antigen presentation. The pathway has been implicated in several forms of malignancy, in the pathogenesis of several genetic diseases (including cystic fibrosis, Angelman’s syndrome, and Liddle syndrome), in immune surveillance/viral pathogenesis, and in the pathology of muscle wasting. Many diseases are associated with an abnormal UPP and negatively affect cell cycle and division, the cellular response to stress and to extracellular modulators, morphogenesis of neuronal networks, modulation of cell surface receptors, ion channels, the secretory pathway, DNA repair, and biogenesis of organelles.
[0008] Aberrations in the process have recently been implicated in the pathogenesis of several diseases, both inherited and acquired. These diseases fall in to two major groups: (a) those that result from loss of function with the resultant stabilization of certain proteins, and (b) those that result from gain of function, i.e. abnormal or accelerated degradation of the protein target.
[0009] The UPP is used to induce selective protein degradation, including use of fusion proteins to artificially ubiquitinate target proteins and synthetic small-molecule probes to induce proteasome- dependent degradation. Compounds that act as molecular glues can induce or stabilize protein-protein interactions between a target protein and an E3 ubiquitin ligase ligand, leading to protein ubiquitination and subsequent proteasome-mediated degradation via the recruitment to E3 ubiquitin ligase and subsequent ubiquitination. These drug-like molecules offer the possibility of temporal control over protein expression. Such compounds are capable of inducing the inactivation of a protein of interest upon addition to cells or administration to an animal or human, and could be useful as biochemical reagents and lead to a new paradigm for the treatment of diseases by removing pathogenic or oncogenic proteins. See e.g., Crews, Chem. & Biol. 2010, 17 (6): 551; Schneekloth and Crews, Chem Bio Chem., 2005, 6 (1): 40.
[0010] There is an ongoing need for effective treatments for diseases such as hyperplasias and cancers. However, non-specific effects, and the inability to target and modulate certain classes of proteins altogether, such as transcription factors, remain as obstacles to the development of effective anti-cancer agents. As such, small molecule therapeutic agents that leverage E3 ligase mediated protein degradation to target cancer-associated proteins, such as CDK, including CDK2, hold promise as therapeutic agents. Accordingly, there remains a need for compounds that target CDKs, especially CDK2, for degradation which compounds would be useful as therapeutic agents.
SUMMARY
[0011] Disclosed are compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and methods for use of said compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which bind to and/or degrade one or more cyclin dependent kinases (CDKs). An advantage of
the compounds provided herein is that a broad range of pharmacological activities are possible, consistent with the degradation/inhibition of CDKs and modulation of targeted ubiquitination. In addition, the disclosure provides methods of using the compounds described herein for the treatment or amelioration of a disease condition, such as cancer, e.g., breast cancer, in a subject in need thereof.
[0012] In some embodiments, the disclosed compounds are represented by formula I’:
r or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein
Y is N or C-V;
V is selected from hydrogen, deuterium, and fluoro;
X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy;
R12 and R12 are independently selected from hydrogen, deuterium, and fluoro; or R12 and R12 together are oxo; n is 0 or 1; p is 0 or 1;
R3 and R4 are independently hydrogen or CH3; or R3 and R4 together with the carbon atom to which they are attached form a C3-C6 cycloalkyl;
R13 is hydrogen or -CH2-OR14;
R14 is -C(O)-R15 or -P(O)(OR16)2;
R15 is C1-C4 alkyl or C1-C4 alkoxy; each R16 is independently hydrogen or C1-C4 alkyl;
Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4- to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
Y1 is -O- or -CH2-;
Z is -O- or -CH2-;
R1 and R2 are independently selected from hydrogen, Ci-Cg alkyl, I -(C3-Cg cycloalkyl), and L1-(4- to 7-membered heterocycloalkyl), wherein said Ci-Cg alkyl, G-Cg cycloalkyl and 4- to 7- membered heterocycloalkyl is optionally substituted by one to four R8;
R1 and R2 taken together with the nitrogen atom to which they are attached form a 3- to 11- membered ring optionally containing an additional heteroatom or heteroatom group selected from O, N, N(R17), and S(O)m as a ring member, wherein said 3- to 11-membered ring is optionally substituted by one to four R8;
R17 is hydrogen, C1-C4 alkyl, or C(O)-(Ci-C4 alkyl);
R18 is hydrogen, C1-C4 alkyl, C1-C4 fluoroalkyl, or C(O)-(Ci-C4 alkyl); m is 0, 1 or 2;
L1 is a bond or a C1-C2 alkylene optionally substituted with one to four R9;
Ring A is selected from Cg-Cio aryl ring; C4-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein Ring A is substituted with from 0 to 3 R7 moieties, and each R7 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn;
R10 and R11 are each independently H or C1-C4 alkyl;
Ring B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein Ring B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn, or Ring B is absent; a, b, and c are independently 0 or 1 ;
each of W and W2, if present, is independently Ci-Ce alkylene optionally substituted with 1 to 3 R9 and W1, if present, is -C(O)-, O, S, NR18 or Ci-Ce alkylene optionally substituted with 1 to 3 R9 provided that the aggregate sum of carbon atoms in W, W1 and W2 is no more than 6; or when each of W and W2 are absent, then W1 further comprises C4-C8 heteroalkylene containing 1 to 3 oxygen atoms; and
R9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy.
I or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein
Ring C is
wherein the solid bond 1 attaches Ring C to the piperidinedione ring and the solid bond 2 attaches Ring C to L;
V is selected from hydrogen, deuterium, and fluoro;
X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy;
R12 and R12 are independently selected from hydrogen, deuterium, and fluoro; or R12 and R12 together are oxo; n is 0 or 1; p is 0 or 1;
R13 is hydrogen or -CH2-OR14;
R14 is C(O)-R15 or -P(O)(OR16)2;
R15 is C1-C4 alkyl or C1-C4 alkoxy; each R16 is independently hydrogen or C1-C4 alkyl;
Ring D is selected from G-Go aryl ring, C5-G cycloalkyl ring, 4- to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
R1 and R2 are independently selected from hydrogen, Ci-Cg alkyl, L’-G-G, cycloalkyl, and L1-4-7 membered heterocycloalkyl, wherein said Ci-Cg alkyl, -G, cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by one to four R8;
R1 and R2 taken together with the nitrogen atom to which they are attached form a 4- to 6- membered ring optionally containing an additional heteroatom selected from O, N, N(R17), and S(O)m as a ring member, wherein said 4- to 6-membered ring is optionally substituted by one to four R8;
R17 is hydrogen, Ci-G alkyl, or C(O)-Ci-C4 alkyl;
R18 is hydrogen, Ci-G alkyl, C1-4 fluoroalkyl, or C(O)-Ci-C4 alkyl; m is 0, 1 or 2;
L1 is a bond or a G-G alkylene optionally substituted with one to four R9;
Ring A is selected from Cg-Go aryl ring; G-G cycloalkyl ring; G-G cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R7 moieties, and each R7 is independently selected from halo, hydroxy, cyano, G-G alkyl, G-G fluoroalkyl, G-G alkoxy, G-G fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn;
R10 and R11 are each independently H or G-G alkyl;
Ring B is selected from G-Go aryl; G-G cycloalkyl ring; G-G cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, G-G alkyl, G-G fluoroalkyl, G-G alkoxy, G-G fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn, or B is absent; a, b, and c are independently 0 or 1 ; each of W and W2, if present, is independently G-G alkylene optionally substituted with 1 to 3 R9 and W1, if present, is O, S, NR18 or G-G alkylene optionally substituted with 1 to 3 R9 provided that the aggregate sum of carbon atoms in W, W1 and W2 is no more than 6; or when each of W and W2 are absent, then W1 further comprises G-G heteroalkylene containing 1 to 3 oxygen atoms; and
R9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy.
[0014] In some embodiments, the disclosed compounds are represented by formula IA:
or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein
Ring
wherein the solid bond 1 attaches Ring C to the piperidinedione ring and the solid bond 2 attaches Ring C to L;
V is hydrogen;
X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy;
R12 and R12 are hydrogen, or R12 and R12 together are oxo; n is 0 or 1; p is 0 or 1;
R13 is hydrogen;
Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4 to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6 to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 5-10 membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
Z is -O- or -CH2-;
R1 and R2 are independently selected from hydrogen, Ci-Cg alkyl, L1-(C3-Cg cycloalkyl), and L1-(4- to 7-membered heterocycloalkyl), wherein said Ci-Cg alkyl, C’s-Cg cycloalkyl and 4- to 7- membered heterocycloalkyl is optionally substituted by one to four R8;
R1 and R2 taken together with the nitrogen atom to which they are attached form a 3- to 11- membered ring optionally containing an additional heteroatom or heteroatom group selected from O, N(R17), and S(O)m as a ring member, wherein said 3- to 6-membered ring is optionally substituted by one to four R8;
R17 is hydrogen, C1-C4 alkyl, or C(O)-Ci-C4 alkyl;
R18 is hydrogen, C1-C4 alkyl, C1-4 fluoroalkyl, or C(O)-Ci-C4 alkyl; m is 0, 1 or 2;
L1 is a bond or a C1-C2 alkylene optionally substituted with one to four R9;
Ring A is selected from Cg-Cio aryl ring; C4-C6 cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to
10-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R7 moieties, and each R7 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn;
R10 and R11 are each independently H or C1-C4 alkyl;
B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to
11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn, or B is absent; b and c are independently 0 or 1 ;
W2, if present, is Ci-Cg alkylene optionally substituted with 1 to 3 R9 and W1, if present, is -C(O)-, O, S, NR18 or Ci-Cg alkylene optionally substituted with 1 to 3 R9 provided that the aggregate sum of carbon atoms in W1 and W2 is no more than 4; and
R9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy; or when W is absent then W1 is C4-C8 heteroalkylene containing 1 to 3 oxygen atoms.
IB or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein
Ring
wherein the solid bond 1 attaches Ring C to the piperidinedione ring and the solid bond 2 attaches Ring C to L;
V is hydrogen;
X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy;
R12 and R12 are hydrogen, or R12 and R12 together are oxo; n is 0 or 1; p is 0 or 1;
R13 is hydrogen;
Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4- to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 5-10 membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
Z is -O- or -CH2-;
R1 and R2 are independently selected from hydrogen, Ci-Cg alkyl, L'-G-Cg cycloalkyl, and L1-4-7 membered heterocycloalkyl, wherein said Ci-Cg alkyl, C -Cg cycloalkyl and 4- to 7-membered heterocycloalkyl is optionally substituted by one to four R8;
R1 and R2 taken together with the nitrogen atom to which they are attached form a 3- to 11- membered ring optionally containing an additional heteroatom or heteroatom group selected from O, N(R17), and S(O)m as a ring member, wherein said 3- to 6-membered ring is optionally substituted by one to four R8;
R17 is hydrogen, C1-C4 alkyl, or C(O)-Ci-C4 alkyl;
R18 is hydrogen, C1-C4 alkyl, C1-C4 fluoroalkyl, or C(O)-Ci-C4 alkyl; m is 0, 1 or 2;
L1 is a bond or a C1-C2 alkylene optionally substituted with one to four R9;
L is represented by the formula:
wherein:
Ring A is selected from Cg-Cio aryl ring; C4-C6 cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to
10-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R7 moieties, and each R7 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn;
R10 and R11 are each independently H or C1-C4 alkyl;
B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to
11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn, or B is absent; b and c are independently 0 or 1 ;
W2, if present, is Ci-Cg alkylene optionally substituted with 1 to 3 R9 and W1, if present, is -C(O)-, O, S, NR18 or Ci-Cg alkylene optionally substituted with 1 to 3 R9 provided that the aggregate sum of carbon atoms in W1 and W2 is no more than 4;
R9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy; and when W2 is absent then W1 further comprises C4-C8 heteroalkylene containing 1 to 3 oxygen atoms.
[0016] In some embodiments, the disclosed compounds are represented by formula III:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein
Y is N or C-V;
V is selected from hydrogen, deuterium, and fluoro;
X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and Cwfluoroalkyloxy;
R12 and R12 are independently selected from hydrogen, deuterium, and fluoro; or R12 and R12 together are oxo; n is 0 or 1; p is 0 or 1;
R3 and R4 are independently hydrogen, halo, or CH3; or R3 and R4 together with the carbon atom to which they are attached form a C3-C6 cycloalkyl;
Y1 is -O- or -CH2-;
Z1 is -O-, and R5 is selected from Cg-Cio aryl; 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms; C3-C6 cycloalkyl ring; and C1-C3 alkyl optionally substituted with C1-C3 alkoxy or phenyl; wherein the Cg-Cio aryl and the 6-membered heteroaryl ring are substituted with 0 to 2 R6, and each R6 is independently selected from halo, cyano, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyl; or -Z’-IV is hydrogen;
R13 is hydrogen or -CH2-OR14;
R14 is C(O)-R15 or -P(O)(OR16)2;
R15 is C1-C4 alkyl or C1-C4 alkoxy; each R16 is independently hydrogen or C1-C4 alkyl;
Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4- to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
R18 is hydrogen, C1-C4 alkyl, C1-C4 fluoroalkyl, or C(O)-Ci-C4 alkyl;
L is represented by the formula:
wherein:
Ring A is selected from Cg-Cio aryl ring; C4-C6 cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R7 moieties, and each R7 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn;
R10 and R11 are each independently H or C1-C4 alkyl;
Ring B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn, or B is absent; a, b, and c are independently 0 or 1 ; each of W and W2, if present, is independently Ci-Cg alkylene optionally substituted with 1 to 3 R9 and W1, if present, is -C(O)-, O, S, NR18 or Ci-Cg alkylene optionally substituted with 1 to 3 R9 provided that the aggregate sum of carbon atoms in W, W1 and W2 is no more than 6; or when each of W and W2 are absent, then W1 further comprises C4-C8 heteroalkylene containing 1 to 3 oxygen atoms; and
R9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy.
some embodiments, X is hydrogen or halo. In some embodiments, X is fluoro.
[0018] In some embodiments, Ring D is a Cg-Cio aryl ring. In some embodiments, Ring D is a Cs-Cg cycloalkyl ring. In some embodiments, Ring D is a 6 to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms. In some embodiments, Ring D is a 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms. In some embodiments, Ring D is absent. In some embodiments, Ring D is absent,
[0020] In some embodiments, a is zero in L, and the compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is represented by formula Ila:
[0021] In some embodiments, a and c are zero in L, and the compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is represented by formula lib:
[0022] In some embodiments, B is a 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, -NR10Rn, and -C(O)NR10Rn
[0026] In some embodiments, L is
[0027] In some embodiments, a and c are zero and B is absent in L, and the compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is represented by formula lie:
[0032] In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, p is 1.
[0033] In some embodiments, R1 and R2 are independently selected from hydrogen and Ci-Cg alkyl.
In some embodiments, R1 and R2 taken together with the nitrogen atom to which they are attached form a 3 - to 11 -membered ring optionally containing an additional heteroatom or heteroatom group selected from O, N, N(R17), and S(O)m as a ring member, wherein said 4- to 6-membered ring is optionally
[0034] In some embodiments, Z is -O-. In some embodiments, Z is -CH2-. In some embodiments, Y is C-V. In some embodiments, V is hydrogen. In some embodiments, Y is N. In some embodiments, Y1 is -CH2-.
[0036] In some embodiments, the compound is selected from Table 1 or Table 2, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0037] In some embodiments, the compounds as described herein modulate CDK2. In some embodiments, the compounds as described herein bind to CDK2. In some embodiments, the compounds as described herein degrade CDK2.
[0038] In some embodiments, this disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof. In some embodiments, the pharmaceutical composition comprises an effective amount of the compound, such as an amount effective for modulating or degrading CDK2.
[0039] In some embodiments, this disclosure provides a method for modulating or degrading CDK2, which method comprises contacting CDK2 with a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, under conditions wherein CDK2 is bound to said compound and modulated or degraded.
[0040] In some embodiments, this disclosure provides a method for modulating or degrading CDK2 in a subject, which method comprises administering to said subject a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient, under conditions wherein said CDK2 is bound to said compound and modulated or degraded.
[0041] In some embodiments, this disclosure provides a method for treating a CDK2 dependent disease or disorder, or a disease or disorder that is mediated, at least in part by, CDK2, or a disease characterized by amplification or overexpression of cyclin El (CCNE1) or cyclin E2 (CCNE2) or both CCNE1 and CCNE2, in a subject in need thereof, which method comprises administering to said subject an effective amount of a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient.
[0042] In some embodiments, this disclosure provides a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, for use in treating a CDK2 dependent disease or disorder, or a disease or disorder that is mediated, at least in part by, CDK2, or is a disease characterized by amplification or overexpression of cyclin El (CCNE1) or cyclin E2 (CCNE2) or both CCNE1 and CCNE2.
[0043] In some embodiments, this disclosure provides a use of a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, in the preparation of a medicament for treating a CDK2 dependent disease or disorder, or a disease or disorder that is mediated, at least in part by, CDK2, or is a disease characterized by amplification or overexpression of cyclin El (CCNE1) or cyclin E2 (CCNE2) or both CCNE1 and CCNE2.
[0044] In some embodiments, the CDK2 dependent disease or disorder or the disease or disorder that is mediated, at least in part by, CDK2 is one or more selected from liposarcoma, glioblastoma, bladder cancer, adrenocortical cancer, multiple myeloma, colorectal cancer, non-small cell lung cancer, Human Papilloma Virus-associated cervical, oropharyngeal, penis, anal, thyroid, or vaginal cancer or Epstein- Barr Virus-associated nasopharyngeal carcinoma, gastric cancer, rectal cancer, thyroid cancer, Hodgkin lymphoma, and diffuse large B-cell lymphoma. In some embodiments, the CDK2 dependent disease or disorder or the disease or disorder that is mediated, at least in part by, CDK2 is selected from prostate cancer, breast carcinoma, lymphomas, leukemia, myeloma, bladder carcinoma, colon cancer, cutaneous melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, renal cancer, glioblastoma multiform, glioma, thyroid cancer, parathyroid tumor, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, cholangiocarcinoma, gastric cancer, soft tissue sarcomas, rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid cancers, cancer for which the immune response is deficient, an immunogenic cancer, and Ewing’s sarcoma. In some embodiments, the CDK2 dependent disease or disorder or the disease or disorder that is mediated, at least in part by, CDK2 is selected from rheumatoid arthritis; inflammation; autoimmune disease; lymphoproliferative conditions; acromegaly; rheumatoid spondylitis; osteoarthritis; gout, other arthritic conditions; sepsis; septic shock; endotoxic shock; gram-negative sepsis; toxic shock syndrome; asthma; adult respiratory distress syndrome; chronic obstructive pulmonary disease; chronic pulmonary inflammation; inflammatory bowel disease; Crohn's disease; psoriasis; eczema; ulcerative colitis; pancreatic fibrosis; hepatic fibrosis; acute and chronic renal disease; irritable bowel syndrome; pyresis; restenosis; cerebral malaria; stroke and ischemic injury; neural trauma; Alzheimer's disease; Huntington's disease; Parkinson's disease; acute and chronic pain; allergic rhinitis; allergic conjunctivitis; chronic heart failure; acute coronary syndrome; cachexia; malaria; leprosy; leishmaniasis; Lyme disease; Reiter's syndrome; acute synovitis; muscle degeneration, bursitis; tendonitis; tenosynovitis; herniated, ruptures, or prolapsed intervertebral disk syndrome; osteopetrosis; thrombosis; restenosis; silicosis; pulmonary sarcoidosis; bone resorption diseases, such as osteoporosis; graft-versus-host reaction; Multiple Sclerosis; lupus; fibromyalgia; AIDS and other viral diseases such as Herpes Zoster, Herpes Simplex I or II, influenza virus and cytomegalovirus; and diabetes mellitus. [0045] In some embodiments, this disclosure provides a method for treating hyperplasias in a subject in need thereof which method comprises administering to said subject an effective amount of a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient. [0046] In some embodiments, this disclosure provides a method for treating cancer in a subject in need thereof which method comprises administering to said subject an effective amount of a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or
a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient.
[0047] In one embodiment, the cancer treated in the methods described herein is breast cancer, such as triple negative breast cancer.
[0048] In some embodiments, the methods disclosed herein further comprise administering to the subject one or more additional therapies or therapeutic agents. In some embodiments, the one or more additional therapies or therapeutic agents are one or more selected from surgery, radiotherapy, endocrine therapy, biologic response modifiers, hyperthermia and cryotherapy, agents to attenuate any adverse effects, alkylating drugs, antimetabolites, purine antagonists and pyrimidine antagonists, spindle poisons, podophyllotoxins, antibiotics, nitrosoureas, inorganic ions, enzymes, and hormones.
DETAILED DESCRIPTION
[0049] This disclosure provides compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds and compositions to treat diseases, disorders, or conditions mediated, at least in part, by CDK2.. However, prior to providing a detailed description of the disclosure, the following terms will first be defined. If not defined, terms used herein have their generally accepted scientific meaning.
[0050] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the disclosure. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. As used herein, a phrase in the form “A/B” or in the form “A and/or B” means (A), (B), or (A and B); a phrase in the form “at least one of A, B, and C” means (A), (B), (C), (A and B), (A and C), (B and C), or (A, B, and C).
[0051] A dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -C(O)NH2 is attached through the carbon atom. A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A wavy line or a dashed line drawn through a line in a structure indicates a specified point of attachment of a group. Unless chemically or structurally required, no directionality or stereochemistry is indicated or implied by the order in which a chemical group is written or named.
[0052] The prefix “Cu-V” indicates that the following group has from u to v carbon atoms. For example, “Ci-6 alkyl” indicates that the alkyl group has from 1 to 6 carbon atoms.
[0053] The term “about” when used before a numerical designation, e.g., temperature, time, amount, concentration, and such other, including a range, indicates approximation which may vary depending on the context as will be understood by those skilled in the art. In cases where further definition of “about” is required and not otherwise specified, the term “about” means that the value so modified may vary by +/- 10%.
[0054] “Comprising” or “comprises” means that the compositions and methods so modified include at least the recited elements.
[0055] “Consisting essentially of’ when used to define compositions and methods means that the compositions and methods so modified include at least the recited elements and do not include other materials or steps that would materially affect the basic and novel characteristic(s) of the claimed disclosure. Thus, a composition or method “consisting essentially of’ recited elements could include other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed disclosure.
[0056] “Consisting of’ when used to define compositions and methods means that the compositions and methods so modified include the recited elements and do not include more than trace amounts of other ingredients or do not include other substantial method steps. Embodiments defined by each of these transition terms are within the scope of this disclosure.
[0057] “Alkyl” refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., C1-20 alkyl), 1 to 12 carbon atoms (i.e., C1-12 alkyl), 1 to 8 carbon atoms (i.e., C1-8 alkyl), 1 to 6 carbon atoms (i.e., C1-6 alkyl), or 1 to 4 carbon atoms (i.e., C1-4 alkyl). Examples of alkyl groups include, e.g., methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3 -hexyl, and 3 -methylpentyl. When an alkyl residue having a specific number of carbons is named by chemical name or identified by molecular formula, all positional isomers having that number of carbons may be encompassed; thus, for example, “butyl” includes n-butyl (i.e., -(CFE CFfi), sec-butyl (i.e., -CH(CH3)CH2CH3), isobutyl (i.e., - CH2CH(CH3)2), and tert-butyl (i.e., -C(CH3)3); and “propyl” includes n-propyl (i.e., -(CFE CFfi) and isopropyl (i.e., -CH( CThfi).
[0058] Certain commonly used alternative chemical names may be used. For example, a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, a divalent heteroaryl group, etc., may also be referred to as an “alkylene” group or an “alkylenyl” group (for example, methylenyl, ethylenyl, and propylenyl), an “arylene” group or an “arylenyl” group (for example, phenylenyl or napthylenyl, or quinolinyl for heteroarylene), respectively. Also, unless indicated explicitly otherwise, where combinations of groups are referred to herein as one moiety, e.g., arylalkyl or aralkyl, the last mentioned group contains the atom by which the moiety is attached to the rest of the molecule.
[0059] “Alkenyl” refers to an alkyl group containing at least one (e.g., 1-3, or 1) carbon-carbon double bond and having from 2 to 20 carbon atoms (i.e., C2-20 alkenyl), 2 to 12 carbon atoms (i.e., C2-12 alkenyl), 2 to 8 carbon atoms (i.e., C2-8 alkenyl), 2 to 6 carbon atoms (i.e., C2-6 alkenyl), or 2 to 4 carbon atoms (i.e., C2-4 alkenyl). Examples of alkenyl groups include, e.g., ethenyl, propenyl, butadienyl (including 1,2-butadienyl and 1,3 -butadienyl).
[0060] “Alkynyl” refers to an alkyl group containing at least one (e.g., 1-3, or 1) carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e., C2-20 alkynyl), 2 to 12 carbon atoms (i.e., C2-12 alkynyl), 2 to 8 carbon atoms (i.e., C2-8 alkynyl), 2 to 6 carbon atoms (i.e., C2-6 alkynyl), or 2 to 4 carbon atoms
(i.e., C2-4 alkynyl). The term “alkynyl” also includes those groups having one triple bond and one double bond.
[0061] “Alkoxy” refers to the group “alkyl-O-”. Examples of alkoxy groups include, e.g., methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1 ,2-dimethylbutoxy .
[0062] “Alkylthio” refers to the group “alkyl-S-”. “Alkylsulfmyl” refers to the group “alkyl-S(O)-”. “Alkylsulfonyl” refers to the group “alkyl-S(O)2-”. “Alkylsulfonylalkyl” refers to -alkyl-S(O)2-alkyl.
[0063] “Acyl” refers to a group -C(O)Ry, wherein Ry is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein. Examples of acyl include, e.g., formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, and benzoyl.
[0064] “Amido” refers to both a “C-amido” group which refers to the group -C(0)NRyRz and an “N- amido” group which refers to the group -NRyC(0)Rz, wherein Ry and Rz are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein, or Ry and Rz are taken together to form a cycloalkyl or heterocyclyl; each of which may be unsubstituted or substituted, as defined herein.
[0065] “Amino” refers to the group -NRyRz wherein Ry and Rz are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
[0066] “Amidino” refers to -C(NRy)(NRz2), wherein Ry and Rz are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
[0067] “Aryl” refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic) including fused systems. As used herein, aryl has 6 to 20 ring carbon atoms (i.e., Cg-20 aryl), 6 to 12 carbon ring atoms (i.e., Cg-i2 aryl), or 6 to 10 carbon ring atoms (i.e., Cg-io aryl). Examples of aryl groups include, e.g., phenyl, naphthyl, fluorenyl, and anthryl. Aryl, however, does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl groups are fused with a heteroaryl, the resulting ring system is heteroaryl regardless of point of attachment. If one or more aryl groups are fused with a heterocyclyl, the resulting ring system is heterocyclyl regardless of point of attachment. If one or more aryl groups are fused with a cycloalkyl, the resulting ring system is cycloalkyl regardless of point of attachment.
[0068] “Carbamoyl” refers to both an “0-carbamoyl” group which refers to the group -0-C(0)NRyRz and an “N-carbamoyl” group which refers to the group -NRyC(0)0Rz, wherein Ry and Rz are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
[0069] “Carboxyl ester” or “ester” refer to both -0C(0)Rx and -C(0)0Rx, wherein Rx is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
[0070] “Cycloalkyl” refers to a saturated or partially unsaturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems. The term “cycloalkyl” includes cycloalkenyl groups (i.e., the cyclic group having at least one double bond) and carbocyclic fused ring systems having at least one sp3 carbon atom (i.e., at least one non-aromatic ring). As used herein, cycloalkyl has from 3 to 20 ring carbon atoms (i.e., C3-20 cycloalkyl), 3 to 14 ring carbon atoms (i.e., C3-14 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C3-12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C3-8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C3-6 cycloalkyl). Monocyclic groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic groups include, for example, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, adamantyl, norbomyl, decalinyl, 7,7-dimethyl-bicyclo[2.2. l]heptanyl, and the like. Further, the term cycloalkyl is intended to encompass any non-aromatic ring which may be fused to an aryl ring, regardless of the attachment to the remainder of the molecule. Still further, cycloalkyl also includes “spirocycloalkyl” when there are two positions for substitution on the same carbon atom, for example spiro[2.5]octanyl, spiro[4.5]decanyl, or spiro [5.5 ]undecanyl .
[0071] “Imino” refers to a group -C(NRy)Rz, wherein Ry and Rz are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
[0072] “Imido” refers to a group -C(O)NRyC(O)Rz, wherein Ry and Rz are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
[0073] “Halogen” or “halo” refers to atoms occupying group VIIA of the periodic table, such as fluoro, chloro, bromo, or iodo.
[0074] “Haloalkyl” refers to an unbranched or branched alkyl group as defined above, wherein one or more (e.g., 1 to 6 or 1 to 3) hydrogen atoms are replaced by a halogen. For example, where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be, but are not necessarily, the same halogen. Examples of haloalkyl include, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3 -bromo-2 -fluoropropyl, 1,2-dibromoethyl, and the like.
[0075] “Haloalkoxy” refers to an alkoxy group as defined above, wherein one or more (e.g., 1 to 6 or 1 to 3) hydrogen atoms are replaced by a halogen.
[0076] “Hydroxyalkyl” refers to an alkyl group as defined above, wherein one or more (e.g., 1 to 6 or 1 to 3) hydrogen atoms are replaced by a hydroxy group.
[0077] “Heteroalkyl” refers to an alkyl group in which one or more of the carbon atoms (and any associated hydrogen atoms), excluding any terminal carbon atom(s), are each independently replaced with the same or different heteroatomic group, provided the point of attachment to the remainder of the molecule is through a carbon atom. The term “heteroalkyl” includes unbranched or branched saturated chain having carbon and heteroatoms. By way of example, 1, 2 or 3 carbon atoms may be independently replaced with the same or different heteroatomic group. Heteroatomic groups include, but are not limited to, -NRy-, -O-, -S-, -S(O)-, -S(O)2-, and the like, wherein Ryis hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein. Examples of heteroalkyl groups include, e.g., ethers (e.g., -CH2OCH3, - CH(CH3)OCH3, -CH2CH2OCH3, -CH2CH2OCH2CH2OCH3, etc ), thioethers (e.g., -CH2SCH3, - CH(CH3)SCH3, -CH2CH2SCH3,-CH2CH2SCH2CH2SCH3, etc ), sulfones (e.g, -CH2S(O)2CH3, - CH(CH3)S(O)2CH3, -CH2CH2S(O)2CH3, -CH2CH2S(O)2CH2CH2OCH3, etc ), and amines (e.g., - CH2NRyCH3, -CH(CH3)NRyCH3, -CH2CH2NRyCH3, -CH2CH2NRyCH2CH2NRyCH3, etc., where Ry is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein). As used herein, heteroalkyl includes 2 to 10 carbon atoms, 2 to 8 carbon atoms, or 2 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.
[0078] “Heteroaryl” refers to an aromatic group having a single ring, multiple rings or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, heteroaryl includes 1 to 20 ring carbon atoms (i.e., C1-20 heteroaryl), 3 to 12 ring carbon atoms (i.e., C3-12 heteroaryl), or 3 to 8 carbon ring atoms (i.e., C3-8 heteroaryl), and 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. In certain instances, heteroaryl includes 5-10 membered ring systems, 5-7 membered ring systems, or 5-6 membered ring systems, each independently having 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include, e.g., acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzofuranyl, benzothiazolyl, benzothiadiazolyl, benzonaphthofuranyl, benzoxazolyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, isoquinolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, phenazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, and triazinyl. Examples of the fused- heteroaryl rings include, but are not limited to, benzo [d]thiazolyl, quinolinyl, isoquinolinyl, benzo [b]thiophenyl, indazolyl, benzo [d] imidazolyl, pyrazolo[l,5-a]pyridinyl, and imidazo[l,5- a]pyridinyl, where the heteroaryl can be bound via either ring of the fused system. Any aromatic ring,
having a single or multiple fused rings, containing at least one heteroatom, is considered a heteroaryl regardless of the attachment to the remainder of the molecule (i.e., through any one of the fused rings). Heteroaryl does not encompass or overlap with aryl as defined above.
[0079] “Heterocyclyl” - used interchangeably with “heterocycloalkyl”- refers to a saturated or partially unsaturated cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. The term “heterocyclyl” includes heterocycloalkenyl groups (i.e., the heterocyclyl group having at least one double bond), bridged-heterocyclyl groups, fused-heterocyclyl groups, and spiro-heterocyclyl groups. A heterocyclyl may be a single ring or multiple rings wherein the multiple rings may be fused, bridged, or spiro, and may comprise one or more (e.g., 1 to 3) oxo (=0) or N-oxide (-0 ) moieties. Any non-aromatic ring containing at least one heteroatom is considered a heterocyclyl, regardless of the attachment (i.e., can be bound through a carbon atom or a heteroatom). Further, the term heterocyclyl is intended to encompass any non-aromatic ring containing at least one heteroatom, which ring may be fused to a cycloalkyl, an aryl, or heteroaryl ring, regardless of the attachment to the remainder of the molecule. As used herein, heterocyclyl has 2 to 20 ring carbon atoms (i.e., C2-20 heterocyclyl), 2 to 12 ring carbon atoms (i.e., C2-12 heterocyclyl), 2 to 10 ring carbon atoms (i.e., C2-10 heterocyclyl), 2 to 8 ring carbon atoms (i.e., C2-8 heterocyclyl), 3 to 12 ring carbon atoms (i.e., C3-12 heterocyclyl), 3 to 8 ring carbon atoms (i.e., C3-8 heterocyclyl), or 3 to 6 ring carbon atoms (i.e., C3-6 heterocyclyl); having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur, or oxygen. Examples of heterocyclyl groups include, e.g., azetidinyl, azepinyl, benzodioxolyl, benzo[b][l,4]dioxepinyl, 1,4-benzodioxanyl, benzopyranyl, benzodioxinyl, benzopyranonyl, benzofuranonyl, dioxolanyl, dihydropyranyl, hydropyranyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, furanonyl, imidazolinyl, imidazolidinyl, indolinyl, indolizinyl, isoindolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, oxiranyl, oxetanyl, phenothiazinyl, phenoxazinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, tetrahydropyranyl, trithianyl, tetrahydroquinolinyl, thiophenyl (i.e., thienyl), thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. The term “heterocyclyl” also includes “spiroheterocyclyl” when there are two positions for substitution on the same carbon atom. Examples of the spiro-heterocyclyl rings include, e.g., bicyclic and tricyclic ring systems, such as oxabicyclo[2.2.2]octanyl, 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6- azaspiro[3.4]octanyl, and 6-oxa-l-azaspiro[3.3]heptanyl. Examples of the fused-heterocyclyl rings include, but are not limited to, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrothieno[2,3- c]pyridinyl, indolinyl, and isoindolinyl, where the heterocyclyl can be bound via either ring of the fused system. In some embodiments, the heterocycloalkyl may be substituted with oxo group(s) on a heteroatom (e.g., S=O, S(=O)2).
[0080] ‘ ‘Oxime” refers to the group -CRy(=NOH) wherein Ry is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
[0081] ‘ ‘Oxo” refers to the moiety =0.
[0082] “Sulfonyl” refers to the group -S(O)2Ry, where Ry is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein. Examples of sulfonyl are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.
[0083] “Sulfinyl” refers to the group -S(O)Ry, where Ry is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein. Examples of sulfinyl are methylsulfinyl, ethylsulfinyl, phenylsulfinyl, and toluenesulfinyl.
[0084] “Sulfonamide” refers to the groups -SC>2NRyRz and -NRySC>2Rz, where Ry and Rz are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be unsubstituted or substituted, as defined herein.
[0085] The terms “optional” or “optionally” means that the subsequently described feature, event or circumstance may or may not be present or occur and that the description includes instances where said feature, event or circumstance is present/occurs and instances in which it does not. Also, the term “unsubstituted or substituted” refers to any one or more (e.g., 1 to 5 or 1 to 3) hydrogen atoms on the designated atom or group may or may not be replaced by a moiety other than hydrogen.
[0086] The term “substituted” used herein means any of the above groups (i.e., alkyl, alkenyl, alkynyl, alkylene, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl, and/or heteroalkyl) wherein at least one (e.g., 1 to 5 or 1 to 3) hydrogen atom is replaced by a bond to a non-hydrogen atom such as, but not limited to alkyl, alkenyl, alkynyl, alkoxy, alkylthio, acyl, amido, amino, amidino, aryl, aralkyl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, cycloalkyl, cycloalkylalkyl, guanadino, halo, haloalkyl, haloalkoxy, hydroxyalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -NHNH2, =NNH2, imino, imido, hydroxy, oxo, oxime, nitro, sulfonyl, sulfinyl, alkylsulfonyl, alkylsulfinyl, thiocyanate, -S(O)OH, -S(O)2OH, sulfonamide, thiol, thioxo, N-oxide, or -Si(Ry)3, wherein each Ry is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl.
[0087] In certain embodiments, “substituted” includes any of the above alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl groups in which one or more (e.g., 1 to 5 or 1 to 3) hydrogen atoms are independently replaced with deuterium, halo, cyano, nitro, azido, oxo, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NRgRh, -NRgC(0)Rh,
“substituted” also means any of the above groups in which one or more (e.g., 1 to 5 or 1 to 3) hydrogen atoms are replaced with -C(O)Rg, -C(O)ORg, -C(O)NRgRh, -CH2SO2Rg, or -CH2SO2NRgRh In the foregoing, Rg and Rh are the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and/or heteroarylalkyl. In certain embodiments, “substituted” also means any of the above groups in which one or more (e.g., 1 to 5 or 1 to 3) hydrogen atoms are replaced by a bond to an amino, cyano, hydroxy, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, and/or heteroarylalkyl, or two of Rg and Rh are taken together with the atoms to which they are attached to form a heterocyclyl ring unsubstituted or substituted with oxo, halo, or alkyl unsubstituted or substituted with oxo, halo, amino, hydroxy, or alkoxy.
[0088] Polymers or similar structures of indefinite size arrived at by defining substituents with further substituents appended ad infinitum (e.g., a substituted aryl having a substituted alkyl which is itself substituted with a substituted aryl group, which is further substituted by a substituted heteroalkyl group, etc.) are not intended for inclusion herein. For example, serial substitutions of substituted aryl groups with two other substituted aryl groups are limited to ((substituted aryl)substituted aryl) substituted aryl. Similarly, the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to the skilled artisan. When used to modify a chemical group, the term “substituted” may describe other chemical groups defined herein.
[0089] Any compound or structure given herein, is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds (i.e., the amount of labeled forms is above the natural abundance for that form). These forms of compounds may also be referred to as “isotopically enriched analogs.” Isotopically labeled compounds have structures depicted herein, except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2H, 3H, nC, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 31P, 32P, 35S, 18F, 36C1, 123I, and 125I, respectively. Various isotopically labeled compounds of the present disclosure, for example those into which radioactive isotopes such as 3H and 14C are incorporated. Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.
[0090] The term “isotopically enriched analogs” includes “deuterated analogs” of compounds described herein in which one or more hydrogens is/are replaced by deuterium, such as a hydrogen on a carbon atom. Such compounds exhibit increased resistance to metabolism and are thus useful for increasing the half-life of any compound when administered to a mammal, particularly a human. See,
for example, Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci. 5(12): 524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.
[0091] Deuterium labelled or substituted therapeutic compounds of the disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to absorption, distribution, metabolism, and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements, and/or an improvement in therapeutic index. An 18F, 3H, or nC labeled compound may be useful for PET or SPECT or other imaging studies. Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. It is understood that deuterium in this context is regarded as a substituent in a compound described herein.
[0092] The concentration of such a heavier isotope, specifically deuterium, may be defined by an isotopic enrichment factor. In the compounds of this disclosure any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as “H” or “hydrogen,” the position is understood to have hydrogen at its natural abundance isotopic composition. Accordingly, in the compounds of this disclosure any atom specifically designated as a deuterium (D) is meant to represent deuterium.
[0093] In many cases, the compounds of this disclosure are capable of forming acid and/or base salts by virtue of the presence of amino, and/or carboxyl groups, or groups similar thereto.
[0094] Also provided are pharmaceutically acceptable salts, solvates, stereoisomers, and tautomers of the compounds described herein. Unless the context dictates otherwise, reference to a “compound” as described herein includes reference to its pharmaceutically acceptable salts, solvates, stereoisomers, and tautomers. Also provided are isotopically enriched analogs, deuterated analogs, mixtures of stereoisomers, and prodrugs of the compounds described herein.
[0095] “Pharmaceutically acceptable” or “physiologically acceptable” refer to compounds, salts, compositions, dosage forms, and other materials which are useful in preparing or suitable for use in a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.
[0096] The term “pharmaceutically acceptable salt” of a given compound refers to salts that exhibit the intended efficacy of the reference compound and which are not biologically or otherwise undesirable, e.g., due to toxicity or other properties. “Pharmaceutically acceptable salts” or “physiologically acceptable salts” include, for example, salts with inorganic acids, and salts with an organic acid. In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by
dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare nontoxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts may be prepared from inorganic or organic acids. Salts derived from inorganic acids include, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include, e.g., acetic acid, propionic acid, gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methane sulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like. Likewise, pharmaceutically acceptable base addition salts can be prepared from inorganic or organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, aluminum, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, such as alkyl amines (i.e., NfLfalkyl)). dialkyl amines (i.e., HN(alkyl)2), trialkyl amines (i.e., N(alkyl)3), substituted alkyl amines (i.e., NfLfsubstitiitcd alkyl)), di(substituted alkyl) amines (i.e., HN(substituted alkyl)2), tri(substituted alkyl) amines (i.e., N(substituted alkylfi). alkenyl amines (i.e., NH2(alkenyl)), dialkenyl amines (i.e., HN(alkenyl)2), trialkenyl amines (i.e., N(alkenyl)3), substituted alkenyl amines (i.e., NH2(substituted alkenyl)), di(substituted alkenyl) amines (i.e., HN(substituted alkenyl^), tri(substituted alkenyl) amines (i.e., N(substituted alkenyl^, mono-, di- or tri- cycloalkyl amines (i.e., NH2(cycloalkyl), HN(cycloalkyl)2, N(cycloalkyl)3), mono-, di- or tri- arylamines (i.e., NH2(aryl), HN(aryl)2, N(aryl)3), or mixed amines, etc. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
[0097] Some of the compounds described herein exist as tautomers. Tautomers are in equilibrium with one another. For example, amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, the amide containing compounds are understood to include their imidic acid tautomers. Likewise, the imidic acid containing compounds are understood to include their amide tautomers.
[0098] The compounds described herein, or their pharmaceutically acceptable salts, may include an asymmetric center and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S')- or, as (D)- or (L)- for amino acids. The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms, and various combinations thereof. Optically active (+) and (-), (R)- and (.S)-. or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using
conventional techniques, for example, chromatography and/or fractional crystallization. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.
[0099] A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable . The present disclosure contemplates various stereoisomers, or mixtures thereof, and includes “enantiomers,” which refers to two stereoisomers whose molecules are non-superimposeable mirror images of one another.
[0100] ‘ ‘Diastereomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
[0101] Relative centers of the compounds as depicted herein are indicated graphically using the “thick bond” style (bold or parallel lines) and absolute stereochemistry is depicted using wedge bonds (bold or parallel lines).
[0102] “Prodrug” means any compound which releases an active parent drug according to a structure described herein in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound described herein are prepared by modifying functional groups present in the compound described herein in such a way that the modifications may be cleaved in vivo to release the parent compound. Prodrugs may be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds. Prodrugs include compounds described herein wherein a hydroxy, amino, carboxyl, or sulfhydryl group in a compound described herein is bonded to any group that may be cleaved in vivo to regenerate the free hydroxy, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), amides, guanidines, carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional groups in compounds described herein, and the like. Preparation, selection, and use of prodrugs is discussed in T. Higuchi and V. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series; “Design of Prodrugs,” ed. H. Bundgaard, Elsevier, 1985; and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, each of which are hereby incorporated by reference in their entirety.
[0103] “Subject” refers to a mammal. The mammal can be a human or non-human mammalian organism. A “patient” refers to a human subject.
[0104] “Treating” or “treatment” of a disease or disorder in a subject refers to inhibiting the disease or disorder or arresting its development or ameliorating or causing regression of the disease or disorder.
[0105] Unless otherwise specified, “effective amount” refers to an amount of a compound described herein that is sufficient to achieve the intended effect, such as modulating CDK2 or treating a disease or disorder afflicting a subject.
[0106] “Administration” refers to any art recognized form of administration to a subject including injection (e.g., intravenous, subcutaneous, intramuscular), oral (including oral gavage), pulmonary, transdermal, sublingual, transmucosal (e.g., vaginal, nasal, etc.), and the like.
[0107] The term "ubiquitin ligase" refers to a family of proteins that facilitate the transfer of ubiquitin to a specific substrate protein, targeting the substrate protein for degradation. For example, an E3 ubiquitin ligase protein that alone or in combination with an E2 ubiquitin-conjugating enzyme causes the attachment of ubiquitin to a lysine on a target protein, and subsequently targets the specific protein substrates for degradation by the proteasome. Thus, E3 ubiquitin ligase alone or in complex with an E2 ubiquitin conjugating enzyme is responsible for the transfer of ubiquitin to targeted proteins. In general, the ubiquitin ligase is involved in polyubiquitination such that a second ubiquitin is attached to the first; a third is attached to the second, and so forth. Polyubiquitination marks proteins for degradation by the proteasome. However, there are some ubiquitination events that are limited to mono-ubiquitination, in which only a single ubiquitin is added by the ubiquitin ligase to a substrate molecule. Mono- ubiquitinated proteins are not targeted to the proteasome for degradation, but may instead be altered in their cellular location or function, for example, via binding other proteins that have domains capable of binding ubiquitin. Further complicating matters, different lysines on ubiquitin can be targeted by an E3 to make chains. The most common lysine is Lys48 on the ubiquitin chain. This is the lysine used to make polyubiquitin, which is recognized by the proteasome.
COMPOUNDS
[0108] In one embodiment, this disclosure provides a compound of formula F:
r or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein
Y is N or C-V;
V is selected from hydrogen, deuterium, and fluoro;
X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy;
R12 and R12 are independently selected from hydrogen, deuterium and fluoro; or R12 and R12 together are oxo; n is 0 or 1; p is 0 or 1;
R3 and R4 are independently hydrogen or CH3; or R3 and R4 together with the carbon atom to which they are attached form a C3-C6 cycloalkyl;
R13 is hydrogen or -CH2-OR14;
R14 is -C(O)-R15 or -P(O)(OR16)2;
R15 is C1-C4 alkyl or C1-C4 alkoxy; each R16 is independently hydrogen or C1-C4 alkyl;
Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4- to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
Y1 is -O- or -CH2-;
Z is -O- or -CH2-;
R1 and R2 are independently selected from hydrogen, Ci-Cg alkyl, L1-(G-Cg cycloalkyl), and L1-(4- to 7-membered heterocycloalkyl), wherein said Ci-Cg alkyl, G-Cg cycloalkyl and 4- to 7- membered heterocycloalkyl is optionally substituted by one to four R8;
R1 and R2 taken together with the nitrogen atom to which they are attached form a 3- to 11- membered ring optionally containing an additional heteroatom or heteroatom group selected from O, N, N(R17), and S(O)m as a ring member, wherein said 3- to 6-membered ring is optionally substituted by one to four R8;
R17 is hydrogen, C1-C4 alkyl, or C(0)-(G-C4 alkyl);
R18 is hydrogen, C1-C4 alkyl, C1-4 fluoroalkyl, or C(O)-Ci-C4 alkyl; m is 0, 1 or 2;
L1 is a bond or a G-C2 alkylene optionally substituted with one to four R9;
Ring A is selected from Cg-Cio aryl ring; C4-C6 cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R7 moieties, and each R7 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn;
R10 and R11 are each independently H or C1-C4 alkyl;
Ring B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn, or B is absent; a, b, and c are independently 0 or 1 ; each of W and W2, if present, is independently Ci-Cg alkylene optionally substituted with 1 to 3 R9 and W1, if present, is -C(O)-, O, S, NR18 or Ci-Cg alkylene optionally substituted with 1 to 3 R9 provided that the aggregate sum of carbon atoms in W, W1 and W2 is no more than 6; or when each of W and W2 are absent, then W1 further comprises C4-C8 heteroalkylene containing 1 to 3 oxygen atoms; and
R9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy.
I
or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein
Ring C is
wherein the solid bond 1 attaches Ring C to the piperidinedione ring and the solid bond 2 attaches Ring C to L;
V is selected from hydrogen, deuterium, and fluoro;
X is selected from hydrogen, halo, hydroxy, cyano, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 alkoxy, and C1-4 fluoroalkyloxy;
R12 and R12 are independently selected from hydrogen, deuterium and fluoro or R12 and R12 together are oxo; n is 0 or 1; p is 0 or 1;
R13 is hydrogen or -CH2-OR14;
R14 is -C(O)-R15 or -P(O)(OR16)2;
R15 C1-C4 alkyl or C1-C4 alkoxy; each R16 is independently hydrogen or C1-C4 alkyl;
Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4 to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6 to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
R1 and R2 are independently selected from hydrogen, Ci-Cg alkyl, L'-C’s-Cg cycloalkyl, and I -4-7 membered heterocycloalkyl, wherein said Ci-Cg alkyl, C -Cg cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by one to four R8;
R1 and R2 taken together with the nitrogen atom to which they are attached form a 4- to 6-membered ring optionally containing an additional heteroatom selected from O, N, N(R17), and S(O)m as a ring member, wherein said 4- to 6-membered ring is optionally substituted by one to four R8;
R17 is hydrogen, C1-C4 alkyl, or C(O)-Ci-C4 alkyl;
R18 is hydrogen, C1-C4 alkyl, C1-4 fluoroalkyl, or C(O)-Ci-C4 alkyl; m is 0, 1 or 2;
L1 is a bond or a C1-C2 alkylene optionally substituted with one to four R9;
Ring A is selected from Cg-Cio aryl ring; C4-C6 cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R7 moieties, and each R7 is independently selected from halo, hydroxy, cyano, C1-4 alkyl, Ci-4fluoroalkyl, C1-4 alkoxy, C1-4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn;
R10 and R11 are each independently H or C1-C4 alkyl;
Ring B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 alkoxy, C 1-4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn, or B is absent; a, b, and c are independently 0 or 1 ; each of W and W2, if present, is independently Ci-Cg alkylene optionally substituted with 1 to 3 R9 and W1, if present, is O, S, NR18 or Ci-Cg alkylene optionally substituted with 1 to 3 R9 provided that the aggregate sum of carbon atoms in W, W1 and W2 is no more than 6; or when each of W and W2 are absent, then W1 further comprises C4-C8 heteroalkylene containing 1 to 3 oxygen atoms; and
R9 is independently selected from halo, cyano, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 alkoxy, and C1-4 fluoroalkyloxy.
IA or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein Ring C is
wherein the solid bond 1 attaches Ring C to the piperidinedione ring and the solid bond 2 attaches Ring C to L;
V is hydrogen;
X is selected from hydrogen, halo, hydroxy, cyano, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 alkoxy, and C Mfluoroalkyloxy ;
R12 and R12 are hydrogen or R12 and R12 together are oxo; n is 0 or 1; p is 0 or 1;
R13 is hydrogen;
Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4 to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6 to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 5-10 membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
R1 and R2 are independently selected from hydrogen, Ci-Cg alkyl, L'-C’s-Cg cycloalkyl, and I -4-7 membered heterocycloalkyl, wherein said Ci-Cg alkyl, C -Cg cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by one to four R8;
R1 and R2 taken together with the nitrogen atom to which they are attached form a 3 - to 6-membered ring optionally containing an additional heteroatom selected from O, N(R17), and S(O)m as a ring member, wherein said 3- to 6-membered ring is optionally substituted by one to four R8;
R17 is hydrogen, C1-C4 alkyl, or C(O)-Ci-C4 alkyl;
R18 is hydrogen, C1-C4 alkyl, C1-4 fluoroalkyl, or C(O)-Ci-C4 alkyl; m is 0, 1 or 2;
L1 is a bond or a C1-C2 alkylene optionally substituted with one to four R9;
Ring A is selected from Cg-Cio aryl ring; C4-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 10- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3
R7 moieties, and each R7 is independently selected from halo, hydroxy, cyano, CM alkyl, Ci-4fluoroalkyl, C alkoxy, CM fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn;
R10 and R11 are each independently H or C1-C4 alkyl;
B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11- membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4 to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, CM alkyl, CM fluoroalkyl, CM alkoxy, C 1-4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn, or B is absent; b and c are independently 0 or 1 ;
W2, if present, is Ci-Cg alkylene optionally substituted with 1 to 3 R9 and W1, if present, is -C(O)-, O, S, NR18 or Ci-Cg alkylene optionally substituted with 1 to 3 R9 provided that the aggregate sum of carbon atoms in W1 and W2 is no more than 4; and
R9 is independently selected from halo, cyano, CM alkyl, CM fluoroalkyl, CM alkoxy, and CM fluoroalkyloxy or when W is absent then W1 is C4-C8 heteroalkylene containing 1 to 3 oxygen atoms.
IB or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein Ring C is
wherein the solid bond 1 attaches Ring C to the piperidinedione ring and the solid bond 2 attaches Ring C to L;
V is hydrogen;
X is selected from hydrogen, halo, hydroxy, cyano, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 alkoxy, and C wfluoroalkyloxy ;
R12 and R12 are hydrogen or R12 and R12 together are oxo; n is 0 or 1; p is 0 or 1;
R13 is hydrogen;
Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4 to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6 to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 5-10 membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
R1 and R2 are independently selected from hydrogen, Ci-Cg alkyl, L'-C’s-Cg cycloalkyl, and I -4-7 membered heterocycloalkyl, wherein said Ci-Cg alkyl, C -Cg cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by one to four R8;
R1 and R2 taken together with the nitrogen atom to which they are attached form a 3 - to 6-membered ring optionally containing an additional heteroatom selected from O, N(R17), and S(O)m as a ring member, wherein said 3- to 6-membered ring is optionally substituted by one to four R8;
R17 is hydrogen, C1-C4 alkyl, or C(O)-Ci-C4 alkyl;
R18 is hydrogen, C1-C4 alkyl, C1-4 fluoroalkyl, or C(O)-Ci-C4 alkyl; m is 0, 1 or 2;
L1 is a bond or a C1-C2 alkylene optionally substituted with one to four R9;
Ring A is selected from Cg-Cio aryl ring; C4-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 10- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R7 moieties, and each R7 is independently selected from halo, hydroxy, cyano, C1-4 alkyl, Ci-4fluoroalkyl, C1-4 alkoxy, C1-4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn;
R10 and R11 are each independently H or C1-C4 alkyl;
B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11- membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4 to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R8
moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 alkoxy, Ci-4fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn, or B is absent; b and c are independently 0 or 1 ;
W2, if present, is Ci-Cg alkylene optionally substituted with 1 to 3 R9 and W1, if present, is -C(O)-, O, S, NR18 or Ci-Cg alkylene optionally substituted with 1 to 3 R9 provided that the aggregate sum of carbon atoms in W1 and W2 is no more than 4;
R9 is independently selected from halo, cyano, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 alkoxy, and C1-4 fluoroalkyloxy; and when W2 is absent then W1 further comprises C4-C8 heteroalkylene containing 1 to 3 oxygen atoms.
Ill or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein
Y is N or C-V;
V is selected from hydrogen, deuterium, and fluoro;
X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and Ci-4fluoroalkyloxy;
R12 and R12 are independently selected from hydrogen, deuterium, and fluoro; or R12 and R12 together are oxo; n is 0 or 1; p is 0 or 1;
R3 and R4 are independently hydrogen, halo, or CH3; or R3 and R4 together with the carbon atom to which they are attached form a C3-C6 cycloalkyl;
Y1 is -O- or -CH2-;
Z1 is -O-, and R5 is selected from Cg-Cw aryl; 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms; C3-C6 cycloalkyl ring; and C1-C3 alkyl optionally substituted with C1-C3 alkoxy or phenyl; wherein the Cg-Cw aryl and the 6-membered heteroaryl ring are substituted with 0 to 2 R6, and each R6 is independently selected from halo, cyano, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyl; or -Z^R5 is hydrogen;
R13 is hydrogen or -CH2-OR14;
R14 is C(O)-R15 or -P(O)(OR16)2;
R15 is C1-C4 alkyl or C1-C4 alkoxy; each R16 is independently hydrogen or C1-C4 alkyl;
R18 is hydrogen, C1-C4 alkyl, C1-4 fluoroalkyl, or C(O)-Ci-C4 alkyl;
Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4- to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
Ring A is selected from Cg-Cio aryl ring; C4-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R7 moieties, and each R7 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn;
R10 and R11 are each independently H or C1-C4 alkyl;
Ring B is selected from Cg-Cw aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn, or B is absent; a, b, and c are independently 0 or 1 ; each of W and W2, if present, is independently Ci-Cg alkylene optionally substituted with 1 to 3 R9 and W1, if present, is -C(O)-, O, S, NR18 or Ci-Cg alkylene optionally substituted with 1 to 3 R9
provided that the aggregate sum of carbon atoms in W, W1 and W2 is no more than 6; or when each of W and W2 are absent, then W1 further comprises C4-C8 heteroalkylene containing 1 to 3 oxygen atoms; and
R9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy.
[0113] In some embodiments, Ring
some embodiments, R12 and R12 are independently selected from hydrogen, deuterium, and fluoro. In some embodiments, R12 and R12 are hydrogen. In some embodiments, R12 and R12 are fluoro. In some embodiments, R12 and R12 are deuterium. In some embodiments, R12 and R12 together are oxo.
[0116] In some embodiments, X is hydrogen or halo. In some embodiments, X is hydrogen. In some embodiments, X is halo. In some embodiments, X is fluoro or chloro. In some embodiments, X is hydrogen, fluoro, or chloro.
[0117] In some embodiments, X is hydroxy. In some embodiments, X is cyano. In some embodiments, X is C1-C4 alkyl. In some embodiments, X is C1-C4 fluoroalkyl. In some embodiments, X is C1-C4 alkoxy. In some embodiments, X is C1-C4 fluoroalkyloxy.
[0118] In some embodiments, Y is C-V. In some embodiments, Y is N.
[0119] In some embodiments, V is hydrogen. In some embodiments, V is deuterium. In some embodiments, V is fluoro.
[0120] In some embodiments, R13 is hydrogen. In some embodiments, R13 is -CH2-OR14.
[0121] In some embodiments, R14 is -C(O)-R15. In some embodiments, R14 is -P(O)(OR16)2.
[0122] In some embodiments, R15 is C1-C4 alkyl. In some embodiments, R15 is C1-C4 alkoxy.
[0123] In some embodiments, n is 0. In some embodiments, n is 1.
[0124] In some embodiments, R3 and R4 are independently hydrogen or CH3. In some embodiments, R3 and R4 are hydrogen. In some embodiments, R3 is hydrogen and R4 is CH3. In some embodiments, R3 and R4 are CH3. In some embodiments, R3 and R4 together with the carbon atom to which they are attached form a C3-C6 cycloalkyl. In some embodiments, R3 and R4 together with the carbon atom to which they are attached form cyclopropyl.
[0125] In some embodiments, p is 1. In some embodiments, p is 0.
[0126] In some embodiments, Y1 is -O-. In some embodiments, Y1 is -CH2-.
[0127] In some embodiments, Z is -O-. In some embodiments, Z is -CH2-.
[0128] In some embodiments, Z1 is -O-, and R5 is selected from Cg-Cio aryl; 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms; C3-C6 cycloalkyl ring; and C1-C3 alkyl optionally substituted with C1-C3 alkoxy or phenyl; wherein the Cg-Cio aryl and the 6-membered heteroaryl ring are substituted with 0 to 2 R6, and each R6 is independently selected from halo, cyano, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyl.
[0129] In some embodiments, R5 is Cg-Cio aryl, wherein the Cg-Cio aryl is substituted with 0 to 2 R6, and each R6 is independently selected from halo, cyano, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4
[0130] In some embodiments, R5 is 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, wherein the 6-membered heteroaryl ring is substituted with 0 to 2 R6, and each R6 is independently selected from halo, cyano, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyl. In some
[0131] In some embodiments, R5 is C3-Cg cycloalkyl ring. In some embodiments, R5 is
[0132] In some embodiments, R5 is C1-C3 alkyl optionally substituted with C1-C3 alkoxy or phenyl. In some embodiments,
[0133] In some embodiments, -Z’-I is hydrogen.
[0134] In some embodiments, Ring D is a Cg-Cio aryl ring. In some embodiments, Ring D is a Cs-Cg cycloalkyl ring. In some embodiments, Ring D is a 4- to 5 -membered heterocycloalkyl ring with 1 ring nitrogen atom. In some embodiments, Ring D is a 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms. In some embodiments, Ring D is a 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms. In some embodiments, Ring D is absent.
[0136] In some embodiments, Ring A is Cg-Cio aryl ring substituted with from 0 to 3 R7 moieties. In some embodiments, Ring A is C4-Cg cycloalkyl ring substituted with from 0 to 3 R7 moieties. In some embodiments, Ring A is Cs-Cg cycloalkenyl ring substituted with from 0 to 3 R7 moieties. In some embodiments, Ring A is 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O, wherein Ring A is substituted with from 0 to 3 R7 moieties. In some embodiments, Ring A is 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, wherein Ring A is substituted with from 0 to 3 R7 moieties. In some embodiments, Ring A is 4- to 11- membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein Ring A is substituted with from 0 to 3 R7 moieties.
[0137] In some embodiments, Ring A is a 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring
[0138] In some embodiments, Ring B is Cg-Cio aryl, wherein Ring B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn. In some embodiments, Ring B is Cs-Cg cycloalkyl ring, wherein Ring B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn. In some embodiments, Ring B is Cs-Cg cycloalkenyl ring, wherein Ring B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn. In some embodiments, Ring B is 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; wherein Ring B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and - C(O)NR10Rn.
[0139] In some embodiments, Ring B is 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; wherein Ring B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn. In some embodiments, Ring B is 4- to 11-membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein Ring B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn. In some embodiments, Ring B is absent.
Ila where each of b, c, Ring A, B, W1, and W2 is as defined herein.
[0142] In one embodiment, a and c are zero in L which is then represented by formula lib:
lib where each of b, Ring A, B, and W1 is as defined herein.
[0144] In one embodiment, a and c are zero and B is absent in L which is then represented by formula lie:
where each of b, Ring A, W1 is as defined herein.
[0146] In some embodiments, B is missing, c is zero and W1 is CH2.
[0148] In some embodiments, R1 and R2 are independently selected from hydrogen, Ci-Cg alkyl, L1- (C3-C6 cycloalkyl), and L1-(4- to 7-membered heterocycloalkyl), wherein said Ci-Cg alkyl, Cs-Cg cycloalkyl and 4- to 7-membered heterocycloalkyl is optionally substituted by one to four R8. In some embodiments, R1 and R2 are independently selected from hydrogen and Ci-Cg alkyl.
[0149] In some embodiments, R1 and R2 taken together with the nitrogen atom to which they are attached form a 3- to 11 -membered ring optionally containing an additional heteroatom or heteroatom group selected from O, N, N(R17), and S(O)m as a ring member, wherein said 3- to 11-membered ring is optionally substituted by one to four R8.
[0151] In one embodiment, there is provided a compound selected from the compounds of Table 1, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof:
[0152] In one embodiment, there is provided a compound selected from the compounds of Table 2, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0153] In some embodiments, this disclosure provides for a method for modulating or degrading CDK2, which method comprises contacting CDK2 with a compound of formula I’, I, IA, IB, or III, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, under conditions wherein CDK2 is modulated or degraded.
[0154] In some embodiments, there is provided a method to modulate or degrade CDK2 in a subject, which method comprises administering to said subject an effective amount of a compound of formula I’, I, IA, IB, or III, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient.
[0155] In some embodiments, there is provided a method for treating cancer in a subject in need thereof, which method comprises selecting a subject whose cancer is mediated at least in part by CDK2 and administering to said subject an effective amount of a compound of formula I’, I, IA, IB, or III, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient.
General Synthetic Methods
[0156] The compounds described herein can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are
given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
[0157] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and P. G. M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley, New York, 1999, and references cited therein.
[0158] The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such as Sigma Aldrich (St. Louis, Missouri, USA), Bachem (Torrance, California, USA), Emka-Chemce (St. Louis, Missouri, USA). Others may be prepared by procedures, or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser ’s Reagents for Organic Synthesis, Volumes 1-15 (John Wiley, and Sons, 2016), Rodd’s Chemistry of Carbon Compounds, Volumes 1-5, and Suppiementals (Elsevier Science Publishers, 2001), Organic Reactions , Volumes 1-40 (John Wiley, and Sons, 2019), March ’s Advanced Organic Chemistry, (John Wiley, and Sons, 8th Edition, 2019), and Larock’s Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
Synthesis of Representative Compounds
[0159] The synthetic realization and optimization of the bifunctional molecules as described herein may be approached in a step-wise or modular fashion. For example, identification of compounds that bind to the target molecules (CDK2) can involve high or medium throughput screening campaigns if no suitable ligands are immediately available. It is not unusual for initial ligands to require iterative design and optimization cycles to improve suboptimal aspects as identified by data from suitable in vitro and pharmacological and/or ADMET assays. Part of the optimization/SAR campaign would be to probe positions of the ligand that are tolerant of substitution and that might be suitable places on which to attach the linker chemistry previously referred to herein. Where crystallographic or NMR structural data are available, these can be used to focus such a synthetic effort.
[0160] In a very analogous way one can identify and optimize ligands for an E3 Ligase.
[0161] The general synthesis of the compounds described herein is set forth in the reaction schemes below. In some embodiments, compounds of formula F, formula I, formula III, and sub-formulae thereof are prepared as shown in Schemes 1-10. In the Schemes below, substituents R1, R2, V, Z, n, p, Ring C, Ring D, and L are as defined throughout the specification. Q is a leaving group (including, but not limited to, Br, Cl, I, triflate, and the like) and PG is a protecting group (including, but not limited to, Boc and the like).
[0162] Other starting materials used herein are either well known in the art, commercially available, or can be prepared by conventional synthetic methods.
Scheme 1
[0163] In Scheme 1, benzyl (l-(tert-butyl)-3-((lS,37?)-3-hydroxycyclopentyl)-lH-pyrazol-5- yl)carbamate, compound 1A, is disclosed in US2020/247784 which is incorporated herein by reference in its entirety or can be prepared by art recognized procedures.
[0164] As to the reaction in Scheme 1, in the first step at least a stoichiometric equivalent of 4- nitrophenyl carbonochloridate, compound 2 A is combined with compound 1A in a diluent such as tetrahydrofuran, dioxane, DMF and the like, typically in the presence of a suitable base such as pyridine, triethylamine and the like. The reaction is typically maintained at from about 20 °C to about 60 °C until it is substantially complete. Conventional workup of the reaction solution can be followed by isolation/purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 3A.
[0165] In the next step, the tert-butyl ester (t-Bu) protecting group is removed under conventional conditions. The t-Bu group is illustrative only and other conventional carboxylic acid blocking groups such as benzyl, methyl, ethyl and the like could be used.
[0166] In the next step, at least a stoichiometric amount of a suitably substituted amine compound, compound 5A in a diluent such as tetrahydrofuran, dioxane, DMF and the like, typically in the presence of a suitable base such as diisopropylethylamine, pyridine, triethylamine and the like. The reaction is typically maintained at from about 20 °C to about 60 °C until it is substantially complete. Conventional
workup of the reaction solution can be followed by isolation/purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 6A.
[0167] In the next step, the pyrazole nitrogen of compound 6A is protected with ethyl formate group. At least a stoichiometric amount of ethyl carbonochloridate, 7A is combined with compound 6A in an inert diluent such as dichloromethane, dichloroethane, THF, and the like. The reaction is typically maintained at from about 20 °C to about 50 °C until it is substantially complete. Conventional workup of the reaction solution can be followed by isolation/purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 8 A. The ethyl formate group is illustrative only and other conventional amino blocking groups such as benzyl, t-butoxycarbonyl (Boc), 9-fluorenylmethoxycarbonyl (Fmoc), benzyloxycarbonyl (Cbz) and the like could be used.
[0168] In the final step, the benzyloxycarbonyl (Cbz) protecting group is removed by conventional conditions to provide for compound 9A. The Cbz group is illustrative only and other conventional amino blocking groups such as benzyl, 9-fluorenylmethoxycarbonyl (Fmoc), benzyloxycarbonyl (Cbz), p-nitrobenzyloxy carbonyl and the like. Upon reaction completion, conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 9A.
Scheme 2
[0169] As to the reaction in Scheme 2, in the first step, a conventional Buchwald-Hartwig amination reaction wherein at least a stoichiometric equivalent of a mono-protected diamine, compound 11A, is combined with compound 10A, in an inert diluent such as DMF, dioxane, toluene, and the like, typically in the presence of a palladium catalyst (e.g, Pd(dba)2, Pd2(dba)3, PdC12[P(o-tolyl)3]2) and a suitable base such as sodium tert-butoxide, LiHMDS, cesium carbonate, and the like. The reaction is typically maintained at from 80° to 120°C for a period of time sufficient for substantial completion of the reaction as evidenced by e.g., thin layer chromatography. Conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 12A.
[0170] In the final step, the methyl ester protecting group is removed under conventional basic hydrolytic conditions to provide for compound 13 A. The methyl ester group is illustrative only and
other conventional carboxylic acid protecting groups such as benzyl, ethyl, tert-butyl and the like can be used. Upon reaction completion, conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 13 A.
17A
Scheme 3
[0171] As to the reaction in Scheme 3, in the first step, a Ni catalysed photoredox-catalyzed crosscoupling reaction, wherein at least a stoichiometric equivalent of a suitable alkyl halide, compound 15A is combined with 3-(5-bromo-l-oxoisoindolin-2-yl)piperidine-2, 6-dione, compound 14A, under conventional reaction conditions [Angew. Chem., Int. Ed. 2019, 58, 6152-6163] well known in the art, including the use of (Ir(dF(CF3)ppy)2(dtbbpy))PFg and NiCh as co-catalysts usually in the presence of a base such as sodium carbonate, potassium carbonate and the like. The reaction is typically conducted in an inert solvent such as DME, THF, DMF, and the like under a blue LED. The reaction is typically maintained at from 20°C to 50°C until it is substantially complete. Conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography, and the like to provide for compound 16A.
[0172] In the final step, the t-butoxycarbonyl (t-BOC) protecting group is removed by conventional conditions. The t-BOC group is illustrative only and other conventional amino blocking groups such as benzyl, 9-fluorenylmethoxycarbonyl (Fmoc), benzyloxycarbonyl (Cbz), p-nitrobenzyloxycarbonyl and the like. Upon reaction completion, conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 17A.
21A
Scheme 4
[0173] As to the reaction in Scheme 4, in the first step, a Ni catalysed photoredox-catalyzed crossCoupling reaction, wherein at least a stoichiometric equivalent of a suitable amine, compound 19A is combined with compound 18A, under conventional reaction conditions [Angew. Chem., Int. Ed. 2019, 58, 6152-6163] well known in the art, including the use of (Ir(dF(CF3)ppy)2(dtbbpy))PFg and NiBr2 as co-catalysts usually in the presence of a base such as sodium carbonate, potassium carbonate, DABCO and the like. The reaction is typically conducted in an inert solvent such as DME, THF, DMF, and the like under a blue LED. The reaction is typically maintained at from 20°C to 60°C until it is substantially complete. Conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography, and the like to provide for compound 20A.
[0174] In the final step, the trimethylsilylethoxymethy (SEM) and t-butoxycarbonyl (t-BOC) protecting group are removed by conventional conditions. The SEM and t-BOC group are illustrative only and other conventional amino blocking groups such as benzyl, 9-fluorenyhnethoxycarbonyl (Fmoc), benzyloxycarbonyl (Cbz), p-nitrobenzyloxycarbonyl and the like could be used. Upon reaction completion, conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 21 A.
Scheme 5
[0175] As to the reaction in Scheme 5, in the first step, a Ni catalysed photoredox-catalyzed crossCoupling reaction, wherein at least a stoichiometric equivalent of a suitable amine, compound 22A is combined with compound 18A, under conventional reaction conditions [Angew. Chem., Int. Ed. 2019, 58, 6152-6163] well known in the art, including the use of (Ir(dF(CF3)ppy)2(dtbbpy))PFg and NiBn as co-catalysts usually in the presence of a base such as sodium carbonate, potassium carbonate, DABCO and the like. The reaction is typically conducted in an inert solvent such as DME, THF, DMF, and the like under a blue LED. The reaction is typically maintained at from 20°C to 60°C until it is substantially complete. Conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography, and the like to provide for compound 23A.
[0176] In the final step, the trimethylsilylethoxymethy (SEM) protecting group is removed by conventional conditions. The SEM group are illustrative only and other conventional amino blocking groups such as benzyl, 9-fluorenylmethoxycarbonyl (Fmoc), benzyloxycarbonyl (Cbz), p- nitrobenzyloxycarbonyl and the like could be used. Upon reaction completion, conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 24 A.
[0177] As to the reaction in Scheme 6, in the first step, at least a stoichiometric amount of aminopyrazole, compound 9A, is combined with compound 13A under conventional amidation reaction conditions (Angewandte Chemie - International Edition, 2020, 59, 3028-3032) well known in the art including the use of N,N-dicyclohexylcarbodiimide (DCC), as an activation agent for the carboxyl group. Other activation agents are well known in the art. The reaction is typically conducted in an inert solvent such as chloroform, methylene chloride, toluene, N,N-dimethylformamide, and the like. The reaction is typically conducted at from about 0° to about 30° C for a period of time sufficient for substantial completion of the reaction as evidenced by e.g., thin layer chromatography. Upon reaction completion, conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 25A.
[0178] In the final step, the ethyl formate and N- protecting groups are removed by conventional conditions, such as basic hydrolytic or acidic conditions to provide for compound 26A. The ethyl formate group is illustrative only and other conventional N-pyrazole protecting groups such as benzyl, tert-butyl and the like can be used. Upon reaction completion, conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPEC), and the like to provide for compound 26A.
Scheme 7
[0179] As to the reaction in Scheme 9, at least a stoichiometric amount of aminopyrazole, compound 9A, is combined with compound 27A under conventional amidation reaction conditions (Angewandte Chemie - International Edition, 2020, 59, 3028-3032) well known in the art including the use of N,N- dicyclohexylcarbodiimide (DCC), as an activation agent for the carboxyl group. Other activation agents are well known in the art. The reaction is typically conducted in an inert solvent such as chloroform, methylene chloride, toluene, N,N-dimethylformamide, and the like. The reaction is typically conducted at from about 0° to about 30° C for a period of time sufficient for substantial completion of the reaction as evidenced by e.g., thin layer chromatography. Upon reaction completion, conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like to provide for compound 28 A.
[0180] With E3 and CDK2 coupling partners in hand, one skilled in the art can use known synthetic methods fortheir combination. Thus a library of bifunctional molecules can be realized and profiled in in vitro and in vivo pharmacological and ADMET/PK studies. As with the E3 binding moiety and CDK2 binding moiety, the final bifiinctional molecules can be subject to iterative design and optimization cycles in order to identify molecules with desirable properties.
[0181] In some instances, protecting group strategies and/or functional group interconversions (FGis) may be required to facilitate the preparation of the desired materials. Such chemical processes are well known to the synthetic organic chemist and many of these may be found in texts such as "Greene's Protective Groups in Organic Synthesis" Peter G. M. Wuts and Theodora W. Greene (Wiley), and "Organic Synthesis: The Disconnection Approach" Stuart Warren and Paul Wyatt (Wiley).
Scheme 8
[0182] As to the reaction in Scheme 8, at least a stoichiometric amount of a suitable amine, compound 26A is combined with compound 24A under conventional reductive amination reaction conditions well known in the art including the use of NaCNBtU. NaBH(OAc)3, NaBH4 and the like. The reaction is typically conducted in an inert solvent such as MeCN, MeOH, THF, and the like. The reaction is typically conducted at from about 0 °C to about 30 °C for a period of time sufficient for substantial completion of the reaction as evidenced by e.g., thin layer chromatography. Upon reaction completion, conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like are optionally used to provide a compound of formula I.
Scheme 9
[0183] As to the reaction in Scheme 9, at least a stoichiometric amount of a suitable amine, compound 28A is combined with compound 21A under conventional reductive amination reaction conditions well known in the art including the use of NaCNBHs. NaBH(OAc)3, NaBPh and the like. The reaction is typically conducted in an inert solvent such as MeCN, MeOH, THF, and the like. The reaction is typically conducted at from about 0 °C to about 30 °C for a period of time sufficient for substantial completion of the reaction as evidenced by e.g., thin layer chromatography. Upon reaction completion, conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like are optionally used to provide a compound of formula I.
Scheme 10
[0184] As to the reaction in Scheme 10, at least a stoichiometric amount of a suitable amine, compound 28A is combined with compound 17A under conventional reductive amination reaction conditions well known in the art including the use of NaCNBHs. NaBH(OAc)3, NaBtE and the like. The reaction is typically conducted in an inert solvent such as MeCN, MeOH, THF, and the like. The reaction is typically conducted at from about 0 °C to about 30 °C for a period of time sufficient for substantial completion of the reaction as evidenced by e.g., thin layer chromatography. Upon reaction completion, conventional workup of the reaction solution can be followed by isolation / purification processes such as crystallization, chromatography, high performance liquid chromatography (HPLC), and the like are optionally used to provide a compound of formula I.
Methods of Use
[0185] The compounds and compositions described herein are useful in methods for treating a CDK2 dependent disease or disorder or a disease or disorder that is mediated, at least in part, by CDK2. In some embodiments, the CDK2 dependent disease or disorder is a disease characterized by amplification or overexpression of cyclin El (CCNE1) or cyclin E2 (CCNE2) or both CCNE1 and CCNE2. The methods comprise administering to a subject suffering from a CDK2 dependent disease or disorder an effective amount of a compound as described herein, e.g., a compound of formula F, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer
thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient.
[0186] Thus, there is provided a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient, for use in treating a CDK2 dependent disease or disorder or a disease or disorder that is mediated, at least in part, by CDK2, or is a disease characterized by amplification or overexpression of cyclin El (CCNE1) or cyclin E2 (CCNE2) or both CCNE1 and CCNE2. In one embodiment, there is provided a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient for use in treating an CDK2 dependent disease or disorder.
[0187] In one embodiment, there is provided a use of a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, in the preparation of a medicament for treating a CDK2 dependent disease or disorder or a disease or disorder that is mediated, at least in part, by CDK2, or is a disease characterized by amplification or overexpression of cyclin El (CCNE1) or cyclin E2 (CCNE2) or both CCNE1 and CCNE2.
[0188] In one embodiment, the method relates to a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient, for use in manufacture of a medicament for reducing CDK2 protein levels where reduction of such protein levels treats or ameliorates the disease or disorder.
[0189] In one embodiment, the methods described herein comprise use of a prodrug of a compound as described herein.
[0190] In one embodiment, the method relates a compound as described herein, e.g., a compound of formula I’, formula I, formula III, or any subformula thereof, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable excipient wherein the CDK2 degradation at 1 pM concentration of the compound as described herein is in the range of about 25%-99%. The CDK2 degradation is measured by the assay described in the biological example. In some embodiments, the CDK2 degradation is from about 25% to about 50%, from about 45% to about 70%, from about 65% to about 90% or from about 75% to about 99%. In some embodiments, the CDK2 degradation is from about 25% to about 35%, from about 35% to about 45%, from about 45% to about 55%, from about 55% to about 65%, from about 65% to about 75%, from about 75% to about 85%, from about 85% to
about 99%. In some embodiments, the CDK2 degradation is more than 60%. In some embodiments, the CDK2 degradation is more than 70%. In some embodiments, the CDK2 degradation is more than 80%. In some embodiments, the CDK2 degradation is more than 90%.
[0191] The compounds and compositions described herein are useful in treating CDK2 dependent diseases or disorders such as cancers including, but not limited to, liposarcoma, glioblastoma, bladder cancer, adrenocortical cancer, multiple myeloma, colorectal cancer, non-small cell lung cancer, Human Papilloma Virus-associated cervical, oropharyngeal, penis, anal, thyroid, or vaginal cancer or Epstein- Barr Virus-associated nasopharyngeal carcinoma, gastric cancer, rectal cancer, thyroid cancer, Hodgkin’s lymphoma, or non-Hodgkin’s lymphoma (e.g., diffuse large B-cell lymphoma). The cancer may be selected from prostate cancer, breast carcinoma, lymphomas, leukemia, myeloma, bladder carcinoma, colon cancer, cutaneous melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, renal cancer, glioblastoma multiform, glioma, thyroid cancer, parathyroid tumor, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, cholangiocarcinoma, gastric cancer, soft tissue sarcomas, rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid cancers, cancer for which the immune response is deficient, an immunogenic cancer, and Ewing’s sarcoma. In one embodiment, the CDK2 -dependent disease or disorder is a disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triplenegative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, and gastrointestinal stromal tumor (GIST). In another embodiment, the cancer is selected from non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myelogenous leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the CDK2 -dependent disease or disorder is a disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple- negative breast cancer (TNBC), nasopharyngeal cancer (NPC), and microsatellite stable colorectal cancer (mssCRC). In certain embodiments, compounds or compositions described herein are active against solid tumors.
[0192] The compounds of the disclosure can be administered in effective amounts to treat or prevent or reduce the risks of developing a disease or disorder as discussed herein and/or to prevent or reduce the rate of the development or progression thereof in a subject.
[0193] In general, methods of using the compounds of the present application comprise administering to a subject in need thereof a therapeutically effective amount of a compound as described herein.
[0194] In certain embodiments, compounds as described herein are useful in the treatment of proliferative disorders (e.g., cancer, benign neoplasms, inflammatory disease, and autoimmune diseases). In certain embodiments, according to the methods of treatment of the present application, levels of cell proteins of interest, e.g., pathogenic and oncogenic proteins are modulated, or their growth is inhibited or the proteins are degraded by contacting said cells with an compound or composition, as described herein. In other embodiments, the compounds are useful in treating cancer.
[0195] Thus, in another aspect of the application, methods for the treatment of cancer are provided comprising administering a therapeutically effective amount of a compound or composition, as described herein, to a subject in need thereof. In certain embodiments, a method for the treatment of cancer is provided comprising administering a therapeutically effective amount of a compound, or a pharmaceutical composition comprising a compound as described herein to a subject in need thereof, in such amounts and for such time as is necessary to achieve the desired result. In some embodiments, the compounds of present application are administered orally or intravenously. In certain non-limiting embodiments of the present application a “therapeutically effective amount” of the compound or pharmaceutical composition is that amount effective for killing or inhibiting the growth of tumor cells. The compounds and compositions, according to the method of the present application, may be administered using any amount and any route of administration effective for killing or inhibiting the growth of tumor cells. Thus, the expression “amount effective to kill or inhibit the growth of tumor cells,” as used herein, refers to a sufficient amount of agent to kill or inhibit the growth of tumor cells. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease, the particular anticancer agent, its mode of administration, and the like.
[0196] Another aspect of the application relates to a method of treating or lessening the severity of a disease or condition associated with a proliferation disorder in a patient, said method comprising a step of administering to said patient, a compound described herein (e.g., compound of formula I’, formula I, or formula III) or a composition comprising said compound.
[0197] It will be appreciated that the compounds and compositions, according to the method of the present application, may be administered using any amount and any route of administration effective for the treatment of cancer and/or disorders associated with cell hyperproliferation. For example, when using the compounds for the treatment of cancer, the expression “effective amount” as used herein, refers to a sufficient amount of agent to inhibit proliferation, or refers to a sufficient amount to reduce the effects of cancer. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the diseases, the particular anticancer agent, its mode of administration, and the like.
[0198] The present application also provides methods of protecting against a proliferative disorder in a subject in need thereof or the treatment of a proliferative disorder in a subject in need thereof by administering a therapeutically effective amount of compound or composition as described herein to a subject in need of such treatment. The proliferative disorder can be cancer or a precancerous condition. The present application also provides the use of compound as described herein for the preparation of a medicament useful for the prevention of a proliferative disorder.
[0199] As used herein, the term “proliferative disorder” refers to conditions in which unregulated or abnormal growth, or both, of cells can lead to the development of an unwanted condition or disease, which may or may not be cancerous. Exemplary proliferative disorders of the application encompass a
variety of conditions wherein cell division is deregulated. Exemplary proliferative disorder include, but are not limited to, neoplasms, benign tumors, malignant tumors, pre-cancerous conditions, in situ tumors, encapsulated tumors, metastatic tumors, liquid tumors, solid tumors, immunological tumors, hematological tumors, cancers, carcinomas, leukemias, lymphomas, sarcomas, and rapidly dividing cells. The term “rapidly dividing cell” as used herein is defined as any cell that divides at a rate that exceeds or is greater than what is expected or observed among neighboring or juxtaposed cells within the same tissue. A proliferative disorder includes a precancer or a precancerous condition. A proliferative disorder includes cancer. The methods provided herein are used to treat or alleviate a symptom of cancer. The term “cancer” includes solid tumors, as well as, hematologic tumors and/or malignancies. A “precancer cell” or “precancerous cell” is a cell manifesting a proliferative disorder that is a precancer or a precancerous condition. A “cancer cell” or “cancerous cell” is a cell manifesting a proliferative disorder that is a cancer. Any reproducible means of measurement may be used to identify cancer cells or precancerous cells. Cancer cells or precancerous cells can be identified by histological typing or grading of a tissue sample (e.g., a biopsy sample). Cancer cells or precancerous cells can be identified through the use of appropriate molecular markers.
[0200] Exemplary non-cancerous conditions or disorders include, but are not limited to, rheumatoid arthritis; inflammation; autoimmune disease; lymphoproliferative conditions; acromegaly; rheumatoid spondylitis; osteoarthritis; gout, other arthritic conditions; sepsis; septic shock; endotoxic shock; gramnegative sepsis; toxic shock syndrome; asthma; adult respiratory distress syndrome; chronic obstructive pulmonary disease; chronic pulmonary inflammation; inflammatory bowel disease; Crohn's disease; psoriasis; eczema; ulcerative colitis; pancreatic fibrosis; hepatic fibrosis; acute and chronic renal disease; irritable bowel syndrome; pyresis; restenosis; cerebral malaria; stroke and ischemic injury; neural trauma; Alzheimer's disease; Huntington's disease; Parkinson's disease; acute and chronic pain; allergic rhinitis; allergic conjunctivitis; chronic heart failure; acute coronary syndrome; cachexia; malaria; leprosy; leishmaniasis; Lyme disease; Reiter's syndrome; acute synovitis; muscle degeneration, bursitis; tendonitis; tenosynovitis; herniated, ruptures, or prolapsed intervertebral disk syndrome; osteopetrosis; thrombosis; restenosis; silicosis; pulmonary sarcoidosis; bone resorption diseases, such as osteoporosis; graft-versus-host reaction; Multiple Sclerosis; lupus; fibromyalgia; AIDS and other viral diseases such as Herpes Zoster, Herpes Simplex I or II, influenza virus and cytomegalovirus; and diabetes mellitus.
[0201] A “proliferative disorder of the hematologic system” is a proliferative disorder involving cells of the hematologic system. A proliferative disorder of the hematologic system can include lymphoma, leukemia, myeloid neoplasms, mast cell neoplasms, myelodysplasia, benign monoclonal gammopathy, lymphomatoid granulomatosis, lymphomatoid papulosis, polycythemia vera, chronic myelocytic leukemia, agnogenic myeloid metaplasia, and essential thrombocythemia. A proliferative disorder of the hematologic system can include hyperplasia, dysplasia, and metaplasia of cells of the hematologic system.
[0202] One skilled in the art may refer to general reference texts for detailed descriptions of known techniques discussed herein or equivalent techniques. These texts include Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (2005); Sambrook et al., Molecular Cloning, A Laboratory Manual (3rd edition), Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2000); Coligan et al., Current Protocols in Immunology, John Wiley & Sons, N.Y.; Erma et al., Current Protocols in Pharmacology, John Wiley & Sons, N.Y.; Fingl et al., The Pharmacological Basis of Therapeutics (1975), Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 18th edition (1990). These texts can, of course, also be referred to in making or using an aspect of the application.
[0203] In certain embodiments, according to the methods of treatment of the present application, levels of cell proteins of interest, e.g., pathogenic and oncogenic proteins are modulated, or their growth is inhibited by contacting said cells with an compound or composition, as described herein. In other embodiments, the compounds are useful in treating cancer.
[0204] Additionally, the present application provides pharmaceutically acceptable derivatives of the compounds described herein, and methods of treating a subject using such derivative, pharmaceutical compositions thereof, or either of these in combination with one or more additional therapeutic agents. [0205] Other therapies or anticancer agents that may be used in combination with the compounds and compositions disclosed herein including surgery, radiotherapy, endocrine therapy, biologic response modifiers (interferons, interleukins, and tumor necrosis factor (TNF), to name a few), hyperthermia and cryotherapy, agents to attenuate any adverse effects (e.g., antiemetics), and other approved chemotherapeutic drugs, including, but not limited to, alkylating drugs (mechlorethamine, chlorambucil, Cyclophosphamide, Melphalan, Ifosfamide), antimetabolites (Methotrexate), purine antagonists and pyrimidine antagonists (6-Mercaptopurine, 5-Fluorouracil, Cytarabine, Gemcitabine), spindle poisons (Vinblastine, Vincristine, Vinorelbine, Paclitaxel), podophyllotoxins (Etoposide, Irinotecan, Topotecan), antibiotics (Doxorubicin, Bleomycin, Mitomycin), nitrosoureas (Carmustine, Lomustine), inorganic ions (Cisplatin, Carboplatin), enzymes (Asparaginase), and hormones (Tamoxifen, Leuprolide, Flutamide, and Megestrol), to name a few. For a more comprehensive discussion of overview of cancer therapy see The Merck Manual, Twentieth Ed. 2020, the entire contents of which are hereby incorporated by reference. See also the National Cancer Institute (NCI) website (www.nci.nih.gov) and the Food and Drug Administration (FDA) website for a list of the FDA approved oncology drugs (www.fda.gov/cder/cancer/druglistfirame).
[0206] In certain embodiments, a pharmaceutical composition as described herein, comprising a compound as disclosed herein, further comprise one or more additional therapeutically active ingredients (e.g., a chemotherapeutic agent and/or a palliative agent). For purposes of the application, the term “palliative” refers to treatment that is focused on the relief of symptoms of a disease and/or side effects of a therapeutic regimen, but is not considered to be curative. For example, palliative treatments encompass painkillers, antinausea medications and anti-sickness drugs. In addition,
chemotherapy, radiotherapy and surgery can all be used palliatively (that is, to reduce symptoms without going for cure; e.g., for shrinking tumors and reducing pressure, bleeding, pain and other symptoms of cancer).
Administration, Pharmaceutical Compositions
[0207] Administration of the disclosed compounds and pharmaceutical compositions can be accomplished via any mode of administration for therapeutic agents. These modes include systemic or local administration such as oral, nasal, parenteral, transdermal, subcutaneous, vaginal, buccal, rectal or topical administration modes.
[0208] Another aspect of the disclosure is directed to pharmaceutical compositions comprising a compound of Formula I’, Formula I, or Formula III, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may further include an excipient, diluent, or surfactant.
[0209] Depending on the intended mode of administration, the disclosed compositions can be in solid, semi-solid or liquid dosage form, such as, for example, injectables, tablets, suppositories, pills, timerelease capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices. Likewise, they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, and all using forms well known to those skilled in the pharmaceutical arts.
[0210] Illustrative pharmaceutical compositions for oral administration include tablets and gelatin capsules comprising a compound of the disclosure and a pharmaceutically acceptable carrier, such as a) a diluent, e.g., purified water, triglyceride oils, such as hydrogenated or partially hydrogenated vegetable oil, or mixtures thereof, com oil, olive oil, sunflower oil, safflower oil, fish oils, such as EPA or DHA, or their esters or triglycerides or mixtures thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and/or glycine; b) a lubricant, e.g., silica, talcum, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and/or polyethylene glycol; for tablets also; c) a binder, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, magnesium carbonate, natural sugars such as glucose or beta-lactose, com sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, waxes, and/or polyvinylpyrrolidone, if desired; d) a disintegrant, e.g., starches, agar, methyl cellulose, bentonite, xanthan gum, algic acid or its sodium salt, or effervescent mixtures; e) absorbent, colorant, flavorant and sweetener; f) an emulsifier or dispersing agent, such as Tween 80, Labrasol, HPMC, DOSS, caproyl 909, labrafac, labrafil, peceol, transcutol, capmul MCM, capmul PG-12, captex 355, gelucire, vitamin E TGPS or other acceptable emulsifier; and/or g) an agent that enhances absorption of the compound such as cyclodextrin, hydroxypropyl-cyclodextrin, PEG400, PEG200. Compositions can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present pharmaceutical compositions can contain from about 0.1% to about 99%,
from about 5% to about 90%, or from about 1% to about 20% of the disclosed compound by weight or volume.
[0211] Illustrative liquid pharmaceutical compositions, such as injectable compositions can, for example, be prepared by dissolution, dispersion, etc. For example, a compound as described herein can be dissolved in or mixed with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form an injectable isotonic solution or suspension. Proteins such as albumin, chylomicron particles, or serum proteins can be used to solubilize the disclosed compounds. Parental injectable administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions. Injectable s can be prepared in conventional forms, either as liquid solutions or suspensions or solid forms suitable for dissolving in liquid prior to injection.
[0212] The disclosed compounds can be formulated as a suppository that can be prepared from fatty emulsions or suspensions; using polyalkylene glycols such as propylene glycol, as the carrier.
[0213] The disclosed compounds can be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, containing cholesterol, stearylamine or phosphatidylcholines. In some embodiments, a fdm of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, as described in U.S. Pat. No. 5,262,564, which is hereby incorporated by reference in its entirety.
[0214] Disclosed compounds can be delivered by the use of monoclonal antibodies as individual carriers to which the disclosed compounds are coupled. The disclosed compounds can also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspanamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the disclosed compounds can be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, poly orthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and cross-linked or amphipathic block copolymers of hydrogels. In one embodiment, disclosed compounds are not covalently bound to a polymer, e.g., a poly carboxy lie acid polymer, or a polyacrylate.
[0215] In one embodiment, the disclosure provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of the present disclosure. In one embodiment, the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
[0216] The kit of the disclosure may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for
titrating the separate compositions against one another. To assist compliance, the kit of the disclosure typically comprises directions for administration.
[0217] Pharmaceutical dosage forms of a compound of this disclosure may be manufactured by any of the methods well-known in the art, such as, for example, by conventional mixing, sieving, dissolving, melting, granulating, dragee-making, tableting, suspending, extruding, spray-drying, levigating, emulsifying, (nano-/micro-) encapsulating, entrapping, or lyophilization processes. As noted above, the compositions of this disclosure can include one or more physiologically acceptable inactive ingredients that facilitate processing of active molecules into preparations for pharmaceutical use.
[0218] As noted above, the compositions are comprised of, in general, a compound of this disclosure in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are nontoxic, aid administration, and do not adversely affect the therapeutic benefit of the claimed compounds. Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
[0219] Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semi-solid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. In some embodiments, liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols.
[0220] Compressed gases may be used to disperse a compound of this disclosure in an aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc. Other suitable pharmaceutical excipients and their formulations are described in Remington’s Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990).
[0221] The compositions of this disclosure may, if desired, be presented in a pack or dispenser device containing one or more unit dosage forms containing the active ingredient. Such a pack or device may, for example, comprise metal or plastic foil, such as a blister pack, or glass, and rubber stoppers such as in vials. The pack or dispenser device may be accompanied by instructions for administration. Compositions comprising a compound of this disclosure that can be formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
[0222] The amount of the compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound of this disclosure based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. In one embodiment, the compound is present at a level of about 1-80 wt %. Representative pharmaceutical formulations are described below.
Formulation Examples
[0223] The following are representative pharmaceutical formulations containing a compound of this disclosure.
Formulation Example 1 — Tablet formulation
[0224] The following ingredients are mixed intimately and pressed into single scored tablets.
Quantity per
Ingredient tablet, mg compound of this disclosure 400
Cornstarch 50 croscarmellose sodium 25
Lactose 120 magnesium stearate 5
Formulation Example 2 — Capsule formulation
[0225] The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.
Quantity per
Ingredient capsule, mg compound of this disclosure 200 lactose, spray-dried 148 magnesium stearate 2
Formulation Example 3 — Suspension formulation
[0226] The following ingredients are mixed to form a suspension for oral administration.
Ingredient Amount compound of this disclosure 1.0 g fumaric acid 0.5 g sodium chloride 2.0 g methyl paraben 0.15 g propyl paraben 0.05 g granulated sugar 25.0 g sorbitol (70% solution) 13.00 g
V eegum K (V anderbilt Co . ) 1.0 g
Flavoring 0.035 mL
Colorings 0.5 mg
distilled water q.s. to 100 mL
Formulation Example 4 — Injectable formulation
[0227] The following ingredients are mixed to form an injectable formulation.
Ingredient Amount compound of this disclosure 0.2 mg -20 mg sodium acetate buffer solution, 0.4 M 2.0 mL
HC1 (IN) or NaOH (IN) q.s. to suitable pH water (distilled, sterile) q.s. to 20 mL
Formulation Example 5 — Suppository Formulation
[0228] A suppository of total weight 2.5 g is prepared by mixing the compound of this disclosure with Witepsol® H-15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition:
Ingredient Amount
Compound of this disclosure 500 mg
Witepsol® H-15 balance
Dosing
[0229] The dosage regimen utilizing the disclosed compound is selected in accordance with a variety of factors including type, species, age, weight, sex, and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the patient; and the particular disclosed compound employed. A physician or veterinarian can determine and prescribe an effective amount of a compound as described herein to treat or prevent the disease or disorder presented.
[0230] Effective dosage amounts of the disclosed compounds, when used for the indicated effects, range from about 0.5 mg to about 5000 mg of the disclosed compound as needed to treat the condition. Compositions for in vivo or in vitro use can contain about 0.5, 5, 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, or 5000 mg of the disclosed compound, or, in a range of from one amount to another amount in the list of doses. In one embodiment, the compositions are in the form of a tablet that can be scored.
EXAMPLES
[0231] This disclosure is further understood by reference to the following examples, which are intended to be purely exemplary of this disclosure. This disclosure is not limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of this disclosure only.
Any methods that are functionally equivalent are within the scope of this disclosure. Various modifications of this disclosure in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications fall within the scope of the present disclosure.
[0232] In the specification and in the examples below, all temperatures are in degrees Celsius. In addition, the following abbreviations have the following meanings. If not defined, these abbreviations have their art recognized meaning.
Abbreviation Meaning
5 chemical shift (ppm)
ACN or MeCN acetonitrile
Boc tert -butoxycarbonyl
BRET Bioluminescence Resonance Energy Transfer
BuLi n-butyllithium
Cbz benzyloxycarbonyl
CbzCl Benzyloxycarbonyl chloride
DC50 concentration that resulted in a 50% targeted protein degradation
DCM dichloromethane
DHA docosahexaenoic acid
DIEA or DIPEA diisopropylethylamine
DMA dimethylacetamide
DMAP 4-dimethylaminopyridine
DMF N,N -dimethylformamide
DMP Dess-Martin periodinane
DMSO dimethylsulfoxide d6-DMSO deuterated dimethylsulfoxide d4-MeOH deuterated methanol dtbbpy 4,4'-di-tert-butyl-2,2'-dipyridyl
EDCI 1 -ethyl-3 -(3 -dimethylaminopropyl)carbodiimide
EPA eicosapentaenoic acid eq. equivalent(s)
ESI electrospray ionization
EtOAc ethyl acetate
EtOH ethanol
FBS fetal Bovine Serum
FITC fluorescein isothiocyanate
Fmoc fluorenylmethyloxycarbonyl g grams
’H NMR proton nuclear magnetic resonance spectroscopy h hour(s)
HPLC high performance liquid chromatography
IPA isopropyl alcohol
Ir[(dF(CF3)ppy)2dtbbpy]PF6 [4,4'-Bis(l,l-dimethylethyl)-2,2'-bipyridine-N1,N1']bis[3,5-difluoro-
2-[5-(trifluoromethyl)-2-pyridinyl-N]phenyl-C]Iridium(III) hexafluorophosphate
JohnPhos (2-biphenylyl)di-tert-butylphosphine
L liter
LC liquid chromatography
LC-MS liquid chromatography - mass spectrometry
M molar mCPBA meta-chloroperoxybenzoic acid
MeOH methanol mg milligram mmol millimole mL milliliter pL microliter nmol or pmol micromole
mM micromolar pm micron m/z mass-to-charge ratio
MsOH methanesulfonic acid min minute(s)
NiCh glyme Nickel(II) chloride ethylene glycol dimethyl ether complex nm nanometer N normal PBS Phosphate-buffered saline Pd2(dba)3 tris(dibenzylideneacetone)dipalladinm(0) Pd(OAc)2 palladium (II) acetate pM picomolar q.s. amount which is sufficient rt room temperature SEM trimethylsilylethoxymethyl SFC supercritical fluid chromatography t-Bu tert-butyl TEA triethylamine TFA trifluoroacetic acid TFP tri(2-furyl)phosphine THF tetrahydrofuran TMP 2,2,6,6-tetramethylpiperidine T3P propanephosphonic acid anhydride TRITC tetramethylrhodamine TsCl 4-toluenesulfonyl chloride TsOH 4-toluenesulfonic acid
UV ultraviolet
v/v volume/volume ratio weight percent
NMR abbreviations br = broad d = doublet dd = doublet of doublets m = multiplet q = quartet quin = quintet s = singlet t = triplet
Example 1: Synthesis of (lR,3S)-3-(3-(2-(l-((l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperidin-4-yl)methyl)piperidin-4-yl)acetamido)-lH-pyrazol-5-yl)cyclopentyl (2S)-2- methylazetidine-l-carboxylate (Compound P-8)
[0233] To a solution of methyl 3-oxocyclopentane-l-carboxylate (25 g, 175.87 mmol, 1 eq) in methanol (125 mL) was added 4-methylbenzenesulfonic acid hydrate (6.69 g, 35.17 mmol, 0.2 eq) and trimethoxymethane (111.98 g, 1.06 mol, 115.68 mL, 6 eq) at 20°C. The mixture was stirred at 20°C for 16 hours. The reaction mixture was poured into a NaHCCf sat solution (200 mL) and then the mixture was concentrated under reduced pressure to remove methanol. The residue was extracted with ethyl acetate (150 mL). The aqueous layer was extracted with ethyl acetate (150 mL). The combined organic layers were washed with brine (100 mL), dried over sodium sulfate and concentrated under reduced pressure to give methyl 3,3-dimethoxycyclopentane-l-carboxylate which was carried forward without
purification. ’H NMR (400 MHz, CDCh) 5 1.71-1.93 (m, 4H), 1.97-2.08 (m, 2H), 2.82 (quin, J=8.25 Hz, 1H), 3.14 (d, J=7.75 Hz, 6H), 3.61 (s, 3H).
[0234] To a solution of n-BuLi (2.5 M, 403.78 mL, 2 eq) in tetrahydrofuran (360 mL) at -65 °C, was added acetonitrile (41.44 g, 1.01 mol, 53.13 mL, 2 eq) dropwise, the internal reaction temperature was maintained below -55 °C. The mixture was stirred at -65 °C for 1 hour. A solution of methyl 3,3- dimethoxy cyclopentane- 1 -carboxylate (95 g, 504.73 mmol, 1 eq) in tetrahydrofuran (135 mL) was added. The mixture was stirred at -65 °C for 1 hour, then the reaction was warmed to 0 °C. Water (500 mL) was added slowly and the reaction stirred for 1 hour. IN HC1 solution was added to the mixture until the pH = 7. The reaction solution was concentrated under reduced pressure to remove tetrahydrofuran. The aqueous mixture was extracted with ethyl acetate (3 x 500 mL). The combined organic layers were washed with brine (3 x 100 mL), dried over sodium sulfate and concentrated in vacuo to give 3-(3,3-dimethoxycyclopentyl)-3-oxopropanenitrile which was carried forward without purification. ‘H NMR (400 MHz, CDCh) 5 1.77-1.87 (m, 3H), 1.91-1.98 (m, 1H), 1.98-2.04 (m, 3H), 3.15 (d, 7=1.75 Hz, 6H), 3.53 (s, 2H).
[0235] To a suspension of 3-(3,3-dimethoxycyclopentyl)-3-oxopropanenitrile (36.39 g, 292.04 mmol, 1.2 eq, HC1) in ethanol (465 mL) was added saturated aqueous solution of sodium hydroxide (11.68 g, 292.04 mmol, 1.2 eq) and stirred for 1 h. To the mixture was added a solution of 3-(3, 3- dimethoxycyclopentyl)-3-oxo-propanenitrile (48 g, 243.37 mmol, 1 eq) in ethanol (200 mL). The mixture was warmed to 75 °C and stirred for 16 hours. The reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure to give residue. The residue was purified by column chromatography (SiCL, 0 to 100% ethyl acetate in petroleum ether) to give l-(tert-butyl)-3-(3,3-dimethoxycyclopentyl)-lH-pyrazol-5-amine. ’H NMR (400 MHz, CDCL) 5 1.60 (s, 9H), 1.66-1.79 (m, 2H), 1.80-1.87 (m, 2H), 1.92-2.01 (m, 1H), 2.26 (dd, 7=13.27, 8.13 Hz, 1H), 3.08-3.18 (m, 1H), 3.20-3.24 (m, 6H), 3.45-3.53 (m, 2H), 5.42 (s, 1H).
[0236] To a solution of l-(tert-butyl)-3-(3,3-dimethoxycyclopentyl)-lH-pyrazol-5-amine (28 g, 104.73 mmol, 1 eq) in acetonitrile (280 mL) at 0°C was added CbzCl (35.73 g, 209.45 mmol, 29.78 mL, 2 eq). The mixture was warmed to room temperature and stirred for 2 hours. NaHC’CL (28.15 g, 335.12 mmol, 13.03 mL, 3.2 eq) was added and the mixture was stirred for 14 hours. The reaction mixture was filtered and the filtrate was concentrated under vacuum to give benzyl (l-(tert-butyl)-3- (3,3-dimethoxycyclopentyl)-lH-pyrazol-5-yl)carbamate which was carried forward without purification. ’H NMR (400 MHz, CDCh) 5 1.44 (s, 9H), 1.92 (br s, 2H), 2.09 (br d, J=9.43 Hz, 2H), 2.19-2.24 (m, 2H), 4.46 (s, 2H), 5.06 (s, 2H), 5.91-5.99 (m, 1H), 7.24 (br d, J=1.23 Hz, 5H).
[0237] To a solution of benzyl (l-(tert-butyl)-3-(3,3-dimethoxycyclopentyl)-lH-pyrazol-5- yl)carbamate (47 g, 117.06 mmol, 1 eq) in acetone (200 mL) and water (200 mL) was added TsOH (2.62 g, 15.22 mmol, 0.13 eq). The mixture was stirred at 60 °C for 16 hours. The reaction mixture was cooled to room temperature and was concentrated under reduced pressure to remove acetone. The aqueous solution was extracted with dichloromethane (3 x 100 mL). The organic phases were combined and washed with brine (3 x 100 mL), dried over sodium sulfate and concentrated under vacuum to give a residue. The residue was purified by column chromatography (SiCL, 0 to 25% ethyl acetate in petroleum ether) to give a solid. The solid was triturated with methyl tertiary butyl ether (150 mL) to give benzyl (l-(tert-butyl)-3-(3-oxocyclopentyl)-lH-pyrazol-5-yl)carbamate. rH NMR (400 MHz, CDCh) 5 1.58 (s, 9H), 1.99-2.11 (m, 1H), 2.16-2.26 (m, 1H), 2.31-2.40 (m, 2H), 2.47 (d, J=9.01 Hz, 1H), 2.55 (d, J=7.88 Hz, 1H), 3.37-3.47 (m, 1H), 5.20 (s, 2H), 6.10 (br s, 1H), 7.38 (br s, 5H).
[0238] A solution of benzyl (l-(tert-butyl)-3-(3-oxocyclopentyl)-lH-pyrazol-5-yl)carbamate (25 g, 70.34 mmol, 1 eq) in tetrahydrofuran (250 mL) was degassed and purged with nitrogen three times and
cooled to -78 °C. Lithium triethylborohydride (1.0 M, 140.67 mL, 2 eq) was added dropwise at a rate to maintain the internal temperature below -55 °C. The mixture was stirred at -65 °C for 1.5 hours. Methanol (500 mL) was added between 0-10 °C and then stirred for 1 h. The reaction was concentrated in vacuo to give residue. The residue was dissolved in water (200 mL) and extracted with ethyl acetate (3 x 200 mL). The combined organic phases were washed with brine (3 x 200 mL), dried over sodium sulfate, filtered and concentrated in vacuo to give a residue. The residue was purified by column chromatography (SiCL, 0 to 50% ethyl acetate in petroleum ether) to give benzyl ( I -(tcrt-bnty l )-3 -((cz.s )- 3-hydroxycyclopentyl)-lH-pyrazol-5-yl)carbamate. H NMR (400 MHz, CDCh) 5 1.55 (s, 9H), 1.74- 1.85 (m, 2H), 1.86-1.93 (m, 2H), 2.00-2.12 (m, 2H), 3.16-3.27 (m, 1H), 4.34 (br d, J=3.38 Hz, 1H), 4.96-5.07 (m, 1H), 5.19 (s, 2H), 6.06 (br s, 1H), 6.51 (br s, 1H), 7.33-7.41 (m, 5H) and benzyl (l-(tert- butyl)-3-((lra«5)-3-hydroxycyclopentyl)-lH-pyrazol-5-yl)carbamate. ’H NMR (400 MHz, CDCh) 5 1.58 (s, 9H), 1.61-1.77 (m, 3H), 1.88-1.97 (m, 1H), 1.98-2.03 (m, 1H), 2.03-2.12 (m, 1H), 2.12-2.25 (m, 1H), 3.31-3.42 (m, 1H), 4.46 (t, J=5.57, 2.71 Hz, lH), 5.19 (s, 2H), 6.04 (br s, 1H), 6.30 (br s, 1H), 7.37 (br s, 5H).
[0239] The racemic mixture of benzyl ( l-(tcrt-butyl)-3-((c/.s)-3-hydroxycyclopcntyl)- I H-pyrazol-5- yl)carbamate (6 g, 16.79 mmol, 1 eq) was purified into pure enantiomers by chiral SFC (column: DAICEL CHIRALPAK IG (250 mmx50 mm, 10 pm); mobile phase: [0.1% NH4OH in MeOH]; B% CO2: 25%-25%, 3 min) to give benzyl (l-(tert-butyl)-3-((lS,3R)-3-hydroxycyclopentyl)-lH-pyrazol-5- yl)carbamate. ’H NMR (400 MHz, CDCh) 5 1.46 (s, 9H), 1.52 (br d, J=9.76 Hz, 1H), 1.59-1.84 (m, 4H), 1.85-2.01 (m, 3H), 3.08-3.16 (m, 1H), 4.24 (br s, 1H), 4.81 (br s, 1H), 5.O9 (s, 2H), 5.97 (br s, 1H), 6.16 (br s, 1H), 7.16 (s, 1H) and benzyl (l-(tert-butyl)-3-((lR,3S)-3-hydroxycyclopentyl)-lH-pyrazol- 5-yl)carbamate. ‘H NMR (400 MHz, CDC13) 5 1.45 (s, 9H), 1.49-1.59 (m, 1H), 1.59-1.85 (m, 3H), 1.85- 2.02 (m, 3H), 3.08-3.16 (m, 1H), 4.18-4.29 (m, 1H), 4.67-4.99 (m, 1H), 5.05-5.13 (m, 2H), 5.97 (br s, 1H), 6.32 (br s, 1H), 7.27 (br s, 4H).
[0240] To a solution of benzyl (l-(tert-butyl)-3-((lS,3R)-3-hydroxycyclopentyl)-lH-pyrazol-5- yl)carbamate (1 g, 2.80 mmol, 1 eq) in DCM (15 mL) was added pyridine (663.88 mg, 8.39 mmol, 677.43 pL, 3 eq), DMAP (34.18 mg, 279.76 pmol, 0.1 eq) and a solution of (4-
nitrophenyl)carbonochloridate (845.85 mg, 4.20 mmol, 1.5 eq) in DCM (5 mL). The reaction was stirred for 12 hours at room temperature. The solvents were evaporated in vacuo to give a residue. The residue was purified by column chromatography (SiCL, 25% ethyl acetate in petroleum ether) to give benzyl (l-(tert-butyl)-3-((lS,3R)-3-(((4-nitrophenoxy)carbonyl)oxy)cyclopentyl)-lH-pyrazol-5- yl)carbamate. m/z (ESI+) 523 (M+H)+. ‘H NMR (400 MHz, CDC13) 5 1.60 (s, 9 H), 1.84 - 2.05 (m, 4 H), 2.08 - 2.16 (m, 1 H), 2.52 - 2.68 (m, 1 H), 3.04 - 3.23 (m, 1 H), 5.22 (s, 3 H), 6.07 - 6.41 (m, 2 H), 7.32 - 7.56 (m, 7 H), 8.27 (d, J=9.26 Hz, 2 H).
[0241] A solution of benzyl (l-(tert-butyl)-3-((lS,3R)-3-(((4- nitrophenoxy)carbonyl)oxy)cyclopentyl)-lH-pyrazol-5-yl)carbamate (250 mg, 478.42 pmol, 1 eq) in formic acid (3 mL) was stirred at 80 °C for 12 hours. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by chromatography (SiCL, 25% ethyl acetate in petroleum ether) to give benzyl (3-((lS,3R)-3-(((4-nitrophenoxy)carbonyl)oxy)cyclopentyl)-lH- pyrazol-5-yl)carbamate. m/z (ESI+) 467 (M+H)+. ‘H NMR (400 MHz, CDC13) 5 1.86 - 2.03 (m, 3 H), 2.09 - 2.23 (m, 2 H), 2.54 - 2.64 (m, 1 H), 3.20 (br t, J=8.34 Hz, 1 H), 5.20 (s, 2 H), 5.29 (dt, J=5.81, 2.88 Hz, 1 H), 6.37 (br s, 1 H), 7.29 - 7.42 (m, 7 H), 7.83 (br s, 1 H), 8.27 (d, J=9.18 Hz, 2 H).
[0242] To a solution of benzyl (3-((lS,3R)-3-(((4-nitrophenoxy)carbonyl)oxy)cyclopentyl)-lH- pyrazol-5-yl)carbamate (150 mg, 321.58 pmol, 1 eq) and DIPEA (207.81 mg, 1.61 mmol, 280.06 pL, 5 eq) in THF (7 mL) was added (S)-2-methylazetidine hydrochloride (121.09 mg, 1.13 mmol, 3.5 eq, HCI) at 20°C. The mixture was stirred for 4 hours. The mixture was concentrated under reduced pressure to give a residue. The residue was dissolved in ethyl acetate (10 ml), and was washed with IM sodium hydroxide (3 x 5 mL) and brine (5 mL) . The organic layer was dried over sodium sulfate, fdtered and concentrated to (lR,3S)-3-(5-(((benzyloxy)carbonyl)amino)-lH-pyrazol-3-yl)cyclopentyl (S)-2- methylazetidine-1 -carboxylate, m/z (ESI+) 399 (M+H)+. ’H NMR (400 MHz, CDC13) 5 1.29 (br s, 3 H), 1.73 - 1.88 (m, 5 H), 1.99 - 2.07 (m, 1 H), 2.19 - 2.30 (m, 1 H), 2.31 - 2.44 (m, 1 H), 3.08 (quin, J=8.05 Hz, 1 H), 3.79 (br t, J=1.63 Hz, 2 H), 4.20 - 4.31 (m, 1 H), 5.06 - 5.11 (m, 1 H), 5.13 (s, 2 H), 7.26 - 7.34 (m, 4 H), 7.75 (br s, 1 H).
Step 11:
[0243] To a solution of (lR,3S)-3-(5-(((benzyloxy)carbonyl)amino)-lH-pyrazol-3-yl)cyclopentyl (S)- 2 -methylazetidine- 1 -carboxylate (60 mg, 150.58 pmol, 1 eq) in dioxane (10 mb) was added 10% Pd/C (0.1 g) under a nitrogen atmosphere. The suspension was degassed under vacuum and purged with H2 three times. The mixture was stirred under H2 ( 15psi) for 12 hours. The solution was fdtered through celite. The solution was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure at 25°C to give (lR,3S)-3-(5-amino-lH-pyrazol-3-yl)cyclopentyl (S)-2 -methylazetidine- 1- carboxylate. m/z (ESI+) 265 (M+Na)+. ‘HNMR (400 MHz, d6-DMSO) 5 1.29 (d, J=6.20 Hz, 3 H), 1.52 - 1.98 (m, 6 H), 2.22 - 2.40 (m, 2 H), 2.80 - 3.01 (m, 1 H), 3.74 (br d, J=7.03 Hz, 2 H), 4.13 - 4.31 (m, 1 H), 4.44 (br s, 1 H), 4.85 - 5.01 (m, 1 H), 5.17 (s, 1 H), 11.08 (br s, 1 H).
[0244] A solution of l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperidine-4- carbaldehyde [synthesis of 1 -(2-(2,6-dioxopiperidin-3 -yl)- 1 ,3 -dioxoisoindolin-5 -yl)piperidine-4- carbaldehyde is described in WO2021/113557 and is commercially available from Princeton BioMolecular Research, CAS # 2241315-66-0] (280 mg, 758.05 pmol, 1 eq), tert-butyl 2-(piperidin-4- yl)acetate (181.28 mg, 909.66 pmol, 1.2 eq), NaOAc (62.18 mg, 758.05 pmol, 1 eq) and AcOH (45.52 mg, 758.05 pmol, 43.35 pL, 1 eq) in DMA (10 mb) was stirred at 50 °C for 2 hours. NaBFLCN (95.27 mg, 1.52 mmol, 2 eq) was added to the mixture. The reaction was stirred at 50 °C for 12 hours. Water (3mL) was added to the mixture and stirred at 20 °C for 1 h. The mixture was purified by HPLC (Phenomenex Luna Cis 100x40mm><3 pm; mobile phase: 35%-65%, 1% formic aid in water-ACN) to give tert-butyl 2-( 1 -(( 1 -(2-(2,6-dioxopiperidin-3 -yl)- 1 ,3 -dioxoisoindolin-5 -yl)piperidin-4- yl)methyl)piperidin-4-yl)acetate. rH NMR (400 MHz, cU-MeOD) 5 1.23 - 1.40 (m, 4 H), 1.45 (s, 10 H), 1.71 - 1.97 (m, 6 H), 2.05 - 2.23 (m, 4 H), 2.26 - 2.52 (m, 2 H), 2.62 - 2.91 (m, 4 H), 2.95 - 3.07 (m, 3 H), 4.05 (br d, J=13.01 Hz, 2 H), 5.06 (dd, J=12.44, 5.44 Hz, 1 H), 7.21 (dd, J=8.63, 2.25 Hz, 1 H), 7.34 (d, .7=2,25 Hz, 1 H), 7.66 (d, J=8.50 Hz, 1 H).
[0245] To a mixture of tert-butyl 2-(l-((l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperidin-4-yl)methyl)piperidin-4-yl)acetate (100 mg, 180.94 pmol, 1 eq) in DCM (1.5 mL) was added TFA (770.00 mg, 6.75 mmol, 0.5 mL, 37.32 eq). The mixture was stirred at 20 °C for 3 hours. The reaction was concentrated under reduce pressure to give 2-(l-((l-(2-(2,6-dioxopiperidin-3-yl)-l,3- dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperidin-4-yl)acetic acid which was carried forward directly.
[0246] To a mixture (lR,3S)-3-(5-amino-lH-pyrazol-3-yl)cyclopentyl (S)-2 -methylazetidine- 1- carboxylate (53.23 mg, 201.39 pmol, 1 eq), 2-(l-((l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin- 5-yl)piperidin-4-yl)methyl)piperidin-4-yl)acetic acid (80 mg, 161.11 pmol, 0.8 eq) and DIEA (130.14 mg, 1.01 mmol, 175.39 pL, 5 eq) in DCM (0.5 mL) was added T3P (640.78 mg, 1.01 mmol, 598.86 pL, 50% purity, 5 eq). The mixture was stirred at 20 °C for 12 hours. The mixture was concentrated to give a residue. The residue was purified by prep-HPLC (Phenomenex Luna Cis 75 mm x 30 mm x 3 pm; mobile phase: 10%-40%, 1% formic acid in water-ACN) to give (lR,3S)-3-(3-amino-l-(2-(l-((l-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperidin-4-yl)acetyl)-lH- pyrazol-5-yl)cyclopentyl (2S)-2-methylazetidine-l-carboxylate. 1HNMR(400 MHz, di-McOD) 5 1.36 (br d, 7=5.50 Hz, 3 H), 1.42 (br dd, 7=12.01, 2.88 Hz, 2 H), 1.63 (br d, 7=13.63 Hz, 2 H), 1.75 - 1.86 (m, 3 H), 1.86 - 1.94 (m, 4 H), 1.96 (br d, 7=4.25 Hz, 1 H), 2.04 (br s, 1 H), 2.09 (br d, 7=2.50 Hz, 1 H), 2.12 (br dd, 7=7.13, 4.50 Hz, 2 H), 2.15 - 2.25 (m, 2 H), 2.33 - 2.37 (m, 1 H), 2.40 (d, 7=6.88 Hz, 2 H), 2.50 (br d, 7=5.63 Hz, 1 H), 2.68 - 2.74 (m, 1 H), 2.76 (br d, 7=2.75 Hz, 1 H), 2.80 - 2.89 (m, 1 H), 2.96 - 3.10 (m, 5 H), 3.18 (brt, 7=8.19 Hz, 1 H), 3.65 (br d, 7=10.51 Hz, 2 H), 3.85 (brt, 7=7.63 Hz, 2 H), 4.09 (br d, 7=13.38 Hz, 2 H), 4.34 (br d, 7=8.13 Hz, 1 H), 5.01 - 5.14 (m, 2 H), 6.35 (s, 1 H), 7.24 (dd, 7=8.63, 2.25 Hz, 1 H), 7.37 (d, 7=2.13 Hz, 1 H), 7.68 (d, 7=8.50 Hz, 1 H).
Example 2: Synthesis of (lR,3S)-3-(3-(2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperazin-l-yl)methyl)phenyl)acetamido)-lH-pyrazol-5-yl)cyclopentyl (2S)-2- methylazetidine-l-carboxylate (Compound P-11)
[0247] A solution of 2-(4-formylphenyl)acetic acid (100 mg, 609.17 pmol, 1 eq), 2-(2,6- dioxopiperidin-3-yl)-5-(piperazin-l-yl)isoindoline-l, 3-dione (250.26 mg, 731.00 pmol, 1.2 eq), NaOAc (49.97 mg, 609.17 umol, 1 eq) and HOAc (36.58 mg, 609.17 pmol, 34.84 pL, 1 eq) in DMA (10 mL) was stirred at 50°C for 2 hours. NaBH3CN (76.56 mg, 1.22 mmol, 2 eq) was added. The resulting solution was stirred for 12 hours at 50°C. The mixture was quenched with water (0.1 mL). The mixture was purified by pre-HPLC [Phenomenex Luna Cis 100 mm x 40 mm x 3 pm; 25 to 55% 1% formic acid in water in ACN] and lyophilized to give 2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-l,3- dioxoisoindolin-5-yl)piperazin-l-yl)methyl)phenyl)acetic acid. ’H NMR (400 MHz, di-McOD) 52.06 - 2.15 (m, 1 H), 2.67 - 2.79 (m, 2 H), 2.81 - 2.97 (m, 5 H), 3.54 (br d, 7=4.63 Hz, 4 H), 3.62 (s, 2 H), 3.84 (s, 2 H), 5.07 (dd, 7=12.51, 5.50 Hz, 1 H), 7.22 - 7.43 (m, 6 H), 7.70 (d, 7=8.50 Hz, 1 H).
[0248] To a mixture of 2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperazin-l- yl)methyl)phenyl)acetic acid (30 mg, 61.16 pmol, 0.8 eq), (lR,3S)-3-(5-amino-lH-pyrazol-3- yl)cyclopentyl (S)-2 -methylazetidine- 1 -carboxylate (20.21 mg, 76.45 pmol, 1 eq) and DIEA (49.40 mg, 382.25 pmol, 66.58 pL, 5 eq) in DCM (1 mL) was added T3P (243.25 mg, 382.25 pmol, 227.34 pL, 50% purity, 5 eq). The mixture was stirred at 20°C for 12 hours. The mixture was concentrated to give
a residue. The crude product was purified by prep-HPLC [Phenomenex Luna Cis 75 mm x 30 mm x 3 pm; 15 to 35% 1% formic acid in water to ACN] and lyophilized to give (lR,3S)-3-(3-(2-(4-((4-(2- (2,6-dioxopiperidin-3-yl)- 1 ,3-dioxoisoindolin-5-yl)piperazin- 1 -yl)methyl)phenyl)acetamido)- 1H- pyrazol-5-yl)cyclopentyl (2S)-2-methylazetidine-l-carboxylate. ’H NMR (400 MHz, d-i-McOD) 5 1.27 - 1.42 (m, 3 H), 1.74 - 2.15 (m, 7 H), 2.27 - 2.47 (m, 2 H), 2.65 - 2.79 (m, 5 H), 2.80 - 2.91 (m, 1 H), 3.07 (br t, 7=8.07 Hz, 1 H), 3.49 (br s, 4 H), 3.68 (br s, 2 H), 3.82 (br t, 7=7.63 Hz, 2 H), 4.26 - 4.39 (m, 3 H), 5.02 - 5.13 (m, 2 H), 5.29 (s, 1 H), 7.23 (br d, 7=8.50 Hz, 1 H), 7.36 (s, 5 H), 7.68 (d, 7=8.50 Hz, 1 H), 8.28 (s, 1 H).
Example 3: Synthesis of (lR,3S)-3-(3-(2-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5- yl)piperazine-l-carbonyl)phenyl)acetamido)-lH-pyrazol-5-yl)cyclopentyl (2S)-2- methylazetidine-l-carboxylate (Compound P-15)
[0249] To a solution of 3 -(l-oxo-5 -(piperazin- l-yl)isoindolin-2-yl)piperidine-2, 6-dione (700 mg, 2.13 mmol, 1 eq) and 4-(2-(tert-butoxy)-2-oxoethyl)benzoic acid (1.01 g, 4.26 mmol, 2 eq) in DCM (10 mb) was added T3P (3.39 g, 10.66 mmol, 3.17 mb, 5 eq) and DIEA (1.38 g, 10.66 mmol, 1.86 mL, 5 eq). The mixture was stirred at 20 °C for 12 hours. The reaction mixture was diluted with H2O (20 mL) and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with brine (3 x 10 mL), dried over Na2SC>4, fdtered and concentrated under reduced pressure to give tert-butyl 2-(4-(4-(2- (2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazine-l-carbonyl)phenyl)acetate which was used in next step directly without purification. rH NMR (400 MHz, di-MeOD) 5 0.96 - 1.14 (m, 2 H), 1.16 - 1.31 (m, 1 H), 1.33 - 1.40 (m, 5 H), 1.41 - 1 .48 (m, 9 H), 1.60 - 1.86 (m, 2 H), 2.08 - 2.21 (m, 1 H), 2.45 (qd, 7=13.20, 4.69 Hz, 1 H), 2.71 - 2.82 (m, 1 H), 2.82 - 2.97 (m, 1 H), 3.22 (q, J=1.42 Hz, 1 H), 3.59 - 3.66 (m, 2 H), 4.32 - 4.48 (m, 1 H), 5.10 (dd, 7=13.26, 5.13 Hz, 1 H), 7.07 - 7.16 (m, 1 H), 7.32 - 7.49 (m, 3 H), 7.65 (d, 7=8.50 Hz, 1 H), 7.92 - 8.07 (m, 1 H).
Step 2:
[0250] To a solution of tert-butyl 2-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5- yl)piperazine-l-carbonyl)phenyl)acetate (1.8 g, 3.29 mmol, 1 eq) in DCM (20 mb) was added TFA (10.78 g, 94.54 mmol, 7 mb, 28.71 eq) .The mixture was stirred at 20 °C for 2 hours. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep- HPLC [Phenomenex Luna Cis 250 x 50mm x 10 pm; 10 to 40%, 1% TFA in water to ACN] and lyophilized to give 2-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazine-l- carbonyl)phenyl)acetic acid, m/z (ESI+) 419.2 (M+H)+.
[0251] To a solution of 2-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazine-l- carbonyl)phenyl)acetic acid (50 mg, 101.94 pmol, 0.8 eq), [(lR,3S)-3-(3-amino-lH-pyrazol-5- yl)cyclopentyl] (2R)-2 -methylazetidine- 1 -carboxylate (33.68 mg, 127.42 pmol, 1 eq) in pyridine (1.5 mb) was added EDCI (48.85 mg, 254.84 pmol, 2 eq). The mixture was stirred at 20 °C for 12 hours. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC [Phenomenex Luna Cis 150 x 30mm x 5 pm; 1 to 30%, 1% TFA in water to ACN] and lyophilized to give (lR,3S)-3-(3-(2-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5- yl)piperazine- 1 -carbonyl)phenyl)acetamido)- lH-pyrazol-5-yl)cyclopentyl (2S)-2 -methylazetidine- 1 - carboxylate. ’H NMR (400 MHz, d4-MeOD) 5 1.28-1.38 (m, 3H), 1.76-1.97 (m, 5H), 2.07-2.21 (m, 2H), 2.34 (br dd, 7=10.63, 7.75 Hz, 1H), 2.41-2.54 (m, 2H), 2.80 (br s, 1H), 2.88 (br d, 7=13.26 Hz, 1H), 3.13-3.23 (m, 2H), 3.65 (br s, 3H), 3.76 (s, 2H), 3.83 (br t, 7=7.69 Hz, 3H), 3.92 (br s, 2H), 4.27- 4.35 (m, 1H), 4.41 (d, 7=5.75 Hz, 2H), 5.05-5.13 (m, 3H), 6.33 (s, 1H), 7.09-7.13 (m, 2H), 7.43-7.51 (m, 4H), 7.66 (d, 7=8.63 Hz, 1H).
Example 4: Synthesis of (lR,3S)-3-(3-(2-(l-((l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)pyrrolidin-3-yl)methyl)piperidin-4-yl)acetamido)-lH-pyrazol-5-yl)cyclopentyl (2S)-2- methylazetidine-l-carboxylate (Compound P-12)
[0252] A solution of l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)pyrrolidine-3- carbaldehyde (250 mg, 703.54 pmol, 1 eq) [WO2020/38415 Al], tert-butyl 2-(4-piperidyl) acetate (168.25 mg, 844.25 pmol, 1.2 eq), NaOAc (57.71 mg, 703.54 pmol, 1 eq) and AcOH (42.25 mg, 703.54 pmol, 40.24 pL, 1 eq) in DMA (10 mL) was stirred at 50 °C for 2 hours. NaBHA’N (88.42 mg, 1.41 mmol, 2 eq) was added and the resulting solution was stirred for 12 hours at 50 °C. The mixture was quenched with water (0.1 mL). The mixture was purified by prep-HPLC [Phenomenex Luna Cis 200 x 40mm x 10 pm; 35 to 70%, 1% formic acid in water to ACN] and lyophilized to give tert-butyl 2-(l- (( 1 -(2-(2,6-dioxopiperidin-3 -yl)- 1 ,3 -dioxoisoindolin-5 -yl)pyrrolidin-3 -yl)methyl)piperidin-4- yl)acetate. ‘H NMR (400 MHz, d4-MeOD) 5 1.46 (s, 11 H), 1.80 - 1.96 (m, 4 H), 2.05 - 2.15 (m, 1 H), 2.18 - 2.35 (m, 3 H), 2.42 - 2.60 (m, 2 H), 2.61 - 2.97 (m, 6 H), 3.17 - 3.30 (m, 3 H), 3.41 - 3.51 (m, 1 H), 3.52 - 3.62 (m, 1 H), 3.64 - 3.76 (m, 1 H), 5.05 (dd, 7=12.52, 5.48 Hz, 1 H), 6.83 (dd, 7=8.46, 2.15 Hz, 1 H), 6.99 (d, 7=2.15 Hz, 1 H), 7.65 (d, 7=8.34 Hz, 1 H).
[0253] A solution of tert-butyl 2-(l-((l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)pyrrolidin-3-yl)methyl)piperidin-4-yl)acetate (70 mg, 4.24 mmol, 1 eq) in HCl/EtOAc (2 M, 5.83 mL, 89.77 eq) was stirred at 20 °C for 2 h. The mixture was concentrated under reduce pressure to give 2-( 1 -(( 1 -(2-(2,6-dioxopiperidin-3 -yl)- 1 ,3 -dioxoisoindolin-5 -yl)pyrrolidin-3 -yl)methyl)piperidin-4- yl)acetic acid which was used in the next step without further purification. rH NMR (400 MHz, d4-
MeOD) 5 1.23 (t, J=6.97 Hz, 1 H), 1.59 (s, 1 H), 1.66 (br s, 2 H), 1.94 (br s, 1 H), 2.09 (br s, 4 H), 2.34 (br s, 2 H), 2.38 (br s, 1 H), 2.73 (br d, J=14.90 Hz, 2 H), 2.79 - 2.97 (m, 2 H), 3.07 (br d, J=1.55 Hz, 2 H), 3.49 (br d, J=2.50 Hz, 1 H), 3.56 - 3.64 (m, 1 H), 3.67 (br d, J=6.44 Hz, 2 H), 3.79 (br s, 1 H), 5.05 (br d, J=9.30 Hz, 1 H), 6.84 (br s, 1 H), 6.99 (br s, 1 H), 7.65 (br s, 1 H).
[0254] To a mixture of (lR,3S)-3-(3-amino-lH-pyrazol-5-yl)cyclopentyl (S)-2 -methylazetidine- 1- carboxylate (44.51 mg, 168.38 pmol, 1 eq), 2-(l-((l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin- 5-yl)pyrrolidin-3-yl)methyl)piperidin-4-yl)acetic acid (65 mg, 134.71 pmol, 0.8 eq) and T3P (535.76 mg, 841.92 pmol, 500.71 pL, 50% purity, 5 eq) in DCM (0.5 mL) was added DIEA (108.81 mg, 841.92 pmol, 146.64 pL, 5 eq). The mixture was stirred at 20 °C for 12 hours. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep- HPLC [Phenomenex Luna Cis 75 x 30mm x 3 pm; 20 to 60%, 1% formic acid in water to ACN] and lyophilized to give (1R,3S)-
3 -(3 -(2-( 1 -(( 1 -(2-(2,6-dioxopiperidin-3 -yl)- 1 ,3 -dioxoisoindolin-5 -yl)pyrrolidin-3 -yl)methyl)piperidin- 4-yl)acetamido)-lH-pyrazol-5-yl)cyclopentyl (2S)-2-methylazetidine-l -carboxylate. ’H NMR (400 MHz, d4-MeOD) 5 1.28 - 1.41 (m, 3 H), 1.49 - 1.68 (m, 2 H), 1.74 - 2.21 (m, 10 H), 2.29 - 2.43 (m, 2 H), 2.50 - 3.10 (m, 9 H), 3.18 - 3.25 (m, 1 H), 3.33 - 3.52 (m, 5 H), 3.55 - 3.64 (m, 1 H), 3.66 - 3.94 (m,
4 H), 4.26 - 4.39 (m, 1 H), 4.99 - 5.13 (m, 2 H), 5.86 (s, 1 H), 6.84 (dd, J=8.38, 2.00 Hz, 1 H), 7.00 (d, .7=2.00 Hz, 1 H), 7.66 (d, J=8.50 Hz, 1 H), 8.49 (br s, 1 H).
[0255] Additional compounds set forth in Table 3 were prepared following the procedures set forth above, with the exception that the amine was replaced in the example above with an amine depicted in the final product.
Example 5: Synthesis of N-{5-[(lS,3R)-3-(2-pyridyloxy)cyclopentyl]-3-pyrazolyl}p-{4-[2-(2,6- dioxo-3-piperidyl)-l,3-dioxo-5-isoindolinyl]-l-piperidyl}benzamide (Compound P-137)
Step 1:
[0256] To a solution of benzyl ( l -(tcrt-butyl)-5-(( I.S'.3/?)-3-hydroxycyclopcntyl)- l H-pyrazol-3- yl)carbamate (2 g, 5.60 mmol, 1 eq) and 2-fluoropyridine (1.09 g, 11.19 mmol, 961.49 pL, 2 eq) in DMSO (30 mb) was added KO'Bu (1.88 g, 16.79 mmol, 3 eq). The mixture was stirred at 25°C for 1 hour. Water (200 mL) was added and extracted into EtOAc (3 x 200 mL). The combined organic phases were washed with brine (200 mL), dried over Na2SC>4 and concentrated under reduced pressure to give benzyl (l-(tert-butyl)-5-((lS,37?)-3-(pyridin-2-yloxy)cyclopentyl)-lH-pyrazol-3-yl)carbamate.
[0257] To a solution of benzyl ( l-(tert-butyl)-5-(( I.S'.3/?)-3-(pyridin-2-yloxy)cyclopcntyl)- l H- pyrazol-3-yl)carbamate (5 g, 11.51 mmol, 1 eq) in MeOH (50 mL) and THE (50 mL) was added Pd/C (1 g, 10% Pd by wt.). The mixture was purged and degassed with hydrogen 3 times. The mixture was stirred at 25 °C for 12 hours under a hydrogen atmosphere (15 psi). The mixture was fdtered. The fdtrate was concentrated under reduced pressure to give l -(tcrt-butyl)-5-(( I.S'.3/?)-3-(pyridin-2- yloxy)cyclopentyl)- lH-pyrazol-3 -amine .
[0258] To a mixture of 4-(4-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperidin-l- yl)benzoic acid (50 mg, 108.35 pmol, 1 eq) and l-(tert-butyl)-5-((lS,37?)-3-(pyridin-2- yloxy)cyclopentyl)-lH-pyrazol-3-amine (39.06 mg, 130.02 pmol, 1.2 eq) in pyridine (1 mL) was added EDCI (41.54 mg, 216.70 pmol, 2 eq). The mixture was stirred at 25 °C for 2 hours. The mixture was concentrated to give the residue. The residue was diluted with water (3 mL) and
extracted with ethyl acetate (3 x 1 mL). The combined organic phases were washed with brine (1 mb), dried over anhydrous Na2SC>4, filtered and concentrated to give N-( l-(tcrt-butyl)-5-(( I.S'.3/?)-3- (pyridin-2-yloxy)cyclopentyl)-lH-pyrazol-3-yl)-4-(4-(2-(2,6-dioxopiperidin-3-yl)-l,3- dioxoisoindolin-5-yl)piperidin-l-yl)benzamide which was used in the following step without purification.
[0259] A solution ofN-(l-(tert-butyl)-5-((lS,37?)-3-(pyridin-2-yloxy)cyclopentyl)-lH-pyrazol-3-yl)- 4-(4-(2-(2,6-dioxopiperidin-3 -yl)- 1 ,3 -dioxoisoindolin-5 -yl)piperidin- 1 -yl)benzamide (80 mg, 107.55 pmol, 1 eq) in formic acid (1 mL) was stirred for 12 hours at 70 °C. The mixture was dried in vacuo to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Luna Cis 80 mm x 30 mm x 3 gm; mobile phase: [LLO (+ 0.2% formic acid)-ACN]; gradient: 20%-60% B over 8.0 min) to give N-{5-[(lS,37?)-3-(2-pyridyloxy)cyclopentyl]-3-pyrazolyl}p-{4-[2-(2,6-dioxo-3-piperidyl)-l,3- dioxo-5-isoindolinyl]-l-piperidyl}benzamide. rH NMR (400 MHz, dg-DMSO) 5 1.70 - 1.98 (m, 7 H) 2.01 - 2.12 (m, 3 H) 2.57 - 2.68 (m, 3 H) 2.84 - 2.97 (m, 3 H) 3.00 - 3.08 (m, 1 H) 3.12 - 3.17 (m, 1 H) 4.05 (br d, 7=12.38 Hz, 2 H) 5.14 (dd, 7=12.94, 5.19 Hz, 1 H) 5.36 - 5.49 (m, 1 H) 6.36 - 6.49 (m, 1 H) 6.79 (d, 7=8.38 Hz, 1 H) 6.95 (dd, 7=6.57, 5.57 Hz, 1 H) 7.02 (br d, 7=8.88 Hz, 2 H) 7.64 - 7.72 (m, 1 H) 7.76 - 7.95 (m, 5 H) 8.16 (dd, 7=4.75, 1.50 Hz, 1 H) 10.26 - 10.49 (m, 1 H) 11.02 - 11.21 (m, 1 H) 11.93 - 12.32 (m, 1 H).
Example 6: Synthesis of N-{5-[(15,37?)-3-(2-pyridyloxy)cyclopentyl]-3-pyrazolyl}4-{l-[2-(2,6- dioxo-3-piperidyl)-l,3-dioxo-5-isoindolinyl]-4-piperidyl}-3-fluorobenzamide (Compound P-133)
[0260] To a solution of 4-bromo-3 -fluorobenzoic acid (20 g, 91.32 mmol, 1 eq) in CHCI3 (200 mL) was added 2-tert-butyl-l,3-diisopropyl-isourea (63.59 g, 182.64 mmol, 2 eq). The mixture was stirred at 40 °C for 12 hours. The reaction mixture was concentrated under reduced pressure. The crude product was purified by column chromatography (SiCh, 10% ethyl acetate in petroleum ether) to give tert-butyl 4-bromo-3 -fluorobenzoate. 1HNMR (400 MHz, dg-DMSO) 5 1.53 (s, 9 H) 7.58 - 7.69 (m, 2
H) 7.74 - 7.84 (m, 1 H).
[0261] A mixture of tert-butyl 4-bromo-3 -fluorobenzoate (3 g, 10.90 mmol, 1 eq), tert-butyl 4- (4, 4, 5, 5 -tetramethyl- 1,3, 2- dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-l -carboxylate (2.98 g, 16.36 mmol, 1.5 eq), Pd(dppf)C12 (796 mg, 1.09 pmol, 0.1 eq), K2CO3 (4.52 g, 32.71 mmol, 3 eq) in dioxane (30 mL) and H2O (15 mL) was degassed and purged with N2 three times. The mixture was stirred at 105 °C for 12 hours under a nitrogen atmosphere. H2O (10 mL) was added at 20°C, and then diluted with EtOAc (5 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (3 x 10 mL), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, 10% ethyl acetate in petroleum ether) to give tert-butyl 4-(4-(tert-butoxycarbonyl)-2-fluorophenyl)-3,6-dihydropyridine- l(2H)-carboxylate. ’H NMR (400 MHz, CDCI3) 5 1.46 (s, 9 H) 1.55 (s, 9 H) 2.48 (br s, 2 H) 3.59 (br t, J=5.44 Hz, 2 H) 4.05 (br d, J=2.13 Hz, 2 H) 5.99 (br s, 1 H) 7.22 - 7.26 (m, 1 H) 7.60 (dd, J=\ 1.69, 1.56 Hz, 1 H) 7.69 (dd, J=8.00, 1.63 Hz, 1 H).
[0262] To a solution of tert-butyl 4-(4-(tert-butoxycarbonyl)-2-fluorophenyl)-3,6-dihydropyridine- 1(2H) -carboxylate (3.5 g, 9.27 mmol, 1 eq) in MeOH (70 mL) was added Pd/C (0.7 g, 10% wt% Pd)
under a N2 atmosphere. The suspension was degassed and purged with H2 three times. The mixture was stirred under H2 (15 psi) at 20 °C for 12 hours. The mixture was fdtered and concentrated under reduced pressure to give tert-butyl 4-(4-(tert-butoxycarbonyl)-2-fluorophenyl)-3,6-dihydropyridine- l(2H)-carboxylate which was used in next step without further purification. rH NMR (400 MHz, CDCh) 5 1.53 (s, 9 H) 1.63 (s, 9 H) 1.66 - 1.71 (m, 2 H) 1.85 (br d, 7=12.26 Hz, 2 H) 2.88 (brt, 7=11.38 Hz, 2 H) 3.03 - 3.13 (m, 1 H) 4.31 (br s, 2 H) 7.28 - 7.32 (m, 1 H) 7.67 (dd, 7=11.01, 1.50 Hz, 1 H) 7.78 (br d, 7=8.00 Hz, 1 H).
[0263] A solution of tert-butyl 4-(4-(tert-butoxycarbonyl)-2-fluorophenyl)piperidine-l -carboxylate (3.4 g, 8.96 mmol, 1 eq) in TFA (10 mL) and DCM (30 mL) was stirred at 30 °C for 2 hours. The reaction mixture was concentrated under reduced pressure to give 3-fluoro-4-(piperidin-4-yl)benzoic acid which was used in the next step without further purification. 1 H NMR (400 MHz, CDCh) 5 2.18 (br d, 7=6.50 Hz, 4 H) 3.18 - 3.33 (m, 3 H) 3.72 (br d, 7=13.26 Hz, 2 H) 7.38 (t, 7=7.57 Hz, 1 H) 7.81 (dd, 7=10.44, 1.31 Hz, 1 H) 7.94 (dd, 7=7.94, 1.19 Hz, 1 H).
[0264] To a solution of 3-fluoro-4-(piperidin-4-yl)benzoic acid (2 g, 8.96 mmol, 1.5 eq), 2-(2,6- dioxopiperidin-3-yl)-5-fluoroisoindoline-l, 3-dione (1.65 g, 5.97 mmol, 1.0 eq) in DMSO (20 mL) was added DIEA (1.54 g, 11.95 mmol, 2.08 mL, 2 eq). The mixture was stirred at 120 °C for 12 hours. The reaction was purified by prep-HPLC (column: Welch Xtimate Cis 180 mm x 70 mm x 10 pm; mobile phase: [H2O (+0.01%TFA)-ACN]; gradient: 35 %-65% B over 20.0 min) and lyophilized to give 4-( 1 -(2-(2,6-dioxopiperidin-3-yl)- 1 ,3 -dioxoisoindolin-5 -yl)piperidin-4-yl)-3 -fluorobenzoic acid. XH NMR (400 MHz, d6-DMSO) 5 1.70 - 1.82 (m, 2 H) 1.82 - 1.89 (m, 2 H) 1.97 - 2.06 (m, 1 H) 2.54 - 2.64 (m, 2 H) 2.83 - 2.95 (m, 1 H) 3.07 - 3.26 (m, 3 H) 4.21 (br d, 7=13.01 Hz, 2 H) 5.08 (dd, 7=12.88, 5.25 Hz, 1 H) 7.29 (dd, 7=8.57, 1.81 Hz, 1 H) 7.38 (s, 1 H) 7.46 (t, 7=7.75 Hz, 1 H) 7.59 - 7.65 (m, 1 H) 7.70 (dd, 7=16.32, 8.32 Hz, 2 H) 11.08 (s, 1 H).
Step 6:
[0265] To a solution of l-(tert-butyl)-5-(( I.S'.3/?)-3-(pyridin-2-yloxy)cyclopcntyl)-l H-pyrazol-3- amine (37.59 mg, 125.14 pmol, 1.2 eq) in pyridine (1 mL) was added EDCI (39.98 mg, 208.57 pmol, 2 eq) and 4-( 1 -(2-(2,6-dioxopiperidin-3 -yl)- 1 ,3 -dioxoisoindolin-5 -yl)piperidin-4-yl)-3 -fluorobenzoic acid (0.05 g, 104.28 pmol, 1 eq). The mixture was stirred at 30 °C for 12 hours. H2O (2 mL) was added at 20 °C, and then diluted with ethyl acetate (1 mL) and extracted with ethyl acetate (3 x 2 mL). The combined organic layers were washed with saturated brine (3 x 2 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was used in the next step without further purification.
[0266] A solution of N-( l-(tcrt-butyl)-5-(( I.S'.3/?)-3-(pyridin-2-yloxy)cyclopcntyl)-I H-pyrazol-3-yl)- 4-( 1 -(2-(2,6-dioxopiperidin-3 -yl)- 1 ,3 -dioxoisoindolin-5 -yl)piperidin-4-yl)-3 -fluorobenzamidee (50 mg, 65.63 pmol, 1 eq) in formic acid (1 mL) was stirred for 12 hours at 70 °C. The mixture was dried in vacuo to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Luna Cis 80 mm x 30 mm x 3 pm; mobile phase: [H2O (+ 0.2% formic acid)-ACN]; gradient: 20%-60% B over 8.0 min) to give N-{5-[(lS,37?)-3-(2-pyridyloxy)cyclopentyl]-3-pyrazolyl}4-{l-[2-(2,6-dioxo-3- piperidyl)-l,3-dioxo-5-isoindolinyl]-4-piperidyl}-3-fluorobenzamide. 1H NMR (400 MHz, dg-DMSO) 5 1.68 - 1.94 (m, 7 H) 1.97 - 2.13 (m, 3 H) 2.55 - 2.68 (m, 3 H) 2.84 - 2.94 (m, 1 H) 3.07 - 3.23 (m, 4 H) 4.23 (br d, J=\ 1.76 Hz, 2 H) 5.08 (br dd, 7=12.38, 5.25 Hz, 1 H) 5.42 (br s, 1 H) 6.47 (br s, 1 H) 6.78 (br d, 7=8.38 Hz, 1 H) 6.92 - 6.98 (m, 1 H) 7.28 - 7.34 (m, 1 H) 7.39 (br s, 1 H) 7.45 (br t, 7=7.25 Hz, 1 H) 7.63 - 7.72 (m, 2 H) 7.73 - 7.86 (m, 2 H) 8.13 - 8.19 (m, 1 H) 10.75 (br s, 1 H) 11.08 (br s, 1 H) 12.23 (br s, 1 H).
[0267] Additional compounds set forth in Table 4 were prepared following the procedures set forth above, with the exception that the ether was replaced in the example above with an ether as depicted in the final product.
Table 4
[0268] In one embodiment the compounds disclosed herein preferably contain (lR,3S)-cyclopentyl or (lR,3S)-cyclopentyl; such preferred compounds would exclude compounds in Table 1 lacking (1R,3S)- cyclopentyl or (lR,3S)-cyclopentyl.
Biological Examples
Cereblon (CRBN) Target Engagement
[0269] HEK-293T cells were harvested ca. 75% confluent with trypsin and plated (500,000 cells/well) in a 6-well tissue culture plate in 2 m of Dulbecco’s Modified Eagle Medium (DMEM) + 10% Fetal Bovine Serum (FBS) and incubated overnight at 37 °C.
[0270] The NanoLuc-CRBN fusion vector (Nluc-CRBN; Promega) contains the coding region of human E3 ligase component cereblon (CRBN) fused to the C-terminus of the NanoLuc luciferase coding region. A mixture of 10 ng Nluc-CRBN and 990 ng DDB1 Expression Vector (Promega) was added to 125 pL Opti-Minimum Essential Medium (Opti-MEM™; Thermo Fisher) along with 2 pL P3000 reagent (Thermo Fisher) in a 1.5 mb epppendorf tube. This solution was added to Lipofectamine 3000 transfection reagent (5 pL; Thermo Fisher) in Opti-MEM (125 pL), mixed well, and incubated for 15 minutes at room temperature. The transfection mixture was added dropwise to cells and incubated overnight at 37 °C, 5% CO2. Following transfection, cells were washed once with PBS, and trypsin (250 pL) was added and incubated 30-45 sec to dislodge cells. Complete media (2 mL) was added to resuspend cells to form a single cell suspension. Cells were centrifuged at 320x g for 5 min at room temperature, the supernatant was removed, and the cell pellet resuspended in Opti-MEM (3 mL; wash step repeated x2). After final resuspension in 5 mL Opti-MEM, cells were counted and resuspended at 200,000 cells/mL in Opti-MEM.
[0271] Cereblon target engagement was monitored by Bioluminescence Resonance Energy Transfer (BRET) in transfected HEK-293T cells using the NanoBRET TE Intracellular E3 Ligase Assay (Promega). Briefly, 384-well plates (white opaque plates, Coming 3574, low binding surface) were seeded with transfected HEK-293T cells (38 pL/well). 2 pL of 10 pM CRBN tracer (diluted 1:5 in Tracer Dilution Buffer) was added to each well. Plates were centrifuged at 320x g for 1 min at room temperature. Test compounds were added in a 11 -point dilution series (typically 10 pM to 100 pM) using a TECAN D300e Digital Dispenser. Plates were shaken for 2 minutes on a microplate shaker to mix compounds. Plates were centrifuged at 320x g for 1 min at room temperature, and subsequently incubated for 2 hours at 37 °C.
[0272] After incubation, plates were allowed to cool to room temperature for 15 minutes. 20 pL of 3X Complete NanoBRET™ Nano-Gio® Substrate plus Inhibitor Solution (Promega, 1: 166 Substrate and 1:500 dilution of Extracellular NanoLuc® Inhibitor diluted in Opti-MEM) were added to each well. Plates were incubated with shaking at room temperature for 3 minutes covered with foil. Plates were read on a CLARIOstar microplate reader (BMG LabTech), measuring at 450nm (donor emission) and
610nm (acceptor emission). The IC50 values were determined by regression to best fit four-parameter logistic curves using GraphPad Prism.
CDK2 degradation assay
[0273] HiBiT- CDK2 HEK293T cells were harvested ca. 75% confluent with trypsin and plated (500,000 cells/well) in a 6-well tissue culture plate in 2 mL of Dulbecco’s Modified Eagle Medium (DMEM) + 10% Fetal Bovine Serum (FBS) and incubated overnight at 37 °C.
[0274] Representative compounds were evaluated for their ability to degrade CDK2 in the following assay. The CDK2 degradation assays were carried out by harvesting the HiBiT- CDK2 HEK293T reporter ceil lines and resuspending the cells in media formulated for reduced background fluorescence. The respective cell lines were seeded at a density of 4,000 cells/well into 384 well white opaque TC plates (Greiner 781080-20). The cells were incubated overnight to allow for attachment to the assayplate (37°C with humidified air and 5% CO2 for all incubations). Dilutions of the compounds were prepared in dimethyl sulfoxide (DMSO) from 10 mM compound stock solutions in DMSO. The assayplates were treated with appropriate concentrations of the compounds by dispensing the DMSO dilutions in quadruplicate wells with an upper limit of 0.5% final DMSO. After a 6-hour incubation with the compounds. HiBiT lytic buffer, 1: 100 LgBiT and 1:50 HiBiT were added at 30pl/welI, and plates were incubated at room temperature for 2 hours covered with foil. Images were acquired using the ClarioStar plate reader system (cells maintained at 37 °C during imaging). Cell Reporter Xpress software was utilized to segment cells and determine fluorescence intensities, which were used to construct dose-response curves and calculation of degradation DC50S (GraphPad Prism). The percent degradation amounts were calculated visually from the curves generated at a concentration of 1 and 10 micromolar.
CDK2 Target Engagement assay
[0275] HEK-293T cells were harvested ca. 75% confluent with trypsin and plated (500,000 cells/well) in a 6-well tissue culture plate in 2 mL of Dulbecco’s Modified Eagle Medium (DMEM) + 10% Fetal Bovine Serum (FBS) and incubated overnight at 37 °C.
[0276] A mixture of 10 ng NanoLuc-CDK2 and 990 ng CCNE1 Expression Vector (Promega) was added to 125 pL Opti-Minimum Essential Medium (Opti-MEM™; Thermo Fisher) along with 2 pL P3000 reagent (Thermo Fisher) in a 1.5 mL epppendorf tube. This solution was added to Lipofectamine 3000 transfection reagent (5 pL; Thermo Fisher) in Opti-MEM (125 pL), mixed well, and incubated for 15 minutes at room temperature. The transfection mixture was added dropwise to cells and incubated overnight at 37 °C, 5% CO2. Following transfection, cells were washed once with PBS (250 pL). Trypsin (250 pL) was added and incubated 30-45 sec to dislodge cells. Complete media (2 mL) was added to resuspend cells to form a single cell suspension. Cells were centrifuged at 320x g for 5 min at room temperature, the supernatant was removed, and the cell pellet resuspended in Opti-MEM (3 mL;
wash step repeated x2). After final resuspension in 5 mL Opti-MEM, cells were counted and resuspended at 200,000 cells/mL in Opti-MEM + 1% FBS.
[0277] CDK2 target engagement was monitored by Bioluminescence Resonance Energy Transfer (BRET) in transfected HEK-293T cells using the NanoBRET Assay. Briefly, 384-well plates (white opaque plates, Coming 3574, low binding surface) were seeded with transfected HEK-293T cells (38 pL/well). 2 pL of 10 pM K-10 tracer (diluted 1:5 in Tracer Dilution Buffer) was added to each well. Plates were centrifuged at 320x g for 1 min at room temperature. Test compounds were added in a 10- point dilution series (typically 10 pMto 100 pM) using a TECAN D300e Digital Dispenser. Plates were shaken for 20 secondss on a microplate shaker to mix compounds. Plates were centrifuged at 320x g for 1 min at room temperature, and subsequently incubated for 2 hours at 37 °C.
[0278] After incubation, plates were allowed to cool to room temperature for 15 minutes. 20 pL of 3X Complete NanoBRET™ Nano-Gio® Substrate plus Inhibitor Solution (Promega, 1: 166 Substrate and 1:500 dilution of Extracellular NanoLuc® Inhibitor diluted in Opti-MEM) were added to each well. Plates were incubated with shaking at room temperature for 3 minutes covered with foil. Plates were read on a CLARIOstar microplate reader (BMG LabTech), measuring at 450nm (donor emission) and 610nm or 630 nm (acceptor emission). The IC50 values were determined by regression to best fit four- parameter logistic curves using GraphPad Prism.
[0279] Table 5 and Table 6 show results from the assays described above.
Claims
1. A compound of formula I ’ :
r or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein
Y is N or C-V;
V is selected from hydrogen, deuterium, and fluoro;
X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy;
R12 and R12 are independently selected from hydrogen, deuterium, and fluoro; or R12 and R12 together are oxo; n is 0 or 1; p is 0 or 1;
R3 and R4 are independently hydrogen or CH3; or R3 and R4 together with the carbon atom to which they are attached form a C3-C6 cycloalkyl;
R13 is hydrogen or -CH2-OR14;
R14 is -C(O)-R15 or -P(O)(OR16)2;
R15 is C1-C4 alkyl or C1-C4 alkoxy; each R16 is independently hydrogen or C1-C4 alkyl;
Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4- to 5 -membered heterocycloalkyl ring with 1 ring nitrogen atom, 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
Y1 is -O- or -CH2-;
Z is -O- or -CH2-;
R1 and R2 are independently selected from hydrogen, Ci-Cg alkyl, I -(C3-Cg cycloalkyl), and L1-(4- to 7-membered heterocycloalkyl), wherein said Ci-Cg alkyl, C3-C6 cycloalkyl and 4- to 7- membered heterocycloalkyl is optionally substituted by one to four R8;
R1 and R2 taken together with the nitrogen atom to which they are attached form a 3- to 11- membered ring optionally containing an additional heteroatom or heteroatom group selected from O, N, N(R17), and S(O)m as a ring member, wherein said 3- to 11-membered ring is optionally substituted by one to four R8;
R17 is hydrogen, C1-C4 alkyl, or C(O)-(Ci-C4 alkyl);
R18 is hydrogen, C1-C4 alkyl, C1-C4 fluoroalkyl, or C(O)-(Ci-C4 alkyl); m is 0, 1 or 2;
L1 is a bond or a C1-C2 alkylene optionally substituted with one to four R9;
Ring A is selected from Cg-Cio aryl ring; C4-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein Ring A is substituted with from 0 to 3 R7 moieties, and each R7 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn;
R10 and R11 are each independently H or C1-C4 alkyl;
Ring B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein Ring B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn, or Ring B is absent; a, b, and c are independently 0 or 1 ; each of W and W2, if present, is independently Ci-Cg alkylene optionally substituted with 1 to 3 R9 and W1, if present, is -C(O)-, O, S, NR18 or Ci-Cg alkylene optionally substituted with 1 to 3 R9 provided that the aggregate sum of carbon atoms in W, W1 and W2 is no more than 6; or when each of
W and W2 are absent, then W1 further comprises C4-C8 heteroalkylene containing 1 to 3 oxygen atoms; and
R9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy.
7. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 5 or claim 6, wherein X is hydrogen or halo.
8. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-7, wherein Ring D is a Cg-Cio aryl ring.
9. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-7, wherein Ring D is a Cs-Cg cycloalkyl ring.
10. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-7, wherein Ring D is a 6 to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms.
11. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-7, wherein Ring D is a 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms.
12. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-7, wherein Ring D is absent.
14. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-13, wherein Ring A is a 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms.
16. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-15, wherein a is zero in L which is then represented by formula Ila:
18. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-17, wherein B is a 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, -NR10Rn, and -C(O)NR10Rn.
22. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 21, wherein b is 1 and W1 is O or C k
24. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 21, wherein b is 0.
26. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-25, wherein n is 0.
27. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-25, wherein n is 1.
28. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-27, wherein p is 1.
29. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-28, wherein R1 and R2 are independently selected from hydrogen and Ci-Cg alkyl.
30. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-28, wherein R1 and R2 taken together with the nitrogen atom to which they are attached form a 3- to 11 -membered ring optionally containing an additional heteroatom or heteroatom group selected from O, N, N(R17), and S(O)m as a ring member, wherein said 4- to 6-membered ring is optionally substituted by one to four R8.
33. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-32, wherein Z is -O-.
34. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-32, wherein Z is -CH2-.
35. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-34, wherein Y is C-V.
36. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 35, wherein V is hydrogen.
37. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-34, wherein Y is N.
38. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-37, wherein Y1 is -CH2-.
I or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein Ring C is
wherein the solid bond 1 attaches Ring C to the piperidinedione ring and the solid bond 2 attaches Ring C to L;
V is selected from hydrogen, deuterium, and fluoro;
X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy;
R12 and R12 are independently selected from hydrogen, deuterium, and fluoro; or R12 and R12 together are oxo;
n is 0 or 1; p is 0 or 1;
R13 is hydrogen or -CH2-OR14;
R14 is C(O)-R15 or -P(O)(OR16)2;
R15 is C1-C4 alkyl or C1-C4 alkoxy; each R16 is independently hydrogen or C1-C4 alkyl;
Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4- to 5 -membered heterocycloalkyl ring with 1 ring nitrogen atom, 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
R1 and R2 are independently selected from hydrogen, Ci-Cg alkyl, L'-C’s-Cg cycloalkyl, and I -4-7 membered heterocycloalkyl, wherein said Ci-Cg alkyl, C’s-Cg cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by one to four R8;
R1 and R2 taken together with the nitrogen atom to which they are attached form a 4- to 6- membered ring optionally containing an additional heteroatom selected from O, N, N(R17), and S(O)m as a ring member, wherein said 4- to 6-membered ring is optionally substituted by one to four R8;
R17 is hydrogen, C1-C4 alkyl, or C(O)-Ci-C4 alkyl;
R18 is hydrogen, C1-C4 alkyl, C1-4 fluoroalkyl, or C(O)-Ci-C4 alkyl; m is 0, 1 or 2;
L1 is a bond or a C1-C2 alkylene optionally substituted with one to four R9;
Ring A is selected from Cg-Cio aryl ring; C4-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R7 moieties, and each R7 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn;
R10 and R11 are each independently H or C1-C4 alkyl;
Ring B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R8
moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn, or B is absent; a, b, and c are independently 0 or 1 ; each of W and W2, if present, is independently Ci-Cg alkylene optionally substituted with 1 to 3 R9 and W1, if present, is O, S, NR18 or Ci-Cg alkylene optionally substituted with 1 to 3 R9 provided that the aggregate sum of carbon atoms in W, W1 and W2 is no more than 6; or when each of W and W2 are absent, then W1 further comprises C4-C8 heteroalkylene containing 1 to 3 oxygen atoms; and
R9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy.
IA or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein
Ring
, wherein the solid bond 1 attaches Ring C to the piperidinedione ring and the solid bond 2 attaches Ring C to L;
V is hydrogen;
X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy;
R12 and R12 are hydrogen, or R12 and R12 together are oxo; n is 0 or 1; p is 0 or 1;
R13 is hydrogen;
Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4 to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6 to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 5-10 membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
Z is -O- or -CH2-;
R1 and R2 are independently selected from hydrogen, Ci-Cg alkyl, I -(C3-Cg cycloalkyl), and L1-(4- to 7-membered heterocycloalkyl), wherein said Ci-Cg alkyl, C’s-Cg cycloalkyl and 4- to 7- membered heterocycloalkyl is optionally substituted by one to four R8;
R1 and R2 taken together with the nitrogen atom to which they are attached form a 3- to 11- membered ring optionally containing an additional heteroatom or heteroatom group selected from O, N(R17), and S(O)m as a ring member, wherein said 3- to 6-membered ring is optionally substituted by one to four R8;
R17 is hydrogen, C1-C4 alkyl, or C(O)-Ci-C4 alkyl;
R18 is hydrogen, C1-C4 alkyl, C1-4 fluoroalkyl, or C(O)-Ci-C4 alkyl; m is 0, 1 or 2;
L1 is a bond or a C1-C2 alkylene optionally substituted with one to four R9;
Ring A is selected from Cg-Cio aryl ring; C4-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to
10-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R7 moieties, and each R7 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn;
R10 and R11 are each independently H or C1-C4 alkyl;
B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to
11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn, or B is absent; b and c are independently 0 or 1 ;
W2, if present, is Ci-Cg alkylene optionally substituted with 1 to 3 R9 and W1, if present, is -C(O)-, O, S, NR18 or Ci-Cg alkylene optionally substituted with 1 to 3 R9 provided that the aggregate sum of carbon atoms in W1 and W2 is no more than 4; and
R9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy; or when W is absent then W1 is C4-C8 heteroalkylene containing 1 to 3 oxygen atoms.
IB or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein
Ring
wherein the solid bond 1 attaches Ring C to the piperidinedione ring and the solid bond 2 attaches Ring C to L;
V is hydrogen;
X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy;
R12 and R12 are hydrogen, or R12 and R12 together are oxo; n is 0 or 1; p is 0 or 1;
R13 is hydrogen;
Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4- to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 5-10 membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
Z is -O- or -CH2-;
R1 and R2 are independently selected from hydrogen, Ci-Cg alkyl, L'-G-Cg cycloalkyl, and L1-4-7 membered heterocycloalkyl, wherein said Ci-Cg alkyl, C -Cg cycloalkyl and 4- to 7-membered heterocycloalkyl is optionally substituted by one to four R8;
R1 and R2 taken together with the nitrogen atom to which they are attached form a 3- to 11 -membered ring optionally containing an additional heteroatom or heteroatom group selected from O, N(R17), and S(O)m as a ring member, wherein said 3- to 6-membered ring is optionally substituted by one to four R8;
R17 is hydrogen, C1-C4 alkyl, or C(O)-Ci-C4 alkyl;
R18 is hydrogen, C1-C4 alkyl, C1-C4 fluoroalkyl, or C(O)-Ci-C4 alkyl;
m is 0, 1 or 2;
L1 is a bond or a C1-C2 alkylene optionally substituted with one to four R9;
Ring A is selected from Cg-Cio aryl ring; C4-C6 cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to
10-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R7 moieties, and each R7 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn;
R10 and R11 are each independently H or C1-C4 alkyl;
B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to
11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn, or B is absent; b and c are independently 0 or 1 ;
W2, if present, is Ci-Cg alkylene optionally substituted with 1 to 3 R9 and W1, if present, is -C(O)-, O, S, NR18 or Ci-Cg alkylene optionally substituted with 1 to 3 R9 provided that the aggregate sum of carbon atoms in W1 and W2 is no more than 4;
R9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy; and when W2 is absent then W1 further comprises C4-C8 heteroalkylene containing 1 to 3 oxygen atoms.
III or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein
Y is N or C-V;
V is selected from hydrogen, deuterium, and fluoro;
X is selected from hydrogen, halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and Ci-4fluoroalkyloxy;
R12 and R12 are independently selected from hydrogen, deuterium, and fluoro; or R12 and R12 together are oxo; n is 0 or 1; p is 0 or 1;
R3 and R4 are independently hydrogen, halo, or CH3; or R3 and R4 together with the carbon atom to which they are attached form a C3-C6 cycloalkyl;
Y1 is -O- or -CH2-;
Z1 is -O-, and R5 is selected from Cg-Cio aryl; 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms; C3-C6 cycloalkyl ring; and C1-C3 alkyl optionally substituted with C1-C3 alkoxy or phenyl; wherein the Cg-Cio aryl and the 6-membered heteroaryl ring are substituted with 0 to 2 R6, and each R6 is independently selected from halo, cyano, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyl; or -Z^R5 is hydrogen;
R13 is hydrogen or -CH2-OR14;
R14 is C(O)-R15 or -P(O)(OR16)2;
R15 is C1-C4 alkyl or C1-C4 alkoxy; each R16 is independently hydrogen or C1-C4 alkyl;
Ring D is selected from Cg-Cio aryl ring, Cs-Cg cycloalkyl ring, 4- to 5-membered heterocycloalkyl ring with 1 ring nitrogen atom, 6- to 7-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, or is absent;
R18 is hydrogen, C1-C4 alkyl, C1-C4 fluoroalkyl, or C(O)-Ci-C4 alkyl;
Ring A is selected from Cg-Cio aryl ring; C4-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6-membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein ring A is substituted with from 0 to 3 R7 moieties, and each R7 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn;
R10 and R11 are each independently H or C1-C4 alkyl;
Ring B is selected from Cg-Cio aryl; Cs-Cg cycloalkyl ring; Cs-Cg cycloalkenyl ring; 5- to 6- membered heteroaryl ring with 1 to 3 ring heteroatoms independently selected from N, S, and O; 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms; and 4- to 11 -membered heterocycloalkenyl ring with 1 or 2 ring nitrogen atoms, wherein B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkyloxy, NR10Rn, and -C(O)NR10Rn, or B is absent; a, b, and c are independently 0 or 1 ; each of W and W2, if present, is independently Ci-Cg alkylene optionally substituted with 1 to 3 R9 and W1, if present, is -C(O)-, O, S, NR18 or Ci-Cg alkylene optionally substituted with 1 to 3 R9 provided that the aggregate sum of carbon atoms in W, W1 and W2 is no more than 6; or when each of W and W2 are absent, then W1 further comprises C4-C8 heteroalkylene containing 1 to 3 oxygen atoms; and
R9 is independently selected from halo, cyano, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, and C1-C4 fluoroalkyloxy.
46. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 42, wherein X is fluoro.
47. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 42-46, wherein Ring D is a Cg-Cio aryl ring.
48. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 42-46, wherein Ring D is absent.
50. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 42-49, wherein Ring A is a 4- to 11 -membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms.
52. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 42-51, wherein a is zero in L which is then represented by formula Ila:
54. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 42-53, wherein B is a 4- to 11-membered heterocycloalkyl ring with 1 or 2 ring nitrogen atoms, and B is substituted with from 0 to 3 R8 moieties, wherein each R8 is independently selected from halo, hydroxy, cyano, CM alkyl, CM fluoroalkyl, C alkoxy, CMfhioroalkyloxy, -NR10Rn, and -C(O)NR10Rn.
58. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 57, wherein b is 1 and W1 is -CH2-.
60. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 57, wherein b is 0.
62. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 42-61, wherein n is 0.
63. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 42-61, wherein n is 1.
64. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 42-63, wherein p is 1.
65. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 42-64, wherein R5 is Cg-Cio aryl substituted with 0 to 2 R6.
67. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 42-64, wherein R5 is 6-membered heteroaryl ring with 1 or 2 ring nitrogen atoms, and the 6-membered heteroaryl ring is substituted with 0 to 2 R6.
69. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 42-64, wherein R5 is C1-C3 alkyl optionally substituted with C1-C3 alkoxy or phenyl.
71. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 42-64, wherein R5 is a C3-C6 cycloalkyl ring.
73. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 42-72, wherein -Z^R5 is hydrogen.
74. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 42-73, wherein Y is C-V.
75. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 74, wherein V is hydrogen.
76. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 42-73, wherein Y is N.
77. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 42-76, wherein Y1 is -CH2-.
78. A compound selected from Table 1, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
79. A compound selected from Table 2, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
80. A pharmaceutical composition comprising a compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-79 and a pharmaceutically acceptable excipient.
81. A method for treating a CDK2 dependent disease or disorder or a disease or disorder that is mediated, at least in part, by CDK2, or a disease characterized by amplification or overexpression of cyclin El (CCNE1) or cyclin E2 (CCNE2) or both CCNE1 and CCNE2 in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-79 or a pharmaceutical composition of claim 80.
82. The method of claim 81, wherein the CDK2 dependent disease or disorder or the disease or disorder that is mediated, at least in part by, CDK2, is one or more selected from liposarcoma, glioblastoma, bladder cancer, adrenocortical cancer, multiple myeloma, colorectal cancer, non-small cell lung cancer, Human Papilloma Virus-associated cervical, oropharyngeal, penis, anal, thyroid, or vaginal cancer or Epstein-Barr Virus-associated nasopharyngeal carcinoma, gastric cancer, rectal cancer, thyroid cancer, Hodgkin lymphoma, and diffuse large B-cell lymphoma.
83. The method of claim 81, wherein the CDK2 dependent disease or disorder or the disease or disorder that is mediated, at least in part by, CDK2, is one or more selected from prostate cancer, breast carcinoma, lymphomas, leukemia, myeloma, bladder carcinoma, colon cancer, cutaneous melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, renal cancer, glioblastoma multiform, glioma, thyroid cancer, parathyroid tumor, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, cholangiocarcinoma, gastric cancer, soft tissue sarcomas, rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid cancers, cancer for which the immune response is deficient, an immunogenic cancer, and Ewing’s sarcoma.
84. The method of claim 81, wherein the CDK2 dependent disease or disorder or the disease or disorder that is mediated, at least in part by, CDK2, is selected from rheumatoid arthritis; inflammation; autoimmune disease; lymphoproliferative conditions; acromegaly; rheumatoid spondylitis; osteoarthritis; gout, other arthritic conditions; sepsis; septic shock; endotoxic shock; gramnegative sepsis; toxic shock syndrome; asthma; adult respiratory distress syndrome; chronic obstructive pulmonary disease; chronic pulmonary inflammation; inflammatory bowel disease; Crohn's disease; psoriasis; eczema; ulcerative colitis; pancreatic fibrosis; hepatic fibrosis; acute and chronic renal disease; irritable bowel syndrome; pyresis; restenosis; cerebral malaria; stroke and ischemic injury;
neural trauma; Alzheimer's disease; Huntington's disease; Parkinson's disease; acute and chronic pain; allergic rhinitis; allergic conjunctivitis; chronic heart failure; acute coronary syndrome; cachexia; malaria; leprosy; leishmaniasis; Lyme disease; Reiter's syndrome; acute synovitis; muscle degeneration, bursitis; tendonitis; tenosynovitis; herniated, ruptures, or prolapsed intervertebral disk syndrome; osteopetrosis; thrombosis; restenosis; silicosis; pulmonary sarcoidosis; bone resorption diseases, such as osteoporosis; graft-versus-host reaction; Multiple Sclerosis; lupus; fibromyalgia; AIDS and other viral diseases such as Herpes Zoster, Herpes Simplex I or II, influenza virus and cytomegalovirus; and diabetes mellitus.
85. The method of any one of claims 81-84, further comprising administering to the subject one or more additional therapies or therapeutic agents.
86. The method of claim 85, wherein the one or more additional therapies or therapeutic agents are selected from surgery, radiotherapy, endocrine therapy, biologic response modifiers, hyperthermia and cryotherapy, agents to attenuate any adverse effects, alkylating drugs, antimetabolites, purine antagonists and pyrimidine antagonists, spindle poisons, podophyllotoxins, antibiotics, nitrosoureas, inorganic ions, enzymes, and hormones.
87. A compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-79 or a pharmaceutical composition of claim 80, for use in treating a CDK2 dependent disease or disorder or a disease or disorder that is mediated, at least in part by, CDK2, or a disease characterized by amplification or overexpression of cyclin El (CCNE1) or cyclin E2 (CCNE2) or both CCNE1 and CCNE2.
88. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof or composition for use of claim 87, wherein the CDK2 dependent disease or disorder or the disease or disorder that is mediated, at least in part by, CDK2, is one or more selected from liposarcoma, glioblastoma, bladder cancer, adrenocortical cancer, multiple myeloma, colorectal cancer, non-small cell lung cancer, Human Papilloma Virus-associated cervical, oropharyngeal, penis, anal, thyroid, or vaginal cancer or Epstein-Barr Virus-associated nasopharyngeal carcinoma, gastric cancer, rectal cancer, thyroid cancer, Hodgkin lymphoma, and diffuse large B-cell lymphoma.
89. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof or composition for use of claim 87, wherein the CDK2 dependent disease or disorder or the disease or disorder that is mediated, at least in part by, CDK2, is one or more selected from prostate cancer, breast carcinoma, lymphomas, leukemia, myeloma, bladder carcinoma, colon cancer, cutaneous melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, renal cancer, glioblastoma multiform, glioma, thyroid cancer, parathyroid tumor, nasopharyngeal cancer,
tongue cancer, pancreatic cancer, esophageal cancer, cholangiocarcinoma, gastric cancer, soft tissue sarcomas, rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid cancers, cancer for which the immune response is deficient, an immunogenic cancer, and Ewing’s sarcoma.
90. The compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof or composition for use of claim 87, wherein the CDK2 dependent disease or disorder or the disease or disorder that is mediated, at least in part by, CDK2, is one or more selected from rheumatoid arthritis; inflammation; autoimmune disease; lymphoproliferative conditions; acromegaly; rheumatoid spondylitis; osteoarthritis; gout, other arthritic conditions; sepsis; septic shock; endotoxic shock; gramnegative sepsis; toxic shock syndrome; asthma; adult respiratory distress syndrome; chronic obstructive pulmonary disease; chronic pulmonary inflammation; inflammatory bowel disease; Crohn's disease; psoriasis; eczema; ulcerative colitis; pancreatic fibrosis; hepatic fibrosis; acute and chronic renal disease; irritable bowel syndrome; pyresis; restenosis; cerebral malaria; stroke and ischemic injury; neural trauma; Alzheimer's disease; Huntington's disease; Parkinson's disease; acute and chronic pain; allergic rhinitis; allergic conjunctivitis; chronic heart failure; acute coronary syndrome; cachexia; malaria; leprosy; leishmaniasis; Lyme disease; Reiter's syndrome; acute synovitis; muscle degeneration, bursitis; tendonitis; tenosynovitis; herniated, ruptures, or prolapsed intervertebral disk syndrome; osteopetrosis; thrombosis; restenosis; silicosis; pulmonary sarcoidosis; bone resorption diseases, such as osteoporosis; graft-versus-host reaction; Multiple Sclerosis; lupus; fibromyalgia; AIDS and other viral diseases such as Herpes Zoster, Herpes Simplex I or II, influenza virus and cytomegalovirus; and diabetes mellitus.
91. Use of a compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1-79 or a pharmaceutical composition of claim 80, in the preparation of a medicament for treating a CDK2 dependent disease or disorder or a disease or disorder that is mediated, at least in part by, CDK2, or a disease characterized by amplification or overexpression of cyclin El (CCNE1) or cyclin E2 (CCNE2) or both CCNE1 and CCNE2.
92. The use of claim 91, wherein the CDK2 dependent disease or disorder or the disease or disorder that is mediated, at least in part by, CDK2, is one or more selected from liposarcoma, glioblastoma, bladder cancer, adrenocortical cancer, multiple myeloma, colorectal cancer, non-small cell lung cancer, Human Papilloma Virus-associated cervical, oropharyngeal, penis, anal, thyroid, or vaginal cancer or Epstein-Barr Virus-associated nasopharyngeal carcinoma, gastric cancer, rectal cancer, thyroid cancer, Hodgkin lymphoma, and diffuse large B-cell lymphoma.
93. The use of claim 91, wherein the CDK2 dependent disease or disorder or the disease or disorder that is mediated, at least in part by, CDK2, is one or more selected from prostate cancer, breast carcinoma, lymphomas, leukemia, myeloma, bladder carcinoma, colon cancer, cutaneous
melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, renal cancer, glioblastoma multiform, glioma, thyroid cancer, parathyroid tumor, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, cholangiocarcinoma, gastric cancer, soft tissue sarcomas, rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid cancers, cancer for which the immune response is deficient, an immunogenic cancer, and Ewing’s sarcoma.
94. The use of claim 91, wherein the CDK2 dependent disease or disorder or the disease or disorder that is mediated, at least in part by, CDK2, is one or more selected from rheumatoid arthritis; inflammation; autoimmune disease; lymphoproliferative conditions; acromegaly; rheumatoid spondylitis; osteoarthritis; gout, other arthritic conditions; sepsis; septic shock; endotoxic shock; gramnegative sepsis; toxic shock syndrome; asthma; adult respiratory distress syndrome; chronic obstructive pulmonary disease; chronic pulmonary inflammation; inflammatory bowel disease; Crohn's disease; psoriasis; eczema; ulcerative colitis; pancreatic fibrosis; hepatic fibrosis; acute and chronic renal disease; irritable bowel syndrome; pyresis; restenosis; cerebral malaria; stroke and ischemic injury; neural trauma; Alzheimer's disease; Huntington's disease; Parkinson's disease; acute and chronic pain; allergic rhinitis; allergic conjunctivitis; chronic heart failure; acute coronary syndrome; cachexia; malaria; leprosy; leishmaniasis; Lyme disease; Reiter's syndrome; acute synovitis; muscle degeneration, bursitis; tendonitis; tenosynovitis; herniated, ruptures, or prolapsed intervertebral disk syndrome; osteopetrosis; thrombosis; restenosis; silicosis; pulmonary sarcoidosis; bone resorption diseases, such as osteoporosis; graft-versus-host reaction; Multiple Sclerosis; lupus; fibromyalgia; AIDS and other viral diseases such as Herpes Zoster, Herpes Simplex I or II, influenza virus and cytomegalovirus; and diabetes mellitus.
95. A method for modulating or degrading CDK2, comprising contacting CDK2 with a compound, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof of any one of claims 1- 79 or a pharmaceutical composition of claim 80.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263349523P | 2022-06-06 | 2022-06-06 | |
US63/349,523 | 2022-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023239629A1 true WO2023239629A1 (en) | 2023-12-14 |
Family
ID=87136463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/024397 WO2023239629A1 (en) | 2022-06-06 | 2023-06-05 | Compounds and pharmaceutical compositions that degrade cdk2 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023239629A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12097261B2 (en) | 2022-05-06 | 2024-09-24 | Kymera Therapeutics, Inc. | CDK2 degraders and uses thereof |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
WO2002018346A1 (en) * | 2000-08-31 | 2002-03-07 | Pfizer Products Inc. | Pyrazole derivatives and their use as protein kinase inhibitors |
WO2005051919A1 (en) * | 2003-11-26 | 2005-06-09 | Pfizer Products Inc. | Aminopyrazole derivatives as gsk-3 inhibitors |
US20050209297A1 (en) * | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
WO2020038415A1 (en) | 2018-08-22 | 2020-02-27 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
CN110938060A (en) * | 2019-12-10 | 2020-03-31 | 四川大学 | Compound for selectively targeting and degrading CDK subtype and application thereof |
WO2020157652A2 (en) * | 2019-01-31 | 2020-08-06 | Pfizer Inc. | Cdk2 inhibitors |
WO2020206137A1 (en) * | 2019-04-04 | 2020-10-08 | Dana-Farber Cancer Institute, Inc. | Cdk2/5 degraders and uses thereof |
CN111909155A (en) * | 2020-08-21 | 2020-11-10 | 东莞理工学院 | Proteolysis targeting chimera, prodrug molecule for improving oral bioavailability thereof and application |
WO2021113557A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
US20220096642A1 (en) * | 2020-09-28 | 2022-03-31 | Creighton University | Compositions, use, and method for cdk2-protacs for cancer therapy and hearing loss |
CN114349738A (en) * | 2020-10-14 | 2022-04-15 | 清华大学 | Small molecule conjugate for targeted degradation of CDK2 and application thereof |
WO2022140472A1 (en) * | 2020-12-22 | 2022-06-30 | Nikang Therapeutics, Inc. | Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway |
WO2022236058A1 (en) * | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
WO2023069720A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
WO2023069700A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
-
2023
- 2023-06-05 WO PCT/US2023/024397 patent/WO2023239629A1/en unknown
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
WO2002018346A1 (en) * | 2000-08-31 | 2002-03-07 | Pfizer Products Inc. | Pyrazole derivatives and their use as protein kinase inhibitors |
US20050209297A1 (en) * | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
WO2005051919A1 (en) * | 2003-11-26 | 2005-06-09 | Pfizer Products Inc. | Aminopyrazole derivatives as gsk-3 inhibitors |
WO2020038415A1 (en) | 2018-08-22 | 2020-02-27 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
US20200247784A1 (en) | 2019-01-31 | 2020-08-06 | Pfizer Inc. | Cdk2 inhibitors |
WO2020157652A2 (en) * | 2019-01-31 | 2020-08-06 | Pfizer Inc. | Cdk2 inhibitors |
WO2020206137A1 (en) * | 2019-04-04 | 2020-10-08 | Dana-Farber Cancer Institute, Inc. | Cdk2/5 degraders and uses thereof |
WO2021113557A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
CN110938060A (en) * | 2019-12-10 | 2020-03-31 | 四川大学 | Compound for selectively targeting and degrading CDK subtype and application thereof |
CN111909155A (en) * | 2020-08-21 | 2020-11-10 | 东莞理工学院 | Proteolysis targeting chimera, prodrug molecule for improving oral bioavailability thereof and application |
US20220096642A1 (en) * | 2020-09-28 | 2022-03-31 | Creighton University | Compositions, use, and method for cdk2-protacs for cancer therapy and hearing loss |
CN114349738A (en) * | 2020-10-14 | 2022-04-15 | 清华大学 | Small molecule conjugate for targeted degradation of CDK2 and application thereof |
WO2022140472A1 (en) * | 2020-12-22 | 2022-06-30 | Nikang Therapeutics, Inc. | Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway |
WO2022236058A1 (en) * | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
WO2023069720A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
WO2023069700A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
Non-Patent Citations (23)
Title |
---|
"Angewandte Chemie", vol. 59, 2020, pages: 3028 - 3032 |
"Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS |
"Design of Prodrugs", 1985, ELSEVIER |
"Fieser and Fieser's Reagents for Organic Synthesis", vol. 1-15, 2016, JOHN WILEY, AND SONS |
"Larock's Comprehensive Organic Transformations", 1989, VCH PUBLISHERS INC. |
"Supplementals", 2001, ELSEVIER SCIENCE PUBLISHERS |
ANGEW. CHEM., INT. ED., vol. 1-40, 2019, pages 6152 - 6163 |
ANGEWANDTE CHEMIE, vol. 59, 2020, pages 3028 - 3032 |
BEMDSEN ET AL.: "New insights into ubiquitin E3 ligase mechanism", NAT. STRUCT. MOL. BIOL., vol. 21, 2014, pages 301, XP055420625, DOI: 10.1038/nsmb.2780 |
CAS, no. 2241315-66-0 |
COLIGAN ET AL.: "Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY, article "The Pharmacological Basis of Therapeutics (1975" |
CREWS, CHEM. & BIOL., vol. 17, no. 6, 2010, pages 551 |
DESHAIES ET AL.: "RING domain E3 ubiquitin ligases", ANN. REV. BIOCHEM., vol. 78, 2009, pages 399, XP055005600, DOI: 10.1146/annurev.biochem.78.101807.093809 |
FOSTER: "Deuterium Isotope Effects in Studies of Drug Metabolism", TRENDS PHARMACOL. SCI., vol. 5, no. 12, 1984, pages 524 - 527, XP025943358, DOI: 10.1016/0165-6147(84)90534-0 |
LI ET AL.: "Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling", PLOS ONE, no. 3, 2008, pages 1487 |
PETER G. M. WUTSTHEODORA W. GREENE: "Greene's Protective Groups in Organic Synthesis", 2005, JOHN WILEY AND SONS, INC. |
RODD'S CHEMISTRY OF CARBON COMPOUNDS, vol. 1-5 |
SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual", 2000, COLD SPRING HARBOR PRESS, COLD SPRING HARBOR |
SCHNEEKLOTHCREWS, CHEM BIO CHEM., vol. 6, no. 1, 2005, pages 40 |
SPRATTETAL: "RBRE3 ubiquitin ligases: new structures, new insights, new questions", BIOCHEM., vol. 458, 2014, pages 421 |
T. HIGUCHIV. STELLA: "Pro-drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14 |
T. W. GREENEP. G. M. WUTS: "Protecting Groups in Organic Synthesis", 1999, WILEY |
WANG ET AL.: "Roles of F-box proteins in cancer", NAT. REV. CANCER., vol. 14, 2014, pages 233 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12097261B2 (en) | 2022-05-06 | 2024-09-24 | Kymera Therapeutics, Inc. | CDK2 degraders and uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019200723B2 (en) | 2-amino-6-fluoro-N-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof | |
EP3468960B1 (en) | Chemical compounds as atf4 pathway inhibitors | |
CN107530329B (en) | Pyrazolo [1, 5-a ] [1, 3, 5] triazine and pyrazolo [1, 5-a ] pyrimidine derivatives as CDK inhibitors | |
AU2023201775A1 (en) | Compounds, compositions and methods | |
CA2957046C (en) | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | |
WO2018023029A1 (en) | Small molecule activators of parkin enzyme function | |
WO2018167269A1 (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
WO2018225093A1 (en) | Chemical compounds as atf4 pathway inhibitors | |
ES2964534T3 (en) | Phthalazine isoxazole alkoxy derivatives, method of preparation thereof, pharmaceutical composition and use thereof | |
BRPI0720264A2 (en) | protein kinase inhibiting compounds, compositions containing same as well as their uses | |
US20170349607A1 (en) | Compounds active towards bromodomains | |
EP3189048A1 (en) | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors | |
CA3056726A1 (en) | Tricyclic compounds for use in treatment of proliferative disorders | |
AU2021339298A1 (en) | Compounds for suppressing egfr mutant cancer and pharmaceutical use thereof | |
WO2023283428A1 (en) | Heterocycloalkyl and heteroaryl compounds and pharmaceutical compositions that modulate ikzf2 | |
WO2019079485A1 (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and derivatives thereof | |
EP3634952A1 (en) | Chemical compounds as atf4 pathway inhibitors | |
AU2018276190B2 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
US20240246935A1 (en) | Aryl compounds and pharmaceutical compositions that modulate ikzf2 | |
US20240287037A1 (en) | Cycloalkyl compounds and pharmaceutical compositions that modulate ikzf2 | |
WO2023239629A1 (en) | Compounds and pharmaceutical compositions that degrade cdk2 | |
WO2023046128A1 (en) | A cyclin-dependent kinase inhibitor | |
WO2022221786A2 (en) | Compounds and pharmaceutical compositions that modulate brd4 | |
JP2024531273A (en) | Bifunctional degraders of interleukin-1 receptor associated kinase and their therapeutic uses | |
WO2023244806A1 (en) | Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23738263 Country of ref document: EP Kind code of ref document: A1 |